<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacotherapy for trichotillomania - Hoffman, J - 2021 | Cochrane Library</title> <meta content="Pharmacotherapy for trichotillomania - Hoffman, J - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007662.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacotherapy for trichotillomania - Hoffman, J - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007662.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007662.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacotherapy for trichotillomania" name="citation_title"/> <meta content="Jacob Hoffman" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="Taryn Williams" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="Rachel Rothbart" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="Jonathan C Ipser" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="Naomi Fineberg" name="citation_author"/> <meta content="Queen Elizabeth II Hospital" name="citation_author_institution"/> <meta content="Samuel R Chamberlain" name="citation_author"/> <meta content="University of Southampton" name="citation_author_institution"/> <meta content="Dan J Stein" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="dan.stein@uct.ac.za" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD007662.pub3" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/09/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007662.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007662.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007662.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antidepressive Agents, Tricyclic [therapeutic use]; *Antipsychotic Agents [therapeutic use]; Clomipramine; Selective Serotonin Reuptake Inhibitors; *Trichotillomania [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007662.pub3&amp;doi=10.1002/14651858.CD007662.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="eLIOL3Be";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007662\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007662\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007662\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007662\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","pt","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007662.pub3",title:"Pharmacotherapy for trichotillomania",firstPublishedDate:"Sep 28, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Common Mental Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007662.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007662.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007662.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007662.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007662.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007662.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007662.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007662.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007662.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007662.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5886 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007662.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-sec-0180"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-sec-0174"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/appendices#CD007662-sec-0185"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/supinfo/CD007662StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/supinfo/CD007662StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacotherapy for trichotillomania</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/information#CD007662-cr-0004">Jacob Hoffman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/information#CD007662-cr-0005">Taryn Williams</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/information#CD007662-cr-0006">Rachel Rothbart</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/information#CD007662-cr-0007">Jonathan C Ipser</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/information#CD007662-cr-0008">Naomi Fineberg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/information#CD007662-cr-0009">Samuel R Chamberlain</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007662.pub3/information#CD007662-cr-0010"><i class="icon corresponding-author fa fa-envelope"></i>Dan J Stein</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/information/en#CD007662-sec-0196">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 September 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007662.pub3">https://doi.org/10.1002/14651858.CD007662.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007662-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007662-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007662-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007662-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007662-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007662-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007662-abs-0001" lang="en"> <section id="CD007662-sec-0001"> <h3 class="title" id="CD007662-sec-0001">Background</h3> <p>Trichotillomania (TTM; hair‐pulling disorder) is a prevalent and disabling disorder characterised by recurrent hair‐pulling. Here we update a previous Cochrane Review on the effects of medication for TTM. </p> </section> <section id="CD007662-sec-0002"> <h3 class="title" id="CD007662-sec-0002">Objectives</h3> <p>To assess the effects of medication for trichotillomania (TTM) in adults, children and adolescents compared with placebo or other medication. </p> </section> <section id="CD007662-sec-0003"> <h3 class="title" id="CD007662-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, PsycINFO, eleven other bibliographic databases, trial registries and grey literature sources (to 26 November 2020). We checked reference lists and contacted subject experts. </p> </section> <section id="CD007662-sec-0004"> <h3 class="title" id="CD007662-sec-0004">Selection criteria</h3> <p>We selected randomised controlled trials of medication versus placebo or other medication for TTM in adults, children and adolescents. </p> </section> <section id="CD007662-sec-0005"> <h3 class="title" id="CD007662-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane.</p> </section> <section id="CD007662-sec-0006"> <h3 class="title" id="CD007662-sec-0006">Main results</h3> <p>Twelve studies were included. We identified 10 studies in adults (286 participants) with a mean sample size of 29 participants per trial; one study in children and adolescents (39 participants); and, one study in adults and adolescents (22 participants: 18 adults and 4 adolescents). All studies were single‐centre, outpatient trials. Eleven studies compared medication and placebo (334 participants); one study compared two medications (13 participants). Studies were 5 to 13 weeks duration. We undertook meta‐analysis only for opioid antagonists as other comparisons contained a single study, or reported insufficient data. </p> <p><b>Antioxidants versus placebo in adults</b> </p> <p>There was little to no difference in treatment response between antioxidant (35.7%) and placebo groups (28.6%) after six weeks, based on a single trial of silymarin (risk ratio (RR) 2.25, 95% confidence interval (CI) 0.84 to 5.99; 36 participants; low‐certainty evidence). We could not calculate differences in number of dropouts as there were no events in either group (18 participants; low‐certainty evidence). </p> <p><b>Antioxidants versus placebo in adolescents</b> </p> <p>There was little to no difference in treatment response between antioxidant (50%) and placebo groups (25%) after six weeks, based on a single trial of silymarin (RR 2.00, 95% CI 0.28 to 14.20; 8 participants; low‐certainty evidence). We could not calculate differences in number of dropouts as there were no events in either group (8 participants; low‐certainty evidence). </p> <p><b>Antipsychotics versus placebo in adults</b> </p> <p>There may be greater treatment response in the antipsychotic group (85%) compared to the placebo group (17%) after 12 weeks, based on a single trial of olanzapine (RR 5.08, 95% CI 1.4 to 18.37; 25 participants; low‐certainty evidence). We could not calculate differences in number of dropouts as there were no events in either group (25 participants; low‐certainty evidence). </p> <p><b>Cell signal transducers versus placebo in adults</b> </p> <p>There was little to no difference in treatment response between cell signal transducer (42.1%) and placebo groups (31.6%) after 10 weeks, based on a single trial of inositol (RR 1.33, 95% CI 0.57 to 3.11; 38 participants; low‐certainty evidence). We could not calculate differences in number of dropouts as there were no events in either group (38 participants; low‐certainty evidence). </p> <p><b>Glutamate modulators versus placebo in adults</b> </p> <p>There is probably greater treatment response in the glutamate modulator group (56%) compared to the placebo group (16%) after 12 weeks, based on a single trial of N‐acetylcysteine (RR 3.5, 95% CI 1.34 to 9.17; 50 participants; moderate‐certainty evidence). We could not calculate differences in number of dropouts as there were no events in either group (50 participants; low‐certainty evidence). </p> <p><b>Glutamate modulators versus placebo in children and adolescents</b> </p> <p>There was little to no difference in treatment response between the glutamate modulator (25%) and placebo groups (21.1%) in children and adolescents, based on a single trial of N‐acetylcysteine (RR 1.19, 95% CI 0.37 to 3.77; 39 participants; low‐certainty evidence). There was little to no difference in dropouts due to adverse events between glutamate modulator (5%) and placebo (0%) groups, based on a single trial (RR 2.86, 95% CI 0.12 to 66.11; 39 participants; low‐certainty evidence). </p> <p><b>Opioid antagonists versus placebo in adults</b> </p> <p>There may be little to no difference in treatment response between opioid antagonist (37.5%) and placebo groups (25%) after six to eight weeks, based on two studies of naltrexone, but the evidence is very uncertain (RR 2.14, 95% CI 0.25 to 18.17; 2 studies, 68 participants; very low‐certainty evidence). No data were available regarding dropouts due to adverse events. </p> <p><b>Selective serotonin reuptake inhibitors (SSRIs) versus placebo in adults</b> </p> <p>There were no data available for treatment response to SSRIs. There was little to no difference in dropouts due to adverse events in the SSRI group (5.1%) compared to the placebo group (0%) after 6 to 12 weeks, based on two trials of fluoxetine (RR 3.00, 95% CI 0.33 to 27.62; 2 studies, 78 participants; low‐certainty evidence). </p> <p><b>Tricyclic antidepressants (TCAs) with predominantly serotonin reuptake inhibitor (SRI) actions versus placebo in adults</b> </p> <p>There may be greater treatment response in the TCAs with predominantly SRI actions group (40%) compared to the placebo group (0%) after nine weeks, but the evidence is very uncertain, based on a single trial of clomipramine (RR 5.73, 95% CI 0.36 to 90.83; 16 participants; very low‐certainty evidence). There may be increased dropouts due to adverse events in the TCAs with predominantly SRI actions group (30%) compared to the placebo group (0%), but the evidence is very uncertain (RR 4.45, 95% CI 0.27 to 73.81; 16 participants; very low‐certainty evidence). </p> <p><b>TCAs with predominantly SRI actions versus other TCAs in adults</b> </p> <p>There may be greater treatment response in the TCAs with predominantly SRI actions group compared to the other TCAs group after five weeks, based on a single trial comparing clomipramine to desipramine (mean difference (MD) ‐4.00, 95% CI ‐6.13 to ‐1.87; 26 participants; low‐certainty evidence). We could not calculate differences in number of dropouts as there were no events in either group (26 participants; low‐certainty evidence). </p> </section> <section id="CD007662-sec-0007"> <h3 class="title" id="CD007662-sec-0007">Authors' conclusions</h3> <p>There was insufficient evidence from meta‐analysis to confirm or refute the efficacy of any agent or class of medication for the treatment of TTM in adults, children or adolescents. Preliminary evidence suggests there may be beneficial treatment effects for N‐acetylcysteine, clomipramine and olanzapine in adults based on four trials, albeit with relatively small sample sizes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007662-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007662-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007662-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007662-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007662-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007662-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007662-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD007662-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007662-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007662-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007662-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007662-abs-0002" lang="en"> <h3>Drug treatments for chronic hair‐pulling (trichotillomania)</h3> <p>Trichotillomania (TTM) is a common and disabling condition characterised by repeated hair‐pulling leading to hair loss. TTM can be associated with much distress and impairment. It may also be associated with other psychiatric conditions (known as comorbidities) such as depression and anxiety disorders. Researchers have proposed that medication may be useful to treat this condition. </p> <p><b>Who will be interested in this review?</b> </p> <p>‐ People with TTM or other common comorbidities.</p> <p>‐ Families and friends of people who have TTM or other common comorbidities.</p> <p>‐ Mental health clinicians, general practitioners, psychiatrists, psychologists and pharmacists. </p> <p><b>What questions does this review aim to answer?</b> </p> <p>‐ Is medication an effective treatment for TTM in adults or children and adolescents? That is, does it have the intended result? </p> <p>‐ Does medication reduce the severity of symptoms for adults or children and adolescents with TTM? </p> <p>‐ Does medication aid in treating symptoms of depression in adults or children and adolescents with TTM? </p> <p>‐ Is medication effective and tolerable for people with TTM in terms of side effects?</p> <p>‐ Does medication improve quality of life and reduce disability?</p> <p><b>Which studies were included in the review?</b> </p> <p>‐ We included nine studies comparing a medication with a placebo (control substance/not an active drug) for the treatment of TTM in adults. </p> <p>‐ We included one study comparing two different antidepressant drugs with each other for the treatment of TTM in adults. </p> <p>‐ We included one study comparing a medication with a placebo for the treatment of TTM in children and adolescents aged 8 to 17 years. </p> <p>‐ We included one study comparing a medication with a placebo for the treatment of TTM in adolescents and adults aged 12 to 65 years. </p> <p>‐ A total of 298 adults were included from the 11 studies conducted in adults, and a total of 43 children and adolescents were included from the two trials conducted with participants in this age group. </p> <p><b>What does the evidence from the review tell us?</b> </p> <p>There was insufficient evidence from analysis of individual studies or across multiple scientific studies (known as meta‐analysis) to confirm or refute the effectiveness of any specific agent or class of medication for the treatment of TTM in adults, children or adolescents. In adults, evidence suggests tricyclic antidepressants (TCAs; a type of antidepressant) with predominantly serotonin reuptake inhibitor (SRI; increasing serotonin levels in the brain) actions may show a beneficial treatment effect compared to other TCAs, with reduction in TTM symptom severity. However, certainty in the estimate of effect was low and is based on a single trial comparing clomipramine with desipramine. Antipsychotics in adults may show a beneficial treatment effect and possible reduction of TTM symptom severity, with low‐certainty in the estimate of effect, based on a single trial of olanzapine. Glutamate modulators (a type of amino acid modulator) in adults showed a probable beneficial treatment effect and a likely reduction in TTM symptom severity, with moderate‐certainty in the estimate of effect, although based on a single trial of N‐acetylcysteine (NAC; a glutamate modulator). Glutamate modulators in children and adolescents (8 to 17 years old) showed no evidence for beneficial effect in terms of the percentage of participants responding to treatment in a single study of NAC. However, evidence suggests a potential large reduction in TTM symptom severity; however, with low‐certainty in the estimate. There was little to no evidence for beneficial treatment effects in terms of the percentage of participants responding to treatment or reduction of TTM symptom severity reported for antioxidants, cell signal transducers, opioid antagonists or selective serotonin reuptake inhibitors (SSRIs; a type of antidepressant) in adults, children or adolescents. </p> <p>Attrition due to adverse events was only reported for SSRIs and TCAs with predominantly SRI actions in adults and for glutamate modulators in children and adolescents. Glutamate modulators had the least severe side effect profile in adults, while antipsychotics were associated with several adverse side effects, although with low‐certainty in the effect estimate, and based on individual trials for each medication class. There was low‐certainty evidence showing no difference in dropouts due to adverse events between the glutamate modulator group and placebo group in the single study exclusively in children and adolescents. </p> <p><b>What should happen next?</b> </p> <p>There is some evidence that NAC (a glutamate modulator) probably demonstrates efficacy in TTM in adults and possible symptom severity reduction in children and adolescents. There is some evidence that olanzapine (an antipsychotic) and clomipramine (a TCA with predominantly SRI actions) may demonstrate efficacy in TTM in adults, although based on individual trials and therefore not generalisable to other agents in the same medication classes. Studies are few and sample sizes are small, and as a result it is not possible to draw high‐quality conclusions from meta‐analysis. Additional studies, with rigorous designs and appropriately powered samples are needed, particularly in children and adolescents. Future studies could also include people with common comorbidities, as the current evidence base may not be representative of clinical populations, who might have multiple medical and psychiatric conditions. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007662-sec-0180" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007662-sec-0180"></div> <h3 class="title" id="CD007662-sec-0181">Implications for practice</h3> <section id="CD007662-sec-0181"> <p>There was insufficient evidence from meta‐analysis to confirm or refute efficacy of any particular agent or class of medication in the treatment of trichotillomania (TTM) for any age group. Preliminary evidence has suggested beneficial treatment effects of tricyclic antidepressants (TCAs) with predominantly serotonin reuptake inhibitor (SRI) actions (clomipramine 50 mg titrated up to 250 mg per day; low‐certainty evidence), glutamate modulators (N‐acetylcysteine (NAC) 1200 mg per day titrated up to 1200 mg twice daily; moderate‐certainty evidence) and antipsychotics (olanzapine 2.5 mg per day titrated up to 10 mg per day; low‐certainty evidence) in adults, based on three individual trials, all of which had relatively small sample sizes (<a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). There is some low‐certainty evidence that NAC reduces TTM symptom severity in children, also based on a single trial (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>). </p> </section> <h3 class="title" id="CD007662-sec-0182">Implications for research</h3> <section id="CD007662-sec-0182"> <p>The existing evidence base of randomised controlled trials includes a mixture of parallel and cross‐over trials, participants with a range of comorbid disorders and the use of unpublished rating scales. In addition, the existing trials have relatively small sample sizes, and the body of evidence is of low‐certainty because of high attrition rates and lack of intention‐to‐treat analyses. In the future, trials on a variety of agents, of longer duration, with larger sample sizes and using validated rating instruments (such as the Clinical Global Impressions‐Improvement (CGI‐I) and the Massachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS)) are needed. Additionally, inclusion of participants with common comorbidities is encouraged, to better reflect clinical populations. Given the preliminary evidence presented in four small trials of a glutamate modulator, an antipsychotic and a TCA with predominantly SRI actions, further work on these three classes of drugs is needed (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). Studies of other classes, such as SNRIs, may be useful in determining differential effects of serotonergic and noradrenergic agents in the treatment of TTM. Whilst preliminary evidence is encouraging, more studies in children and adolescents are required to investigate the effects of NAC seen in these age groups, and to investigate the efficacy of other agents in children. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007662-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007662-sec-0008"></div> <div class="table" id="CD007662-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antioxidants versus placebo for trichotillomania in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antioxidants versus placebo for trichotillomania in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> antioxidants versus placebo in adults </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Antioxidants versus placebo in adults</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment response</b><sup>a</sup><br/>Clinical Global Impressions ‐ Improvement Scale (CGI‐I) or similar (no. of responders) </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.25</b> <br/>(0.84 to 5.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>36<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was low‐certainty evidence showing no difference in treatment response between the antioxidant group and the placebo group in adults. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b><br/>(187 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b><br/>(186 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><br/>Massachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean MGH‐HPS score for the antipsychotic intervention group was 12.5.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention groups was <b>1.8 lower</b><br/>(6.22 lower to 2.62 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was low‐certainty evidence showing no difference in reduction of TTM symptom severity in the antioxidant group compared to the placebo group on the MGH‐HPS in adults. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b><br/>Dropout rate </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Differences between groups could not be calculated as there were no dropouts due to adverse events in either group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is uncertain about the effect of dropouts due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by two levels due to wide confidence interval and very small sample size ( &lt; 50). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007662-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antioxidants versus placebo for trichotillomania in adolescents</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antioxidants versus placebo for trichotillomania in adolescents</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> antioxidants versus placebo in adolescents </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Antioxidants versus placebo in</b> adolescents </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment response</b><sup>a</sup><br/>Clinical Global Impressions ‐ Improvement Scale (CGI‐I) or similar (no. of responders) </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2</b> <br/>(0.28 to 14.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>8<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was low‐certainty evidence showing no difference in treatment response between the antioxidant group and the placebo group in adolescents. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b><br/>(70 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>666 per 1000</b><br/>(110 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><br/>Massachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean MGH‐HPS score for the antipsychotic intervention group was 6.83.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention groups was<br/><b>5.87 lower</b><br/>(17.46 lower to 5.72 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was low‐certainty evidence showing no difference in reduction of TTM symptom severity in the antioxidant group compared to the placebo group on the MGH‐HPS in adolescents. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b><br/>Dropout rate </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Differences between groups could not be calculated as there were no dropouts due to adverse events in either group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is uncertain about the effect of dropouts due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by two levels due to wide confidence interval and very small sample size ( &lt; 50). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007662-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Antipsychotics versus placebo for trichotillomania in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antipsychotics versus placebo for trichotillomania in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> antipsychotics </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Antipsychotics versus placebo in adults</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment response</b><sup>a</sup><br/>Clinical Global Impressions ‐ Improvement Scale (CGI‐I) </p> <p>(no. of responders)</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 5.08</b> <br/>(1.4 to 18.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>25<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was low‐certainty evidence of benefit on the number of participants who responded to treatment in the antipsychotic group compared to the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>847 per 1000</b><br/>(233 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>848 per 1000</b><br/>(234 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><br/>Massachusetts General </p> <p>Hospital Hair‐Pulling Scale (MGH‐HPS)</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean MGH‐HPS score for the antipsychotic intervention group was 8.38.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention group was<br/><b>4.87 points lower</b><br/>(8.84 to 0.9 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was low‐certainty evidence for a reduction of TTM symptom severity in the antipsychotic group compared to the placebo group on the MGH‐HPS. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b><br/>Dropout rate<br/>Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Differences between groups could not be calculated as there were no dropouts due to adverse events in either group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence was uncertain about the effect of dropouts due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by two levels due to very small sample size ( &lt; 50).<br/><sup>c</sup>Downgraded by two levels due to zero events and very small sample size ( &lt; 50). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007662-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Cell signal transducers versus placebo for trichotillomania in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cell signal transducers versus placebo for trichotillomania in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> cell signal transducers </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cell signal transducers versus placebo in adults</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment response</b><sup>a</sup><br/>Clinical Global Impressions ‐ Improvement Scale (CGI‐I) (no. of responders) </p> <p>Follow‐up: 10 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.33</b> <br/>(0.57 to 3.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>38<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was low‐certainty evidence showing no difference in treatment response between the cell signal transducer group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>316 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>420 per 1000</b><br/>(180 to 982) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>316 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>420 per 1000</b><br/>(180 to 983) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><br/>Massachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) </p> <p>Follow‐up: 10 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean MGH‐HPS score for the cell signal transducer intervention group was 13.2.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention groups was<br/><b>1.3 points lower</b><br/>(5.12 lower to 2.52 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was low‐certainty evidence showing no difference in reduction of TTM symptom severity in the cell signal transducer group compared to the placebo group on the MGH‐HPS. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b><br/>Dropout rate<br/>Follow‐up: 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Differences between groups could not be calculated as there were no dropouts due to adverse events in either group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence was uncertain about the effect of dropouts due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by two levels due to wide confidence interval and very small sample size ( &lt; 50).<br/><sup>c</sup>Downgraded by two levels due to zero events and very small sample size ( &lt; 50). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007662-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Glutamate modulators versus placebo for trichotillomania in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Glutamate modulators versus placebo for trichotillomania in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> glutamate modulators </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Glutamate modulators versus placebo in adults</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment response</b><sup>a</sup><br/>Clinical Global Impressions ‐ Improvement Scale (CGI‐I) (no. of responders) </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.5</b> <br/>(1.34 to 9.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>50<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was moderate‐certainty evidence of benefit on the number of participants who responded to treatment in the glutamate modulator group compared to the placebo group in adults. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>560 per 1000</b><br/>(214 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>560 per 1000</b><br/>(214 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><br/>Massachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean MGH‐HPS score for the glutamate modulator intervention group was 10.4.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention groups was<br/><b>5.6 points lower</b><br/>(8.5 to 2.7 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was moderate‐certainty evidence for a reduction of TTM symptom severity in the glutamate modulator group compared to the placebo group on the MGH‐HPS in adults. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b><br/>Dropout rate<br/>Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Differences between groups could not be calculated as there were no dropouts due to adverse events in either group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence was uncertain about the effect of dropouts due to adverse events in adults.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by one level due to small sample size (50 to 400).<br/><sup>c</sup>Downgraded by two levels due to zero events and small sample size (50 to 400). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007662-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Glutamate modulators versus placebo for trichotillomania in children and adolescents</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Glutamate modulators versus placebo for trichotillomania in children and adolescents</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children and adolescents with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> glutamate modulators </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Glutamate modulators versus placebo in children and adolescents</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment response</b><sup>a</sup><br/>Clinical Global Impressions ‐ Improvement Scale (CGI‐I) (no. of responders) </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.19</b> <br/>(0.37 to 3.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>39<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was low‐certainty evidence showing no difference in treatment response between the glutamate modulator group and the placebo group in children and adolescents. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>211 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>251 per 1000</b><br/>(78 to 794) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>211 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>251 per 1000</b><br/>(78 to 795) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><br/>Massachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean MGH‐HPS score for the glutamate modulator intervention group was 10.7.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention groups was<br/><b>2.83 points lower</b><br/>(3.76 to 1.9 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was low‐certainty evidence for a potentially large reduction of TTM symptom severity in the glutamate modulator group compared to the placebo group on the MGH‐HPS in children and adolescents. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b><sup>c</sup><br/>Dropout rate </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.86</b> <br/>(0.12 to 66.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>39<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was low‐certainty evidence showing no difference in dropouts due to adverse events between groups. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 0/19</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 1/20</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 0/19</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 1/20</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by two levels due to very small sample size ( &lt; 50).<br/><sup>c</sup>Numbers presented as raw values for N (events) in study population (intervention and control groups), and not modelled on RR.<br/><sup>d</sup>Downgraded by two levels due to wide confidence interval and very small sample size ( &lt; 50). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007662-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Opioid antagonists versus placebo for trichotillomania in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Opioid antagonists versus placebo for trichotillomania in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> opioid antagonists </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Opioid antagonists versus placebo in adults</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment response</b><sup>a</sup><br/>Clinical Global Impressions ‐ Improvement Scale (CGI‐I) (no. of responders) &amp; NIMH Trichotillomania Severity Scale (NIMH‐TSS) </p> <p>(no. of responders as &gt; 50% reduction)</p> <p>Follow‐up: 6 to 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.14</b> <br/>(0.25 to 18.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>68<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There is very uncertain evidence showing no effect of opioid antagonists on treatment response. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>535 per 1000</b><br/>(62 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>173 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>370 per 1000</b><br/>(43 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><br/>Massachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean MGH‐HPS score for the opioid antagonist intervention group was 12.21.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention groups was<br/><b>1.14 points lower</b><br/>(4.18 lower to 1.9 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was low‐certainty evidence showing no difference in reduction of TTM symptom severity in the opioid antagonist group compared to the placebo group on the MGH‐HPS. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by one level due to moderate heterogeneity (I² = 59%)<br/><sup>c</sup>Downgraded by two levels due to wide confidence interval and small sample size (50 to 400). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007662-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">SSRIs versus placebo for trichotillomania in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>SSRIs versus placebo for trichotillomania in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> SSRIs </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>SSRIs versus placebo in adults</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data available for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><sup>a</sup><br/>Massachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) mean change score </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change of the MGH‐HPS score for the SSRI intervention group was ‐1.5333.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention groups was<br/><b>0.47 points lower</b><br/>(4.3 lower to 3.36 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of SSRIs on reduction of TTM symptom severity on the MGH‐HPS. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b><sup>e</sup><br/>Dropout rate </p> <p>Follow‐up: 6 to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3</b> <br/>(0.33 to 27.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>78<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was low‐certainty evidence showing no difference in dropouts due to adverse events between groups. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 0/39</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 2/39</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 0/39</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 2/39</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by one level due to serious risk of bias. Concerns with attrition bias. Intention‐to‐treat analysis not used. No reasons for attrition given.<br/><sup>c</sup>Downgraded by one level as mean and standard deviations at endpoint were unavailable. Data provided from correspondence were mean change scores from baseline to endpoint.<br/><sup>d</sup>Downgraded by two levels due to wide confidence interval and very small sample size ( &lt; 50).<br/><sup>e</sup>Numbers presented as raw values for N (events) in study population (intervention and control groups), and not modelled on RR.<br/><sup>f</sup>Downgraded by two levels due to wide confidence interval and small sample size (50 to 400). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007662-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">TCAs with predominantly SRI actions versus placebo for trichotillomania in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TCAs with predominantly SRI actions versus placebo for trichotillomania in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> TCAs with predominantly SRI actions </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>TCAs with predominantly SRI actions versus placebo in adults</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment response</b><sup>a</sup><br/>Clinical Global Impressions ‐ Improvement Scale (CG‐I) (no. of responders) </p> <p>Follow‐up: 9 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 5.73</b> <br/>(0.36 to 90.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>16<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The evidence is very uncertain about the effect of TCAs with predominantly SRI actions on treatment response. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><br/>NIMH Trichotillomania Severity Scale (NIMH‐TSS) </p> <p>Follow‐up: 9 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean NIMH‐TSS score for the TCA with predominantly SRI actions intervention group was 9.3. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention group was<br/><b>3 points lower</b><br/>(6.52 lower to 0.52 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of TCAs with predominantly SRI actions on reduction of TTM symptom severity on the NIMH‐TSS. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b><sup>d</sup><br/>Dropout rate </p> <p>Follow‐up: 9 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 4.45</b> <br/>(0.27 to 73.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>16<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The evidence is very uncertain about the effect of TCAs with predominantly SRI actions on dropouts due to adverse events. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 0/6</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 3/10</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 0/6</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 3/10</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by one level due to serious risk of bias. Concerns with attrition bias. Intention‐to‐treat analysis not used, 3 withdrew from clomipramine group due to adverse events. 40% overall attrition rate in clomipramine group.<br/><sup>c</sup>Downgraded by two levels due to wide confidence interval and very small sample size ( &lt; 50).<br/><sup>d</sup>Numbers presented as raw values for N (events) in study population (intervention and control groups), and not modelled on RR. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007662-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">TCAs with predominantly SRI actions versus other TCAs for trichotillomania in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TCAs with predominantly SRI actions versus other TCAs for trichotillomania in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> TCAs with predominantly SRI actions </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>TCAs with predominantly SRI actions versus other TCAs in adults</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment response</b><sup>a</sup><br/>Physician‐rated Clinical </p> <p>Progress Scale</p> <p>Follow‐up: 5 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Physician‐rated Clinical Progress Scale score for the TCA with predominantly SRI actions intervention group was 4.7. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean treatment response in the intervention group was<br/><b>4 points lower</b><br/>(6.13 to 1.87 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was low‐certainty evidence for a beneficial effect on treatment response in the TCAs with predominantly SRI actions group compared to the other TCAs group on the Physician‐rated Clinical Progress Scale. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><br/>NIMH Trichotillomania Severity Scale (NIMH‐TSS) </p> <p>Follow‐up: 5 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean NIMH‐TSS score for the TCA with predominantly SRI actions intervention group was 10.6 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention groups was<br/><b>3.8 points lower</b><br/>(8.08 lower to 0.48 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was low‐certainty evidence of no difference in reduction of TTM symptom severity in the TCAs with predominantly SRI actions group compared to the other TCAs group on the NIMH‐TSS. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b><br/>Dropout rate </p> <p>Follow‐up: 5 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Differences between groups could not be calculated as there were no dropouts due to adverse events in either group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is uncertain about the effect of dropouts due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by two levels due to wide confidence interval and very small sample size ( &lt; 50).<br/><sup>c</sup>Downgraded by two levels due to zero events and very small sample size ( &lt; 50). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007662-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007662-sec-0009"></div> <section id="CD007662-sec-0010"> <h3 class="title" id="CD007662-sec-0010">Description of the condition</h3> <p>Trichotillomania (TTM) is a disorder characterised by recurrent hair‐pulling, resulting in hair loss (<a href="./references#CD007662-bbs2-0033" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-V). 5th edition. Washington (DC): American Psychiatric Association, 2012.">APA 2012</a>). It was first named in 1889 by François Henri Hallopeau, a French dermatologist (<a href="./references#CD007662-bbs2-0056" title="FrançaK , KumarA , CastilloD , JafferanyM , Hyczy da Costa NetoM , DamevskaK , et al. Trichotillomania (hair pulling disorder): clinical characteristics, psychosocial aspects, treatment approaches, and ethical considerations. Dermatologic Therapy2019;32(4):e12622.">França 2019</a>). The introduction of TTM into the <i>Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised (DSM‐III‐R)</i> encouraged treatment studies to proceed. In the <i>DSM‐III‐R,</i> TTM was conceptualised as an impulse‐control disorder not elsewhere classified. TTM, kleptomania, pyromania and other conditions in the category were characterised by failure to resist an impulse, drive or temptation to perform an act that is harmful to the self or others (<a href="./references#CD007662-bbs2-0031" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). 3rd revised edition. Washington (DC): American Psychiatric Association, 1987.">APA 1987</a>). TTM remained under Impulse‐Control Disorders in <i>DSM‐IV</i>. </p> <p>Based on the diagnostic criteria presented in the <i>Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition</i> (<i>DSM‐5</i>) (<a href="./references#CD007662-bbs2-0033" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-V). 5th edition. Washington (DC): American Psychiatric Association, 2012.">APA 2012</a>), a diagnosis of TTM requires that recurrent hair‐pulling must result in hair loss (criterion A). Evidence of an attempt to decrease or stop hair‐pulling must also be present (criterion B). Furthermore, the diagnosis of TTM can be made only if hair‐pulling is not better accounted for by another disorder (e.g. in response to a delusion, or as part of a body dysmorphic disorder) and is not a result of a general medical condition (criterion C). Finally, for a diagnosis of TTM, recurrent hair‐pulling must cause significant distress or impairment of functioning (criterion D). </p> <p>The Trichotillomania Impact Project has emphasised the immense distress and impairment associated with chronic hair‐pulling (<a href="./references#CD007662-bbs2-0114" title="WoodsDW , FlessnerCA , FranklinME , KeuthenNJ , GoodwinRD , SteinDJ , et al, Trichotillomania Learning Center Advisory Board. The Trichotillomania Impact Project (TIP): exploring phenomenology, functional impairment, and treatment utilization. Journal of Clinical Psychiatry2006;67:1877-88.">Woods 2006</a>). People with TTM often have low levels of self‐esteem, low psychosocial functioning and other comorbid psychiatric disorders, especially mood and anxiety disorders (<a href="./references#CD007662-bbs2-0063" title="GrantJE , ChamberlainSR . Trichotillomania. American Journal of Psychiatry2016;173(9):868–74.">Grant 2016</a>; <a href="./references#CD007662-bbs2-0079" title="LochnerC , KeuthenNJ , CurleyEE , TungES , ReddenSA , RickettsEJ , et al. Comorbidity in trichotillomania (hair‐pulling disorder): a cluster analytical approach. Brain and Behavior2019 ;9(12):e01456.">Lochner 2019</a>; <a href="./references#CD007662-bbs2-0104" title="SteinDJ , GrantJE , FranklinME , KeuthenN , LochnerC , SingerHS , et al. Trichotillomania (hair pulling disorder), skin picking disorder, and stereotypic movement disorder: toward DSM-V. Depression and Anxiety2010;27:611-26.">Stein 2010</a>). Other body‐focused repetitive behaviours (BFRBs) are also important comorbidities that may worsen the severity of the primary disorder (<a href="./references#CD007662-bbs2-0063" title="GrantJE , ChamberlainSR . Trichotillomania. American Journal of Psychiatry2016;173(9):868–74.">Grant 2016</a>). Community prevalence studies indicate that TTM is a common disorder with a point prevalence estimate of 0.5% to 2.0% (<a href="./references#CD007662-bbs2-0063" title="GrantJE , ChamberlainSR . Trichotillomania. American Journal of Psychiatry2016;173(9):868–74.">Grant 2016</a>). In recent years, the prevalence of TTM and other BFRBs has been estimated as significantly higher. In a survey of 82 college students, <a href="./references#CD007662-bbs2-0087" title="OdlaugBL , GrantJE . Impulse-control disorders in a college sample: results from the self-administered Minnesota Impulse Disorders Interview (MIDI). Primary Care Companion Journal of Clinical Psychiatry2010;12(2):PCC.09m00842.">Odlaug 2010</a> found a prevalence rate of 3.91% for TTM, and in a large study of 4335 college students, <a href="./references#CD007662-bbs2-0068" title="HoughtonDC , AlexanderJR , BauerCC , WoodsDW . Body-focused repetitive behaviors: more prevalent than once thought?Psychiatry Research2018;270:389-93.">Houghton 2018</a> found that 12.27% of students met criteria for a clinically significant BFRB, including TTM. The onset of TTM is often in childhood (<a href="./references#CD007662-bbs2-0088" title="OdlaugBL , ChamberlainSR , HarvankoAM , GrantJE . Age at onset in trichotillomania: clinical variables and neurocognitive performance. Primary Care Companion to CNS Disorders2012;14(4):PCC.12m01343. [DOI: 10.4088/PCC.12m01343]">Odlaug 2012</a>); thus, it is important to have effective treatments that have been tested in the young age group. </p> <p>Some overlap has been noted between TTM and conditions such as obsessive‐compulsive disorder (OCD) (<a href="./references#CD007662-bbs2-0060" title="GrantJE , OdlaugBL , Potenza, MN. Addicted to hair pulling? How an alternate model of trichotillomania may improve treatment outcome. Harvard Review of Psychiatry2007;15:80-5.">Grant 2007</a>). Many people report that hair‐pulling is preceded by urges, and that hair‐pulling involves ritualistic behaviours redolent of OCD (<a href="./references#CD007662-bbs2-0106" title="SwedoSE , LeonardHL . Trichotillomania: an obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90.">Swedo 1992</a>). Early work suggested that people with TTM and people with OCD respond to selective serotonin reuptake inhibitors (SSRIs) (<a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>). This and related research led to the inclusion of TTM in a new section of <i>DSM‐5,</i> entitled 'Obsessive‐Compulsive and Related Disorders' (OCRD) (<a href="./references#CD007662-bbs2-0033" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-V). 5th edition. Washington (DC): American Psychiatric Association, 2012.">APA 2012</a>), as well as under OCRDs in the BFRB subcategory in the <i>International Classification of Diseases ‐ 11th revision</i> (<i>ICD‐11</i>) (<a href="./references#CD007662-bbs2-0112" title="World Health Organization. International classification of diseases for mortality and morbidity statistics (11th Revision). https://icd.who.int/browse11/l-m/en (accessed prior to 8 September 2021).">WHO 2018</a>). </p> <p>Whilst TTM is currently categorised as an OCRD, there are also important differences between TTM and OCD in symptomatology, as well as in treatment response. TTM is not characterised by obsessive thoughts, and greater overlap may be evident with other obsessive‐compulsive spectrum disorders, such as skin‐picking and tic disorders (<a href="./references#CD007662-bbs2-0104" title="SteinDJ , GrantJE , FranklinME , KeuthenN , LochnerC , SingerHS , et al. Trichotillomania (hair pulling disorder), skin picking disorder, and stereotypic movement disorder: toward DSM-V. Depression and Anxiety2010;27:611-26.">Stein 2010</a>). Findings that TTM responds to low‐dose antipsychotics and not to SSRIs are redolent of findings on the pharmacotherapy of tic disorders (<a href="./references#CD007662-bbs2-0050" title="EddyCM , RickardsHE , CavannaAE . Treatment strategies for tics in Tourette syndrome. Therapeutic Advances in Neurological Disorders 2011;4(1):25-45.">Eddy 2011</a>). Neuroimaging and treatment studies have strengthened the relationship between TTM and tic disorders (<a href="./references#CD007662-bbs2-0075" title="LamotheH , BaleyteJM , MalletL , PelissoloA . Trichotillomania is more related to Tourette disorder than to obsessive-compulsive disorder. Brazilian Journal of Psychiatry2019;42(1):87-104.">Lamothe 2019</a>). The phenomenology and treatment of TTM may be closer to those of tic disorders than OCD; therefore, it may be helpful to consider TTM as a tic disorder in clinical practice (<a href="./references#CD007662-bbs2-0075" title="LamotheH , BaleyteJM , MalletL , PelissoloA . Trichotillomania is more related to Tourette disorder than to obsessive-compulsive disorder. Brazilian Journal of Psychiatry2019;42(1):87-104.">Lamothe 2019</a>). </p> <p>Research on the psychobiology of TTM has increased in recent decades; however, specific mechanisms are yet to be established. A review of the neurobiology of TTM shows that researchers have studied numerous regions of interest in relation to TTM across all cerebral lobes, involving white and grey matter, in cortical and subcortical structures. These include the basal ganglia, amygdala, hippocampus, cerebellum and somatosensory cortex (<a href="./references#CD007662-bbs2-0040" title="ChamberlainSR , OdlaugBL , BoulougourisV , FinebergNA , GrantJE . Trichotillomania: neurobiology and treatment. Neuroscience &amp; Biobehavioral Reviews2009;33(6):831-42.">Chamberlain 2009</a>). White matter tracts involved in habit generation and suppression have also been implicated (<a href="./references#CD007662-bbs2-0063" title="GrantJE , ChamberlainSR . Trichotillomania. American Journal of Psychiatry2016;173(9):868–74.">Grant 2016</a>). In a functional neuroimaging study (N = 10) using single‐photon emission computed tomography (SPECT), 12 weeks of treatment with 20 mg of citalopram, titrated to a maximum dose of 60 mg, was associated with reduced activation in frontal and striatal regions (<a href="./references#CD007662-bbs2-0102" title="SteinDJ , Van HeerdenB , HugoC , Van KradenburgJ , WarwickJ , Zungu-DirwayiN , et al. Functional brain imaging and pharmacotherapy in trichotillomania single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Progress in Neuro-Psychopharmacology and Biological Psychiatry2002;26:885-90.">Stein 2002</a>). </p> <p>Several different pharmacotherapy and psychotherapy interventions have been studied in the treatment of TTM. Medications, cognitive‐behavioural therapy (CBT) and their combination have been studied in a number of randomised controlled trials (RCTs) and meta‐analyses (<a href="./references#CD007662-bbs2-0037" title="BlochMH , Landeros-WeisenbergerA , DombrowskiP , KelmendiB , WegnerR , NudelJ , et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Journal of Biological Psychiatry2007;62:839-46.">Bloch 2007</a>; <a href="./references#CD007662-bbs2-0056" title="FrançaK , KumarA , CastilloD , JafferanyM , Hyczy da Costa NetoM , DamevskaK , et al. Trichotillomania (hair pulling disorder): clinical characteristics, psychosocial aspects, treatment approaches, and ethical considerations. Dermatologic Therapy2019;32(4):e12622.">França 2019</a>; <a href="./references#CD007662-bbs2-0063" title="GrantJE , ChamberlainSR . Trichotillomania. American Journal of Psychiatry2016;173(9):868–74.">Grant 2016</a>; <a href="./references#CD007662-bbs2-0071" title="JafferanyM , PatelA . Therapeutic aspects of trichotillomania: a review of current treatment options. Primary Care Companion to CNS Disorders2018;20(6):18nr02344.">Jafferany 2018</a>; <a href="./references#CD007662-bbs2-0084" title="McGuireJF , UngD , SellesRR , RahmanO , LewinAB , MurphyTK , et al. Treating trichotillomania: a meta-analysis of treatment effects and moderators for behavior therapy and serotonin reuptake inhibitors. Journal of Psychiatric Research2014;58:76-83.">McGuire 2014</a>; <a href="./references#CD007662-bbs2-0090" title="RehmI , MouldingR , NedeljkovicM . Psychological treatments for trichotillomania: update and future directions. Australasian Psychiatry2015;23(4):365-8.">Rehm 2015</a>). Meta‐analysis of clomipramine and other serotonin reuptake inhibitors (SRIs) in TTM found a significant beneficial treatment effect (<a href="./references#CD007662-bbs2-0037" title="BlochMH , Landeros-WeisenbergerA , DombrowskiP , KelmendiB , WegnerR , NudelJ , et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Journal of Biological Psychiatry2007;62:839-46.">Bloch 2007</a>; <a href="./references#CD007662-bbs2-0084" title="McGuireJF , UngD , SellesRR , RahmanO , LewinAB , MurphyTK , et al. Treating trichotillomania: a meta-analysis of treatment effects and moderators for behavior therapy and serotonin reuptake inhibitors. Journal of Psychiatric Research2014;58:76-83.">McGuire 2014</a>). In a more recent meta‐analysis, selective serotonin reuptake inhibitors (SSRIs) were shown to have no benefit, whilst clomipramine demonstrated a benefit in reducing TTM symptoms (<a href="./references#CD007662-bbs2-0054" title="FarhatLC , OlfsonE , NasirM , LevineJL , LiF , MiguelEC , et al. Pharmacological and behavioral treatment for trichotillomania: an updated systematic review with meta‐analysis. Depression and Anxiety2020;37(8):715-27.">Farhat 2020</a>). In terms of psychotherapy specifically, habit‐reversal therapy (HRT) may have efficacy in the treatment of TTM (<a href="./references#CD007662-bbs2-0037" title="BlochMH , Landeros-WeisenbergerA , DombrowskiP , KelmendiB , WegnerR , NudelJ , et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Journal of Biological Psychiatry2007;62:839-46.">Bloch 2007</a>; <a href="./references#CD007662-bbs2-0056" title="FrançaK , KumarA , CastilloD , JafferanyM , Hyczy da Costa NetoM , DamevskaK , et al. Trichotillomania (hair pulling disorder): clinical characteristics, psychosocial aspects, treatment approaches, and ethical considerations. Dermatologic Therapy2019;32(4):e12622.">França 2019</a>; <a href="./references#CD007662-bbs2-0063" title="GrantJE , ChamberlainSR . Trichotillomania. American Journal of Psychiatry2016;173(9):868–74.">Grant 2016</a>; <a href="./references#CD007662-bbs2-0084" title="McGuireJF , UngD , SellesRR , RahmanO , LewinAB , MurphyTK , et al. Treating trichotillomania: a meta-analysis of treatment effects and moderators for behavior therapy and serotonin reuptake inhibitors. Journal of Psychiatric Research2014;58:76-83.">McGuire 2014</a>). These findings are limited by the small number of individual trials, a lack of trials targeted at children and adolescents, a lack of long‐term follow‐up to establish durability of treatment and a lack of acknowledgement of comorbidities (<a href="./references#CD007662-bbs2-0076" title="LeeMT , FinebergNA , MpavaendaDN . Habit reversal therapy in obsessive compulsive related disorders: a systematic review of the evidence and consort evaluation of randomized controlled trials. Frontiers in Behavioral Neuroscience2019;13:79.">Lee 2019</a>). Whilst pharmacotherapy and psychotherapy have both been utilised for the treatment of TTM, this review focuses on medication. </p> </section> <section id="CD007662-sec-0011"> <h3 class="title" id="CD007662-sec-0011">Description of the intervention</h3> <p>Early studies of treatment of TTM in adults focused on the use of antidepressants such as SSRIs (e.g. citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline; <a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0042" title="ChristensonGA , CrowSJ , MitchellJE , MackenzieTB , CrosbyRD . Fluvoxamine in the treatment of trichotillomania. CNS Spectrums1998;3(9):64-71.">Christenson 1998</a>; <a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0057" title="GabrielA . A case of resistant trichotillomania treated with risperidone-augmented fluvoxamine. Canadian Journal of Psychiatry2001 ;46(3):285-6.">Gabriel 2001</a>; <a href="./references#CD007662-bbs2-0058" title="GaddeKM , Wagner RH 2nd, ConnorKM , FoustMS . Escitalopram treatment of trichotillomania. International Clinical Psychopharmacology2007;22(1):39-42.">Gadde 2007</a>; <a href="./references#CD007662-bbs2-0069" title="IancuI , WeizmanA , KindlerS , SassonY , ZoharJ . Serotonergic drugs in trichotillomania. Journal of Nervous and Mental Disease1996;184(10):641-4.">Iancu 1996</a>; <a href="./references#CD007662-bbs2-0074" title="KoranLM , RingoldA , HewlettW . Fluoxetine for trichotillomania: an open clinical trial. Psychopharmacology Bulletin1992;28(22):145-9.">Koran 1992</a>; <a href="./references#CD007662-bbs2-0081" title="MahrG . Fenfluramine and trichotillomania. Psychosomatics1993;34(3):284-84.">Mahr 1993</a>; <a href="./references#CD007662-bbs2-0101" title="StanleyMA , BowersTC , SwannAC , TaylorDJ . Treatment of trichotillomania with fluoxetine. Journal of Clinical Psychiatry1991;52(6):282.">Stanley 1991</a>; <a href="./references#CD007662-bbs2-0021" title="SteinDJ , HollanderE , De CarciaC , CohenL , SimeonD . Behavioural response to m-chlorophenylpiperazine and clonidine in trichotillomania. Journal of Serotonin Research1997;4(1):11-5. ">Stein 1997</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>; <a href="./references#CD007662-bbs2-0113" title="WinchelRM , JonesJS , StanleyB , MolchoA , StanleyM . Clinical characteristics of trichotillomania and its response to fluoxetine. Journal of Clinical Psychiatry1992;53(9):304-8.">Winchel 1992</a>), serotonin‐noradrenaline reuptake inhibitors (SNRIs; e.g. venlafaxine; <a href="./references#CD007662-bbs2-0018" title="NinanPT , KnightB , KirkL , RothbaumBO , KelseyJ , NemeroffCB . A controlled trial of venlaflaxine in trichotillomania: interim phase I results. Psychopharmacology Bulletin1998;34(2):221-4. ">Ninan 1998</a>), and tricyclic antidepressants (TCAs) with predominantly serotonin reuptake inhibitor (SRI) actions (e.g. clomipramine; <a href="./references#CD007662-bbs2-0013" title="BlackDW , BlumN . Trichotillomania treated with clomipramine and a topical steroid. American Journal of Psychiatry1992;149(6):842-3. ">Black 1992</a>; <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>; <a href="./references#CD007662-bbs2-0089" title="PollardCA , IbeIO , KrojankerDN , KitchenAD , BronsonSS , FlynnTM . Clomipramine treatment of trichotillomania: a follow-up report on four cases. Journal of Clinical Psychiatry1991;52(3):128-30.">Pollard 1991</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>). Other traditional psychotropic agents have also been studied, including antipsychotic agents (e.g. haloperidol, olanzapine, quetiapine, risperidone; <a href="./references#CD007662-bbs2-0053" title="EppersonCN , FasulaD , WasylinkS , PriceLH , McDougleCJ . Risperidone addition in serotonin reuptake inhibitor-resistant trichotillomania: three cases. Journal of Child and Adolescent Psychopharmacology1999;9(1):43-9.">Epperson 1999</a>; <a href="./references#CD007662-bbs2-0094" title="SentürkV , TanriverdiN . Resistant trichotillomania and risperidone. Psychosomatics2002;43(5):429-30.">Sentürk 2002</a>; <a href="./references#CD007662-bbs2-0108" title="Van AmeringenM , ManciniC , OakmanJM , FarvoldenP . The potential role of haloperidol in the treatment of trichotillomania. Journal of Affective Disorders1999;56:219-26.">Van Ameringen 1999</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>; <a href="./references#CD007662-bbs2-0111" title="WhiteMP , KoranLM . Open-label trial of aripiprazole in the treatment of trichotillomania. Journal of Clinical Psychopharmacology2011;31(4):503-6.">White 2011</a>; <a href="./references#CD007662-bbs2-0115" title="Yasui-FurukoriN , KanekoS . The efficacy of low-dose aripiprazole treatment for trichotillomania. Clinical Neuropharmacology2011;34(6):258-9.">Yasui‐Furukori 2011</a>), mood stabilisers (e.g. lithium; <a href="./references#CD007662-bbs2-0095" title="SharmaV , CorpseC . Lithium treatment of trichotillomania with comorbid bipolar II disorder. Archives of Women's Mental Health2008;11(4):305-6.">Sharma 2008</a>), anticonvulsant agents (e.g. gabapentin, lamotrigine, levetiracetam, tiagabine, topiramate; <a href="./references#CD007662-bbs2-0027" title="AdewuyaEC , ZinserW , ThomasC . Trichotillomania: a case of response to valproic acid. Journal of Child and Adolescent Psychopharmacology2008;18(5):533-6.">Adewuya 2008</a>; <a href="./references#CD007662-bbs2-0077" title="LeombruniP , GastaldiF . Oxcarbazepine for the treatment of trichotillomania. Clinical Neuropharmacology2010;33(2):107-8.">Leombruni 2010</a>; <a href="./references#CD007662-bbs2-0078" title="LochnerC , SeedatS , NiehausDJ , SteinDJ . Topiramate in the treatment of trichotillomania: an open-label pilot study. International Clinical Psychopharmacology2006;21(5):255-9.">Lochner 2006</a>), opioid antagonists (e.g. naltrexone; <a href="./references#CD007662-bbs2-0047" title="De SousaA . An open-label pilot study of naltrexone in childhood-onset trichotillomania. Journal of Child and Adolescent Psychopharmacology2008;18(1):30-3.">De Sousa 2008</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>), and other antidepressants such as bupropion (<a href="./references#CD007662-bbs2-0073" title="KlipsteinKG , BermanL . Bupropion XL for the sustained treatment of trichotillomania. Journal of Clinical Psychopharmacology2012;32(2):298-9.">Klipstein 2012</a>). More recent studies have investigated a range of different agents from other classes such as cell signal transducers (e.g. inositol; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>), cannabinoids (e.g. dronabinol; <a href="./references#CD007662-bbs2-0061" title="GrantJE , OdlaugBL , ChamberlainSR , KimSW . Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: a pilot study. Psychopharmacology2011;218(3):493-502.">Grant 2011</a>), and antioxidants (e.g. silymarin; <a href="./references#CD007662-bbs2-0062" title="GrantJE , OdlaugBL . Silymarin treatment of obsessive-compulsive spectrum disorders. Journal of Clinical Psychopharmacology2015;35(3):340-2.">Grant 2015</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>). In particular, the use of N‐acetylcysteine (NAC), a glutamate modulator, has been increasingly examined in recent years in adults and children, with varying results (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0055" title="FrançaK , LottiT . N‐acetyl cysteine in the treatment of trichotillomania. Dermatologic Therapy2017;30(3):e12446.">França 2017</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0086" title="OdlaugBL , GrantJE . N-acetyl cysteine in the treatment of grooming disorders. Journal of Clinical Psychopharmacology2007;27(2):227-9.">Odlaug 2007</a>; <a href="./references#CD007662-bbs2-0092" title="Rodrigues-BarataAR , TostiA , Rodríguez-PichardoA , Camacho-MartínezF . N-acetylcysteine in the treatment of trichotillomania. International Journal of Trichology2012;4(3):176.">Rodrigues‐Barata 2012</a>; <a href="./references#CD007662-bbs2-0097" title="Silva-NettoR , JesusG , NogueiraM , TavaresH . N-acetylcysteine in the treatment of skin-picking disorder. Brazilian Journal of Psychiatry2014;36(1):101.">Silva‐Netto 2014</a>; <a href="./references#CD007662-bbs2-0105" title="StewartRS , NejtekVA . An open-label, flexible dose study of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2003;64(1):49-52.">Stewart 2003</a>; <a href="./references#CD007662-bbs2-0107" title="TaylorM , BhagwandasK . N‐acetylcysteine in trichotillomania: a panacea for compulsive skin disorders?British Journal of Dermatology2014;171(5):1253-5.">Taylor 2014</a>). </p> <p>Few studies examine the effects of medication specifically in children and adolescents under 18 years old (<a href="./references#CD007662-bbs2-0027" title="AdewuyaEC , ZinserW , ThomasC . Trichotillomania: a case of response to valproic acid. Journal of Child and Adolescent Psychopharmacology2008;18(5):533-6.">Adewuya 2008</a>; <a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0047" title="De SousaA . An open-label pilot study of naltrexone in childhood-onset trichotillomania. Journal of Child and Adolescent Psychopharmacology2008;18(1):30-3.">De Sousa 2008</a>; <a href="./references#CD007662-bbs2-0017" title="GolubchikP , SeverJ , WeizmanA , ZalsmanG . Methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder and comorbid trichotillomania: a preliminary report. Clinical Neuropharmacology2011;34(3):108-10. ">Golubchik 2011</a>). To date, NAC is the only drug studied under randomised, placebo‐controlled conditions in children and adolescents with TTM (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>). Naltrexone has shown promising results in an open‐label pilot study in children with TTM (<a href="./references#CD007662-bbs2-0047" title="De SousaA . An open-label pilot study of naltrexone in childhood-onset trichotillomania. Journal of Child and Adolescent Psychopharmacology2008;18(1):30-3.">De Sousa 2008</a>). Valproic acid has also shown good results, albeit in a single case study (<a href="./references#CD007662-bbs2-0027" title="AdewuyaEC , ZinserW , ThomasC . Trichotillomania: a case of response to valproic acid. Journal of Child and Adolescent Psychopharmacology2008;18(5):533-6.">Adewuya 2008</a>). </p> </section> <section id="CD007662-sec-0012"> <h3 class="title" id="CD007662-sec-0012">How the intervention might work</h3> <p>Several functional pathways have been hypothesised to be involved in TTM, involving affect regulation, behavioural addiction and cognitive control (<a href="./references#CD007662-bbs2-0103" title="SteinDJ , ChamberlainSR , FinebergN . An ABC model of habit disorders: hair-pulling, skin-picking, and other stereotypic conditions. CNS Spectrums2006;11(11):824-7.">Stein 2006</a>). Certain neuroanatomical structures, including areas of the basal ganglia, amygdala, hippocampus, cerebellum and somatosensory cortex, have also been implicated (<a href="./references#CD007662-bbs2-0040" title="ChamberlainSR , OdlaugBL , BoulougourisV , FinebergNA , GrantJE . Trichotillomania: neurobiology and treatment. Neuroscience &amp; Biobehavioral Reviews2009;33(6):831-42.">Chamberlain 2009</a>). These in turn may involve multiple neurotransmitter systems, including the monoaminergic (serotonergic, dopaminergic, noradrenergic), aminergic (glutamatergic, GABAergic) and others (opioid, cannabinoid). </p> <p>SSRIs, such as fluoxetine and citalopram, are strongly serotonergic and have little effect on dopamine and noradrenaline reuptake. Inhibiting the reuptake of serotonin from the synaptic cleft leads to increased serotonergic neurotransmission, and clinical efficacy is observed at 70% to 80% serotonin receptor occupancy (<a href="./references#CD007662-bbs2-0100" title="StahlSM . Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd edition. Cambridge (UK): Cambridge University Press, 2008.">Stahl 2008</a>). TCAs, such as amitriptyline, also exhibit their effect through inhibiting the reuptake of catecholamines, such as noradrenaline and serotonin (<a href="./references#CD007662-bbs2-0100" title="StahlSM . Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd edition. Cambridge (UK): Cambridge University Press, 2008.">Stahl 2008</a>). Within this class, clomipramine exhibits predominantly serotonin reuptake inhibition, whilst other agents, such as desipramine, exhibit predominantly noradrenaline reuptake inhibition. SNRIs, such as venlafaxine, exhibit both serotonin and noradrenaline reuptake inhibition properties, increasing the activity of both of these monoamines in the brain. </p> <p>In contrast, antipsychotics, such as olanzapine, are antagonists at certain dopamine and serotonin receptors, thereby modulating downstream effects of these monoamines (<a href="./references#CD007662-bbs2-0100" title="StahlSM . Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd edition. Cambridge (UK): Cambridge University Press, 2008.">Stahl 2008</a>). Mood stabilisers (e.g. lithium) and anticonvulsants, such as gabapentin and lamotrigine, invariably decrease glutamatergic neurotransmission or increase GABAergic activity, resulting in a generalised reduction of cerebral activity (<a href="./references#CD007662-bbs2-0100" title="StahlSM . Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd edition. Cambridge (UK): Cambridge University Press, 2008.">Stahl 2008</a>). </p> <p>Glutamatergic dysfunction in an area of the reward circuitry, the nucleus accumbens, has been implicated in the pathogenesis of OCD (<a href="./references#CD007662-bbs2-0039" title="ChakrabartyK , BhattacharyyaS , ChristopherR , KhannaS . Glutamatergic dysfunction in OCD. Neuropsychopharmacology2005;30(9):1735-40.">Chakrabarty 2005</a>). This region is thought to play a role in other conditions for which impulse‐control and compulsive behaviours are predominant features, including TTM. The glutamate modulator NAC increases synaptic glutamate concentrations and stimulates inhibitory metabotropic glutamate receptors to restore glutamatergic homeostasis (<a href="./references#CD007662-bbs2-0034" title="BakerDA , McFarlandK , LakeRW , ShenH , TodaS , KalivasPW . N‐acetyl cysteine‐induced blockade of cocaine‐induced reinstatement. Annals of the New York Academy of Sciences2003;1003(1):349-51.">Baker 2003a</a>). Cannabinoid agonists, such as dronabinol, may also exert their effect by modulating glutamatergic neurotransmission in the basal ganglia and mesolimbic reward system (<a href="./references#CD007662-bbs2-0061" title="GrantJE , OdlaugBL , ChamberlainSR , KimSW . Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: a pilot study. Psychopharmacology2011;218(3):493-502.">Grant 2011</a>; <a href="./references#CD007662-bbs2-0109" title="Van der SteltM , Di MarzoV . Cannabinoid receptors and their role in neuroprotection. Neuromolecular Medicine2005;7(1-2):37-50.">Van der Stelt 2005</a>). </p> <p>Opioid antagonists, such as naltrexone, may be useful in the treatment of substance‐use disorders, possibly by inhibiting the sensation of reward associated with the addictive behaviour. It has been proposed that opioid antagonists may also be beneficial in the treatment of other disorders characterised by repetitive behaviours by modulating mesolimbic dopamine (<a href="./references#CD007662-bbs2-0070" title="IkemotoS . Brain reward circuitry beyond the mesolimbic dopamine system: a neurobiological theory. Neuroscience &amp; Biobehavioral Reviews2010;35(2):129-50.">Ikemoto 2010</a>). </p> <p>Inositol is an intracellular, carbocyclic sugar and a component of the phosphatidyl inositol second messenger system linked to serotonin, dopamine and glutamate metabolism (<a href="./references#CD007662-bbs2-0038" title="CamfieldDA , SarrisJ , BerkM . Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidence. Progress in Neuro-Psychopharmacology and Biological Psychiatry2011;35(4):887-95.">Camfield 2011</a>). Silymarin is a milk thistle derivative with antioxidant and anti‐inflammatory properties, which may have a beneficial effect on dopamine functioning (<a href="./references#CD007662-bbs2-0080" title="LuP , MamiyaT , LuL , MouriA , NiwaM , KimHC , et al. Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment. Behavioural Brain Research2010;207(2):387-93.">Lu 2010</a>). </p> <p>Thus, it is possible that medications may target hypothesised mechanisms (e.g. altering the reward system), reducing hair‐pulling, or may be effective by addressing comorbid depression and OCD. Further work is needed to fully understand the mechanisms underlying TTM and how medication may be effectively utilised. </p> </section> <section id="CD007662-sec-0013"> <h3 class="title" id="CD007662-sec-0013">Why it is important to do this review</h3> <p>Previous reviews of pharmacological treatment for TTM concluded that no consistent and robust evidence supports the efficacy of any pharmacological agent in the treatment of TTM (<a href="./references#CD007662-bbs2-0037" title="BlochMH , Landeros-WeisenbergerA , DombrowskiP , KelmendiB , WegnerR , NudelJ , et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Journal of Biological Psychiatry2007;62:839-46.">Bloch 2007</a>; <a href="./references#CD007662-bbs2-0063" title="GrantJE , ChamberlainSR . Trichotillomania. American Journal of Psychiatry2016;173(9):868–74.">Grant 2016</a>; <a href="./references#CD007662-bbs2-0084" title="McGuireJF , UngD , SellesRR , RahmanO , LewinAB , MurphyTK , et al. Treating trichotillomania: a meta-analysis of treatment effects and moderators for behavior therapy and serotonin reuptake inhibitors. Journal of Psychiatric Research2014;58:76-83.">McGuire 2014</a>; <a href="./references#CD007662-bbs2-0117" title="RothbartR , AmosT , SiegfriedN , IpserJC , FinebergN , ChamberlainSR , et al. Pharmacotherapy for trichotillomania. Cochrane Database of Systematic Reviews2013, Issue 11. Art. No: CD007662. [DOI: 10.1002/14651858.CD007662.pub2]">Rothbart 2013</a>). As a number of additional trials have been published in recent years, an updated systematic review of medication for TTM is timely. A systematic synthesis of treatment data can also serve as the basis for future treatment guidelines, whilst assisting clinicians in effectively managing this disorder and identifying gaps in the current research base. </p> <p>The authors updated the systematic review of RCTs of the pharmacotherapy of TTM, incorporating additional published trials, adding Summary of Findings tables and quality assessment according to GRADE, which have been added to Cochrane's standards since the initial publication. These were included as per Cochrane guidelines and using Cochrane software (<a href="./references#CD007662-bbs2-0067" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>; <a href="./references#CD007662-bbs2-0091" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre,The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007662-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007662-sec-0014"></div> <p>To assess the effects of medication for TTM in adults, children and adolescents compared with placebo or other medication. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007662-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007662-sec-0015"></div> <section id="CD007662-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007662-sec-0017"> <h4 class="title">Types of studies</h4> <p>All published and unpublished RCTs, including studies with multiple treatment groups, cross‐over trials and cluster‐randomised controlled trials (cluster‐RCTs), were considered for inclusion in the review. We excluded pseudo‐randomised trials in the interest of minimising bias. </p> </section> <section id="CD007662-sec-0018"> <h4 class="title">Types of participants</h4> <section id="CD007662-sec-0019"> <h5 class="title">Participant characteristics</h5> <p>We included participants meeting the <i>DSM‐III‐R</i> (<a href="./references#CD007662-bbs2-0030" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 3rd edition. Washington (DC): American Psychiatric Press, 1980.">APA 1980</a>) (or later) criteria for TTM in this review. We did not exclude trials consisting of participants who failed to satisfy the criteria of tension preceding the onset of hair‐pulling (criterion B) and pleasure, gratification or relief following hair‐pulling (criterion C), as people without these symptoms may nevertheless present with clinically significant hair‐pulling (<a href="./references#CD007662-bbs2-0041" title="ChristensonGA , PyleRL , MitchellJE . Estimated lifetime prevalence of trichotillomania in college students. Journal of Clinical Psychiatry1991;52(10):415-7.">Christenson 1991b</a>; <a href="./references#CD007662-bbs2-0049" title="Du ToitPL , Van KradenburgJ , NiehausDJ , SteinDJ . Characteristics and phenomenology of hair-pulling: an exploration of subtypes. Comprehensive Psychiatry2001;42(3):247-56.">Du Toit 2001</a>). </p> <p>We applied no restrictions in terms of age, gender or ethnicity.</p> </section> <section id="CD007662-sec-0020"> <h5 class="title">Comorbidities</h5> <p>We did not exclude participants with other comorbid psychiatric conditions.</p> </section> <section id="CD007662-sec-0021"> <h5 class="title">Setting</h5> <p>We placed no restrictions on study setting.</p> </section> <section id="CD007662-sec-0022"> <h5 class="title">Subsets of participants</h5> <p>Trials that included a subset of participants and met study inclusion criteria were also included in the analysis. </p> </section> </section> <section id="CD007662-sec-0023"> <h4 class="title">Types of interventions</h4> <section id="CD007662-sec-0024"> <h5 class="title">Experimental interventions</h5> <p>For conducting searches and considering studies for inclusion in the review, we grouped specific medication interventions according to medication class. We included trials of medications in any of the following classes. </p> <p> <ul id="CD007662-list-0001"> <li> <p>Antioxidants (e.g. silymarin).</p> </li> <li> <p>Anticonvulsants (e.g. gabapentin, lamotrigine, levetiracetam, tiagabine, topiramate).</p> </li> <li> <p>Antipsychotics (e.g. haloperidol, olanzapine, quetiapine, risperidone).</p> </li> <li> <p>Benzodiazepines (e.g. alprazolam, bromazepam, clonazepam).</p> </li> <li> <p>Cell signal transducers (e.g. inositol).</p> </li> <li> <p>Glutamate modulators (e.g. N‐acetylcysteine (NAC)).</p> </li> <li> <p>Monoamine oxidase inhibitors (MAOIs) (e.g. brofaromine, moclobemide, phenelzine).</p> </li> <li> <p>Mood stabilisers (e.g. lithium).</p> </li> <li> <p>Opioid antagonists (e.g. naltrexone).</p> </li> <li> <p>Selective serotonin reuptake inhibitors (SSRIs) (e.g. citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline). </p> </li> <li> <p>Serotonin‐noradrenaline reuptake inhibitors (SNRIs) (e.g. venlafaxine).</p> </li> <li> <p>Tricyclic antidepressants (TCAs) with predominantly SRI actions (e.g. clomipramine).</p> </li> <li> <p>Other TCAs (e.g. amitriptyline, desipramine, imipramine).</p> </li> </ul> </p> </section> <section id="CD007662-sec-0025"> <h5 class="title">Control conditions</h5> <p>Placebo or any agent in the medication classes listed above, or both.</p> </section> </section> <section id="CD007662-sec-0026"> <h4 class="title">Types of outcome measures</h4> <section id="CD007662-sec-0027"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007662-list-0002"> <li> <p><b>Treatment response:</b> response to treatment determined using the Clinical Global Impressions‐Improvement item (CGI‐I, a widely‐used scale ranging from 1 = ‘very much improved’ to 7 = ‘very much worse’), used as a dichotomous measure of treatment response in which responders are defined as having a change item score of 1 = ‘very much improved’ or 2 = ‘much improved’ (<a href="./references#CD007662-bbs2-0064" title="GuyW . ECDEU Assessment Manual for Psychopharmacology. Washington (DC): US National Institute of Health, 1976.">Guy 1976</a>). Where both dichotomous and continuous data for the CGI‐I were presented, we included only the categorical measure of ‘responders’ versus ‘non‐responders’. Where CGI‐I was not employed, we used other dichotomous measures of treatment response as reported in the original publication. Where no dichotomous measure was available, we report a continuous measure. </p> </li> <li> <p><b>Reduction of TTM symptom severity:</b> reduction in TTM symptom severity based on outcome measures such as the Massachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) (<a href="./references#CD007662-bbs2-0072" title="KeuthenNJ , O’SullivanRL , RicciardiJN , SheraD , SavageCR , BorgmannAS , et al. The Massachusetts General Hospital (MGH) hairpulling scale: 1. development and factor analyses. Psychotherapy and Psychosomatics1995;64(3-4):141-5.">Keuthen 1995</a>), or similar, where available. The MGH‐HPS is a seven‐item, self‐report scale that rates urges to pull hair, actual amount of pulling, perceived control over behaviour and distress associated with hair‐pulling over the past seven days on a severity scale from 0 to 4 for each item (total scores range from 0 to 28, with higher scores reflecting greater illness severity). Clinician‐rated scales such as the National Institute for Mental Health ‐ Trichotillomania Severity and Impact Scales (NIMH‐TSS and NIMH‐TIS) are also reported where available. The NIMH‐TSS is a six‐item assessment, with total scores ranging from 0 to 20. Higher scores indicate greater severity or impairment. Where multiple scales were used within a study, we report on all for which data are available in the main text and data analysis. For the summary of findings tables, we prioritise reporting MGH‐HPS as a well‐validated scale for use in TTM, although it is a self‐report scale. </p> </li> </ul> </p> </section> <section id="CD007662-sec-0028"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007662-list-0003"> <li> <p><b>Reduction of comorbid symptoms of depression:</b> reduction in comorbid symptoms of depression quantified by the widely‐used Beck Depression Inventory scale (BDI: <a href="./references#CD007662-bbs2-0036" title="BeckAT , WardC , MendelsonM . Beck Depression Inventory (BDI). Archives of General Psychiatry1961;4:561-71.">Beck 1961</a>), Hamilton Depression Rating scale (HAM‐D: <a href="./references#CD007662-bbs2-0065" title="HamiltonM . A rating scale for depression. Journal of Neurology, Neurosurgery &amp; Psychiatry1960;23:56-62.">Hamilton 1960</a>), or Montgomery‐Asberg Depression Rating Scale (MADRS: <a href="./references#CD007662-bbs2-0085" title="MontgomerySA , AsbergM . A new depression scale designed to be sensitive to change. British Journal of Psychiatry1979;134:382-9.">Montgomery 1979</a>). The Hamilton Depression scale (HAM‐D) is a multiple‐item questionnaire with 17 to 29 items (depending on the version). People are rated on a 3‐ or 5‐point scale. A score of 0 to 7 is considered to be normal, and a score of 20 or higher, is moderate, severe or very severe. The Beck Depression Inventory (BDI) is a 21‐question multiple‐choice self‐report, one of the most widely‐used psychometric tests for measuring the severity of depression. A score of 0 to 9 indicates minimal depression, 10 to 18 mild depression, 19 to 29 moderate depression, and 30 to 63 severe depression. The MADRS is a 10‐item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in people with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Usual cutoff points are 0 to 6 ‐ normal/symptom absent; 7 to 19 – mild depression; 20 to 34 ‐ moderate depression; and above 34 – severe depression. Where multiple scales were used within one study, we report only one of them on a hierarchical basis, reporting HAM‐D if available, then BDI, MADRS or any other measure available. Where no data were available, and this was not an outcome of interest in the primary study, we do not report on this outcome. </p> </li> <li> <p><b>Tolerability of treatment:</b> tolerability of treatment using the following surrogate measures of medication acceptability. Where no data were available, and these were not outcomes of interest in the primary study, we do not report on these outcomes. </p> <ul id="CD007662-list-0004"> <li> <p><b>Dropouts due to adverse events:</b> total proportion of people who withdrew from RCTs because of adverse events. </p> </li> <li> <p><b>Common adverse events ( &gt; 20%):</b> most common drug‐related adverse events (&gt; 20% of participants given the medication affected), as well as significant differences between medication and control groups in the occurrence of drug‐related adverse events. We do not report statistics for adverse events affecting less than 20% of participants but report the rates where available. </p> </li> </ul> </li> <li> <p><b>Quality of life ‐ functional disability:</b> quality of life measures, such as the Quality of Life Enjoyment and Satisfaction Questionnaire (Q‐LES‐Q: <a href="./references#CD007662-bbs2-0052" title="EndicottJ , NeeJ , HarrisonW , BlumenthalR . Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacology Bulletin1993;29(2):321-6.">Endicott 1993</a>), as well as measures of functional disability, such as the Sheehan Disability Scale (SDS: <a href="./references#CD007662-bbs2-0096" title="SheehanDV , Harnett-SheehanK , RajBA . The measurement of disability. International Clinical Psychopharmacology1996;11(Suppl 3):89-95.">Sheehan 1996</a>, which includes subscales that assess impairment related to work, social life and family), were included when provided. The Sheehan Disability Scale is a composite of three self‐rated items designed to measure the extent to which three major sectors in an individual's life are impaired by panic, anxiety, phobic or depressive symptoms. The person rates the extent to which his or her work, social life or leisure activities, and home life or family responsibilities are impaired by his or her symptoms on a 10‐point visual analogue scale. The numerical ratings of 0 to 10 can be translated into a percentage if desired. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The Q‐LES‐Q is a lengthy, 90‐item questionnaire that assesses eight domains of life quality: physical health, subjective feelings, work, household duties, school, leisure activities, social relationships, and general activities. Where multiple scales were used within one study, we report only one of them on a hierarchical basis, reporting SDS if available; otherwise, we report Q‐LES‐Q or any other available measure. Where no data were available, and this was not an outcome of interest in the primary study, we do not report on this outcome. </p> </li> </ul> </p> </section> <section id="CD007662-sec-0029"> <h5 class="title">Timing of outcome assessment</h5> <p>When studies reported response rates from baseline at various time points of the trial, treatment indices were subdivided as follows. </p> <p> <ul id="CD007662-list-0005"> <li> <p>Early response – between one and four weeks; the time point closest to two weeks was given preference. </p> </li> <li> <p>Acute phase treatment response – between 6 and 12 weeks; the time point as stated in the original study as the trial endpoint was given preference. </p> </li> <li> <p>Follow‐up response – between four and six months; the time point closest to 24 weeks was given preference. </p> </li> </ul> </p> <p>The acute phase treatment response – that is between 6 and 12 weeks from baseline – was our primary outcome of interest. </p> </section> </section> </section> <section id="CD007662-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <p>We applied no date or language restrictions to the search for RCTs in any of the sources listed below. </p> <section id="CD007662-sec-0031"> <h4 class="title">Electronic searches</h4> <p>An information specialist with the Cochrane Common Mental Disorders (CCMD) group ran searches on the following databases and international trial registers. The search strategies are reported in <a href="./appendices#CD007662-sec-0186">Appendix 1</a>. </p> <p> <ul id="CD007662-list-0006"> <li> <p>Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR) (all available years) (archived database, current to June 2016). </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2020, Issue 11) in the Cochrane Library (searched 26 November 2020). </p> </li> <li> <p>MEDLINE Ovid (1946 to 26 November 2020).</p> </li> <li> <p>Embase Ovid (1974 to 26 November 2020).</p> </li> <li> <p>PsycINFO Ovid (from 1806 to 26 November 2020).</p> </li> <li> <p>Proquest Dissertations and Thesis Database (PQDT) (all available years, searched 26 November 2020). </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 26 November 2020). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>; searched 2 December 2019). </p> </li> </ul> </p> <p>We ran additional searches on the following databases, using a single term 'trichotillomania', unless otherwise stated. </p> <p> <ul id="CD007662-list-0007"> <li> <p>CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature; 1982 to 21 January 2021). </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database; 1982 to 21 January 2021) (search: 'trichotillomania' or 'tricotilomania')<i>.</i> </p> </li> <li> <p>African Index Medicus (all available years, searched 21 January 2021).</p> </li> <li> <p>Informit Health Collection (Australia) (1970 to 2020) (searched 21 January 2021).</p> </li> <li> <p>Index Medicus for the Eastern Mediterranean Region (1984 to 2020) (searched 21 January 2021). </p> </li> <li> <p>IndMed (India) (1985 to 2020) (searched 21 January 2021).</p> </li> <li> <p>KoreaMed (1997 to 2020) (searched 21 January 2021).</p> </li> <li> <p>Ukraine and the Russian Federation – Panteleimon (1998 to 2020) (searched 21 January 2021). </p> </li> <li> <p>Western Pacific Region Index Medicus (all available years, searched 21 January 2021).</p> </li> </ul> </p> <p>We also ran an update of the international trial registers at this time.</p> <p> <ul id="CD007662-list-0008"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 21 January 2021); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>; searched 21 January 2021). </p> </li> </ul> </p> <p>Searches conducted for the previous version of the review, <a href="./references#CD007662-bbs2-0117" title="RothbartR , AmosT , SiegfriedN , IpserJC , FinebergN , ChamberlainSR , et al. Pharmacotherapy for trichotillomania. Cochrane Database of Systematic Reviews2013, Issue 11. Art. No: CD007662. [DOI: 10.1002/14651858.CD007662.pub2]">Rothbart 2013</a>, are reported in <a href="./appendices#CD007662-sec-0187">Appendix 2</a>.<br/>  </p> </section> <section id="CD007662-sec-0032"> <h4 class="title">Searching other resources</h4> <section id="CD007662-sec-0033"> <h5 class="title">Reference lists</h5> <p>We scanned the bibliographies of all identified trials for additional studies.</p> </section> <section id="CD007662-sec-0034"> <h5 class="title">Correspondence</h5> <p>We obtained published and unpublished trials from key researchers, as identified by the frequency with which they are cited in the bibliographies of RCTs and open‐label studies. </p> </section> <section id="CD007662-sec-0035"> <h5 class="title">Grey literature searches</h5> <p>One review author (JH) performed a search of the following sources of grey literature, theses databases and conference abstracts (all available years to 21 January 2021). </p> <p> <ul id="CD007662-list-0009"> <li> <p>OpenGrey (previously OpenSIGLE) (<a href="http://greynet.org/" target="_blank">greynet.org/</a>). </p> </li> <li> <p>Healthcare Management Information Consortium (HMIC; <a href="https://elh.nhs.wales/databases/databases/health-management-information-consortium-hmic/" target="_blank">elh.nhs.wales/databases/databases/health-management-information-consortium-hmic/</a>) (Ovid). </p> </li> <li> <p>National Technical Information Service (<a href="https://www.ntis.gov/" target="_blank">www.ntis.gov/</a>). </p> </li> <li> <p>Psycextra (<a href="https://www.apa.org/pubs/databases/psycextra" target="_blank">www.apa.org/pubs/databases/psycextra</a>). </p> </li> </ul> </p> <p>Theses databases</p> <p> <ul id="CD007662-list-0010"> <li> <p>Open Access Theses and Dissertations (<a href="https://oatd.org/" target="_blank">oatd.org/</a>). </p> </li> <li> <p>DART – Europe e‐theses portal (<a href="https://www.dart-europe.org/basic-search.php" target="_blank">www.dart-europe.org/basic-search.php</a>). </p> </li> <li> <p>Networked Digital Library of Theses and Dissertations (<a href="http://www.ndltd.org/" target="_blank">www.ndltd.org/</a>). </p> </li> </ul> </p> <p>Conference abstracts</p> <p> <ul id="CD007662-list-0011"> <li> <p>Abstracts of the American Psychiatric Association (APA) Annual Meeting (<a href="https://www.psychiatry.org/psychiatrists/search-directories-databases/library-and-archive" target="_blank">www.psychiatry.org/psychiatrists/search-directories-databases/library-and-archive</a>); </p> </li> <li> <p>European College of Neuropsychopharmacology Annual Meeting (<a href="https://www.ecnp.eu/" target="_blank">www.ecnp.eu/</a>; abstracts published in <i>European Neuropsychopharmacology</i>). </p> </li> </ul> </p> <p>We also searched the following pharmaceutical industry trial registers: AstraZeneca; Bristol‐Myers Squibb; Eli Lilly; GlaxoSmithKline; Novartis; Roche and Pfizer/Wyeth. </p> <p>Finally, we conducted a forwards citation search on the Web of Science (reports of included studies) to identify any additional research. </p> </section> </section> </section> <section id="CD007662-sec-0036"> <h3 class="title" id="CD007662-sec-0036">Data collection and analysis</h3> <p>We used Review Manager 5 (RevMan 5) to perform all analyses reported in this review (<a href="./references#CD007662-bbs2-0091" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre,The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> <section id="CD007662-sec-0037"> <h4 class="title">Selection of studies</h4> <p>Two review authors (JH, TW) independently examined the titles and abstracts of all studies obtained through the search strategy. The same two review authors obtained and independently assessed the full texts of relevant articles that appeared to meet the inclusion criteria. Each review author then independently applied the full eligibility criteria for inclusion in the review to the full‐text articles. Any conflicts of opinion were discussed, and arbitrated by another review author (DJS) if necessary, until consensus was reached. </p> </section> <section id="CD007662-sec-0038"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (JH, TW) independently collected data. We resolved any disagreements regarding the data collection procedures through discussion with a third review author (DJS). We created digital data extraction sheets for the purpose of manually recording descriptive information, summary statistics of the outcomes, quality scale ratings and associated commentary. We used Google Forms to set up a data extraction tool to streamline data extraction and entry directly into Excel (example at <a href="https://forms.gle/zqgpAics3PB6q7ud6" target="_blank">forms.gle/zqgpAics3PB6q7ud6</a>). A script was written in Python using the Spyder IDE (version 3.3.6) to aid extraction of trial data housed as XML on ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>). Where available, we compared trial information to published data. Once collated, we entered data into Review Manager 5 (RevMan 5) software, which was used to conduct the meta‐analysis. We contacted investigators by email to try to obtain missing information. No reports required translation. </p> <p>We collected the following information from each included study.</p> <p> <ul id="CD007662-list-0012"> <li> <p>Description of the trial, including the primary researcher, year of publication, trial protocol identification, number of centres involved, country where the research was conducted and the source of funding. </p> </li> <li> <p>Characteristics of the intervention, including the number of participants randomly assigned to the treatment and control groups, the total number of dropouts per group and the number who dropped out because of adverse effects. </p> </li> <li> <p>Characteristics of trial methodology, including the recruitment process, diagnostic (e.g. <i>DSM‐IV</i> (<a href="./references#CD007662-bbs2-0032" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 4th text revision edition. Washington (DC): American Psychiatric Association, 2000.">APA 2000</a>)) and exclusionary criteria employed, the screening instrument used (e.g. the Structured Clinical Interview for <i>DSM‐IV</i> (SCID) (<a href="./references#CD007662-bbs2-0099" title="SpitzerR , WilliamsJ , GibbonsM . Instructional Manual for the Structured Clinical Interview for DSM-IV. New York (NY): New York State Psychiatric Institute, 1996.">Spitzer 1996</a>)) for the primary and comorbid diagnoses, the presence of comorbid major depressive disorder (MDD), the use of a placebo run‐in, whether a minimal severity criterion was employed and the length of the study. </p> </li> <li> <p>Characteristics of samples, including total number of participants, gender distribution and age distribution, mean age at diagnosis with TTM, mean length of time since diagnosis with TTM, whether participants have been treated with the medication in the past (treatment naivety), the number of participants in the sample with psychiatric comorbidities and the baseline severity of TTM, as assessed by the primary outcome measure reported in the trial or another commonly employed scale. </p> </li> <li> <p>Characteristics of the drug, including the drug class, dose, route and frequency of drug administration throughout all trial phases, the duration of the trial and details of any washout period or placebo run‐in where applicable. </p> </li> <li> <p>Characteristics of the control measure, including type of control utilised and methods for concealing the placebo where applicable. </p> </li> <li> <p>Outcome measures employed (primary and secondary) and summary continuous (means and standard deviations) and dichotomous (number of responders) data. We included additional information, such as whether data reflected the intention‐to‐treat (ITT) with last observation carried forward (LOCF) or completer/observed cases (OC) sample, and the minimal period required for inclusion of participants in the LOCF analyses. We recorded other methods of estimating the outcome for participants who dropped out of the study, such as the mixed effects (ME) model. </p> </li> </ul> </p> <section id="CD007662-sec-0039"> <h5 class="title">Main comparisons</h5> <p>We compared the following medications, grouped by class, against placebo or other active agents, for treating TTM in adults, children and adolescents. </p> <p> <ul id="CD007662-list-0013"> <li> <p>Antioxidants (e.g. silymarin).</p> </li> <li> <p>Antipsychotics (e.g. olanzapine).</p> </li> <li> <p>Cell signal transducers (e.g. inositol).</p> </li> <li> <p>Glutamate modulators (e.g. N‐acetylcysteine).</p> </li> <li> <p>Opioid antagonists (e.g. naltrexone).</p> </li> <li> <p>SSRIs (e.g. fluoxetine, sertraline).</p> </li> <li> <p>TCAs with predominantly SRI actions (e.g. clomipramine).</p> </li> </ul> </p> <p>We planned the following comparisons and grouped specific pharmacological interventions according to medication class based on the included studies. </p> <p>Comparison 1: antioxidants versus placebo in adults.</p> <p>Comparison 2: antioxidants versus placebo in children and adolescents.</p> <p>Comparison 3: antipsychotics versus placebo in adults.</p> <p>Comparison 4: cell signal transducers versus placebo in adults.</p> <p>Comparison 5: glutamate modulators versus placebo in adults.</p> <p>Comparison 6: glutamate modulators versus placebo in children and adolescents.</p> <p>Comparison 7: opioid antagonists versus placebo in adults.</p> <p>Comparison 8: SSRIs versus placebo in adults.</p> <p>Comparison 9: TCAs with predominantly SRI actions versus placebo in adults.</p> <p>Comparison 10: TCAs with predominantly SRI actions versus other TCAs in adults.</p> </section> </section> <section id="CD007662-sec-0040"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (JH, TW) independently examined the components of each included trial for risk of bias using a standard form. This form included information on sequence generation, allocation concealment, blinding (participants, personnel and outcome assessor), incomplete outcome data, selective outcome reporting and other sources of bias. We assessed the methodological components of the trials as having a low, high or unclear risk of bias, as per the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007662-bbs2-0067" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>, hereafter referred to as the <i>Cochrane Handbook</i>). When differences arose, we resolved these through discussion with a third review author (DJS). </p> <p>Sequence generation</p> <p> <ul id="CD007662-list-0014"> <li> <p>Low risk: investigators described a random component in the sequence generation process, such as the use of a random number table, coin tossing, cards or envelope shuffling. </p> </li> <li> <p>High risk: investigators described a non‐random component in the sequence generation process, such as the use of odd or even date of birth, algorithm based on the day or date of birth, or hospital or clinic record number. </p> </li> <li> <p>Unclear: insufficient information was provided to permit judgement of the sequence generation process. </p> </li> </ul> </p> <p>Allocation concealment</p> <p> <ul id="CD007662-list-0015"> <li> <p>Low risk: participants and investigators enrolling participants could not foresee assignment (e.g. central allocation or sequentially numbered, opaque, sealed envelopes). Measures were taken to ensure placebo unidentifiable from intervention (e.g. masking of smell of drug and placebo). </p> </li> <li> <p>High risk: participants and investigators enrolling participants could foresee upcoming assignment (e.g. open random allocation schedule, such as a list of random numbers, or envelopes that were unsealed or non­opaque or were not sequentially numbered). Placebo was distinct from intervention drug and no attempt was made to conceal this (e.g. clear versus opaque syrup used). </p> </li> <li> <p>Unclear: insufficient information was provided to permit judgement of allocation concealment, or the method was not described. </p> </li> </ul> </p> <p>Blinding</p> <p> <ul id="CD007662-list-0016"> <li> <p>Low risk: blinding of participants, key study personnel and outcome assessors were described, and it is unlikely that blinding could have been broken; or lack of blinding was described in a situation where non‐blinding was not likely to introduce bias. </p> </li> <li> <p>High risk: no blinding or incomplete blinding was described, and the outcome was likely to be influenced by lack of blinding. </p> </li> <li> <p>Unclear: insufficient information was provided to permit judgement of adequacy or otherwise of the blinding. </p> </li> </ul> </p> <p>Incomplete outcome data</p> <p> <ul id="CD007662-list-0017"> <li> <p>Low risk: no outcome data were missing, reasons for missing outcome data were unlikely to be related to true outcome, or missing outcome data were balanced in number across groups. Intention‐to‐treat analysis was employed. </p> </li> <li> <p>High risk: reason for missing outcome data was likely to be related to the true outcome, with imbalance in numbers across groups or in reasons for missing data. Intention‐to‐treat analysis was not employed, and no explanation given. </p> </li> <li> <p>Unclear: reporting of attrition or exclusions was insufficient.</p> </li> </ul> </p> <p>Selective outcome reporting</p> <p> <ul id="CD007662-list-0018"> <li> <p>Low risk: a protocol that clearly stated the primary outcome as the same as in the final trial report was available. </p> </li> <li> <p>High risk: the primary outcome differs between the protocol and the final trial report.</p> </li> <li> <p>Unclear: no trial protocol was available, or reporting was insufficient to determine whether selective reporting was present. </p> </li> </ul> </p> <p>Other sources of bias</p> <p> <ul id="CD007662-list-0019"> <li> <p>Low risk: no evidence suggested bias from other sources.</p> </li> <li> <p>High risk: potential bias from other sources was present (e.g. early stopping of trial, fraudulent activity, extreme baseline imbalance or bias related to specific study design). </p> </li> <li> <p>Unclear: insufficient information was provided to permit judgement of adequacy or otherwise of other forms of bias. </p> </li> </ul> </p> </section> <section id="CD007662-sec-0041"> <h4 class="title">Measures of treatment effect</h4> <section id="CD007662-sec-0042"> <h5 class="title">Dichotomous data</h5> <p>We calculated the risk ratio (RR) and the 95% confidence interval (CI) for the dichotomous outcomes of interest, including treatment response (CGI‐I or related measure) and dropouts due to adverse events. We also calculated the number needed to treat for an additional beneficial outcome (NNTB). NNTB is defined as the inverse of the absolute risk difference due to the medication intervention. In this review, we use NNTB to indicate the number of participants who require treatment with medication, relative to a control, before a single additional participant in the medication group responds to treatment. As the outcome measured is favourable, a negative NNT was defined as the NNTB. </p> </section> <section id="CD007662-sec-0043"> <h5 class="title">Continuous data</h5> <p>We calculated effect size as mean difference (MD) for continuous summary data where a single outcome scale was used to measure the outcome of interest within a single study or across multiple studies (e.g. MGH‐HPS, NIMH‐TSS or related measure). For primary outcomes, where multiple scales were used within a single study, we report all as MD. Where multiple scales were employed across multiple studies for a single primary outcome, we planned to calculate the standardised mean difference (SMD). However, this was not required. For secondary outcomes where multiple scales were applied, we selected a single appropriate scale in a hierarchical manner and report the MD (e.g. HAM‐D, SDS or related measure). </p> </section> <section id="CD007662-sec-0044"> <h5 class="title">Skewed data</h5> <p>When evidence indicated that data were skewed, we planned to obtain individual participant data (when possible) for the purpose of normalising the data through the use of log transformation techniques. If this proved unsuccessful, we planned to exclude those studies that provided skewed data from the analysis. For the purposes of this review, the following constituted evidence of skewness: cases in which the difference between the observed mean and the lowest possible value or the highest possible value on the scale is less than twice as large as the standard deviation (<a href="./references#CD007662-bbs2-0029" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313:1200.">Altman 1996</a>), or cases in which data are reported as skewed by the authors. </p> </section> </section> <section id="CD007662-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <section id="CD007662-sec-0046"> <h5 class="title">Studies with multiple treatment groups</h5> <p>We did not include any studies with multiple treatment groups in this review. In future updates of the review, if trials with three or more arms are identified, it may be appropriate to do a multi‐arm trial analysis, wherein the placebo group would be split and shared between two or more groups with smaller sample sizes. In this way, the two or more intervention groups can be analysed as subgroups (<a href="./references#CD007662-bbs2-0067" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> <p>In our analyses, for most comparisons, only one study provided data on primary and secondary outcomes. For continuous outcomes, in order to understand the results for each measure used within one trial, and where multiple sclaes were used, these were displayed in one meta‐analysis. For these analyses, we have not displayed totals, as these would be misleading. </p> </section> <section id="CD007662-sec-0047"> <h5 class="title">Cross‐over trials</h5> <p>We included cross‐over trials in the calculation of outcomes of interest only: (1) when it was possible to extract medication and placebo or comparator data from the first treatment period; or (2) when inclusion of data from both treatment periods was justified by a washout period of sufficient duration as to minimise the risk of carry‐over effects. We defined an adequate washout period in accordance with clinical practice as at least two weeks for all agents, except for fluoxetine, for which a minimum washout period of four weeks was required, given the long plasma half‐life of this agent. We included cross‐over trials that lacked a washout period if the agents compared were of the same class and had similar properties. For trials in which the washout period was regarded as adequate, we included data from both periods when it was possible to determine the standard error of the mean difference in response between groups (<a href="./references#CD007662-bbs2-0051" title="ElbourneER , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31:140-9.">Elbourne 2002</a>). We obtained the summary statistics required to derive the standard error from the trial report. In the future, for trials for which this information is missing, we plan to impute the summary statistics by averaging the relevant statistic from other included cross‐over trials with comparable control conditions. </p> </section> <section id="CD007662-sec-0048"> <h5 class="title">Cluster‐randomised trials</h5> <p>We did not include any cluster‐RCTs in this review. In future updates of the review, if cluster‐RCTs are identified, we would apply an intraclass correlation (ICC) for the sample to account for the effect of clustering. We would use the ICC reported in the publication, or, if necessary, we would contact study authors to request this information. If we were unable to obtain this information, we would calculate an ICC estimate using the average of the ICCs obtained from the other studies included in the analysis. We would undertake the analysis by using generic inverse variance (GIV). </p> </section> </section> <section id="CD007662-sec-0049"> <h4 class="title">Dealing with missing data</h4> <p>We conducted all analyses as ITT. We used the total number of participants randomly assigned to the different comparison groups as the denominator in comparisons of treatment response. Only data from trials that provided information on the original group size (before dropouts) were eligible for inclusion in the analyses of treatment response. We gave preference to the inclusion of summary statistics for continuous outcome measures derived from mixed effects (ME) models, followed by last observation carried forward (LOCF) and observed cases (OC) summary statistics (in that order). This is in line with evidence that ME methods are more robust to bias than LOCF analyses (<a href="./references#CD007662-bbs2-0110" title="VerbekeM , MolenberghsG . Linear Mixed Models for Longitudinal Data. New York (NY): Springer, 2000.">Verbeke 2000</a>). </p> </section> <section id="CD007662-sec-0050"> <h4 class="title">Assessment of heterogeneity</h4> <p>For trials in which the methods and clinical characteristics were sufficiently homogeneous that they could be combined, we assessed statistical heterogeneity of treatment response and reduction of symptom severity visually from the forest plot. This helped us to determine whether differences between the results of trials were greater than would be expected by chance alone. We assessed heterogeneity by using the Chi<sup>2</sup> test of heterogeneity. If the Chi<sup>2</sup> test had a P value of less than 0.10, we interpreted this as evidence of heterogeneity, given the low power of the Chi<sup>2</sup> statistic when the number of trials is small (<a href="./references#CD007662-bbs2-0046" title="DeeksJJ , HigginsJPT , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook..">Deeks 2021</a>). </p> <p>In addition, we used the I<sup>2</sup> heterogeneity statistic, as reported by RevMan 5, to test the robustness of the Chi<sup>2</sup> statistic to differences in the number of trials included in the groups compared within each subgroup analysis (<a href="./references#CD007662-bbs2-0066" title="HigginsJT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(6):557-60.">Higgins 2003</a>). </p> <p>Thresholds for the interpretation of I<sup>2</sup> can be misleading because the importance of inconsistency depends on several factors. A rough guide for interpretation was followed: </p> <p> <ul id="CD007662-list-0020"> <li> <p>0% to 40%: may not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: may represent considerable heterogeneity.</p> </li> </ul> </p> <p>We assessed differences on continuous measures in medication efficacy between these groups by means of Deeks’ stratified test of heterogeneity (<a href="./references#CD007662-bbs2-0044" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: EggerM , DaveySG , AltmanDG , editors(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd edition. London (UK): BMJ Publication Group, 2001.">Deeks 2001</a>). This method subtracts the sum of the Chi<sup>2</sup> statistics available for each of the subgroups in the study from the Chi<sup>2</sup> statistic available for all of the trials, to obtain a measure (Q<sub>b</sub>) of heterogeneity between groups. We determined differences in treatment response on the CGI‐I by noting whether the confidence intervals for the effect sizes of the subgroups overlap. This method was chosen in preference to the stratified test because of inaccuracies in the calculation in RevMan 5 of the Chi<sup>2</sup> statistic for dichotomous measures (<a href="./references#CD007662-bbs2-0046" title="DeeksJJ , HigginsJPT , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook..">Deeks 2021</a>). </p> </section> <section id="CD007662-sec-0051"> <h4 class="title">Assessment of reporting biases</h4> <p>Publication is not necessarily related to study quality, and indeed publication may imply certain biases (<a href="./references#CD007662-bbs2-0048" title="DickersinK , MinYI , MeinertCL . Factors influencing the publication of research results: follow-up of applications submitted to two substantial review boards. Journal of the American Medical Association1992;267(3):374-8.">Dickersin 1992</a>; <a href="./references#CD007662-bbs2-0098" title="SongF , EastwoodAJ , GilbodyS , DuleyL , SuttonAJ . Publication and related biases. Health Technology Assessment2000;4:1-115.">Song 2000</a>). We planned to assess small‐sample effects (including publication bias) through visual inspection of a funnel plot of treatment response. This is possible, however, only when more than 10 studies are included in the funnel plot. We did not carry out this assessment in this review due to insufficient studies within comparisons. </p> </section> <section id="CD007662-sec-0052"> <h4 class="title">Data synthesis</h4> <p>In conducting a meta‐analysis, we obtained categorical and continuous treatment effects from a random‐effects model (the random‐effects model includes both within‐study sampling error and between‐studies variation in determining the precision of the confidence interval around the overall effect size, whereas the fixed‐effect model takes only within‐study variation into account). The outcomes are expressed in terms of an average effect size, as well as by means of 95% confidence intervals. </p> <p>In future updates, if appropriate, we may consider using 'multiple‐treatment meta‐analyses' (MTM) methodology to compare and analyse intervention groups across studies. This method relies on the strong assumption that studies of different comparisons are similar in all ways other than the interventions being compared (<a href="./references#CD007662-bbs2-0067" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD007662-sec-0053"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to undertake subgroup analyses to assess the degree to which methodological differences between trials might have systematically influenced differences observed in primary treatment outcomes. The a priori subgroups that we planned to explore included the following. </p> <p> <ul id="CD007662-list-0021"> <li> <p>Involvement of participants from a single centre or from multiple centres. Single‐centre trials may be associated with lower sample size but less variability in clinician ratings (<a href="./references#CD007662-bbs2-0116" title="YoussefNCM , ReinhartK , SakrY . The pros and cons of multicentre studies. Netherlands Journal of Critical Care2008;12(3):120-2.">Youssef 2008</a>). </p> </li> <li> <p>Whether trials were industry‐funded. In general, published trials that are sponsored by pharmaceutical companies appear more likely to report positive findings than trials that are not supported by for‐profit companies (<a href="./references#CD007662-bbs2-0028" title="Als-NielsenB , ChenW , GluudC , KjaergardLL . Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?Journal of the American Medical Association2003;290:921-8.">Als‐Nielsen 2003</a>; <a href="./references#CD007662-bbs2-0035" title="BakerCB , JohnsrudMT , CrismonML , RobertAR , WoodsSW . Quantitative analysis of sponsorship bias in economic studies of antidepressants. British Journal of Psychiatry2003;183:498-506.">Baker 2003b</a>). </p> </li> </ul> </p> <p>In addition, we planned to use the following criterion to assess the extent of clinical sources of heterogeneity. </p> <p> <ul id="CD007662-list-0022"> <li> <p>Whether the sample included participants diagnosed with major depressive disorder (MDD). Such an analysis might assist in determining the extent to which the efficacy of a medication used in treating TTM is independent from its ability to reduce symptoms of depression—an important consideration given the classification of many of these medications as antidepressants. </p> </li> </ul> </p> <p>We did not include enough studies to permit subgroup analysis or investigation of the clinical sources of heterogeneity. </p> </section> <section id="CD007662-sec-0054"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses determine the robustness of the review authors’ conclusions to methodological assumptions made in conducting the meta‐analysis. There were not enough included studies to permit sensitivity analyses. However, in future updates, we plan to conduct sensitivity analyses to determine whether treatment response varies as a function of: </p> <p> <ul id="CD007662-list-0023"> <li> <p>the use of treatment response versus non‐response as an outcome statistic. This comparison may be necessary in the light of evidence that treatment response may result in less consistent outcome statistics than non‐response (<a href="./references#CD007662-bbs2-0045" title="DeeksJJ . Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine2002;21:1575-600.">Deeks 2002</a>), when the control group event rate is higher than 50%. This sensitivity analysis would accordingly be performed only if most trials report a control group event rate higher than 50%; </p> </li> <li> <p>the exclusion of participants who were lost to follow‐up (LTFU). We planned to determine this through a 'worst case/best case' scenario (Deeks 2008). In the worst case, all missing data for the treatment group are recorded as non‐responders, whereas in the best case, all missing data for the control group are treated as non‐responders. Should conclusions regarding treatment efficacy not differ between these two comparisons, it can be assumed that missing data in trial reports do not have a significant influence on outcome; </p> </li> <li> <p>the exclusion of results based on LOCF or OC;</p> </li> <li> <p>the exclusion of cross‐over trials;</p> </li> <li> <p>the exclusion of cluster‐randomised trials; or</p> </li> <li> <p>varying ICCs in cluster‐randomised trials.</p> </li> </ul> </p> </section> <section id="CD007662-sec-0055"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We compiled summary of findings tables to summarise the evidence presented for the outcomes of treatment response, reduction of TTM symptom severity and tolerability of treatment (e.g. dropouts due to adverse events). These outcomes are displayed in the summary of findings tables for all comparisons. Where multiple scales were reported for reduction of TTM symptom severity, we report only a single outcome measure for each comparison in our summary of findings tables, prioritising MGH‐HPS where available, but report on all outcome scales used within the text and data analysis sections of this review. We summarised the findings and graded the certainty of the evidence, in a fixed format using GRADEpro software (<a href="./references#CD007662-bbs2-0059" title="GRADEpro GDT. Version accessed prior to 8 September 2021. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). </p> <p>We classified reasons for downgrading the certainty of the evidence as ‘serious’ (downgrading the certainty rating by one level) or ‘very serious’ (downgrading the certainty rating by two levels). We graded the certainty of evidence based on these five factors: </p> <p> <ul id="CD007662-list-0024"> <li> <p>limitations in the design and implementation of the trial;</p> </li> <li> <p>indirectness of evidence;</p> </li> <li> <p>unexplained heterogeneity or inconsistency of results;</p> </li> <li> <p>imprecision of results;</p> </li> <li> <p>high probability of publication bias.</p> </li> </ul> </p> <p>With regards to grading the certainty of the evidence, for risk of bias, we downgraded by one level for every identified source of potential bias. For inconsistency, we downgraded by zero levels if heterogeneity amongst studies was less than 30%, by one level if heterogeneity was between 30% and 60%, and by two levels if heterogeneity was greater than 60%. For indirectness, we downgraded based on judgement (four factors). Downgrading for indirectness was based on any concerns related to differences in the study populations, differences in interventions, differences in outcome measures (surrogate outcomes) and indirect comparisons. We did not downgrade due to publication bias as there were insufficient studies to generate funnel plots (<a href="./references#CD007662-bbs2-0093" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editors. Handbook for grading the quality of evidence and strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>). </p> <p>For imprecision, we downgraded by two levels for a 95% confidence interval that crossed the significance threshold (0 for SMD and MD, 1 for RR) and by zero to two levels depending on the sample size. Sample size thresholds for downgrading were determined using power analysis for 1 study and SMD = 0.3 ‐ 1, tested using both fixed‐effect and random‐effects models. A total of 47 participants were required to detect a change of SMD = 1 at 80% power with a random‐effects model (low heterogeneity). Using a fixed‐effect model, 36 participants are required. For 50% power, 17 participants are required for fixed‐effect and 23 are required for random‐effects model analyses. To detect an effect size of 0.3, a sample size of 469 is required to reach 80% power using a random‐effects model and 353 are needed using a fixed‐effect model. The thresholds used for downgrading the certainty of the evidence based on pooled sample size were: 0 levels if more than 400 participants; ‐1 level if 50 to 400 participants; and ‐2 levels if less than 50 participants in the analysis. </p> <p>We classified the overall certainty in the evidence (or quality of the evidence) for each comparison according to the following categories. </p> <p> <ul id="CD007662-list-0025"> <li> <p>High certainty: further evidence is unlikely to change our confidence in the estimate of effect. </p> </li> <li> <p>Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> </li> <li> <p>Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> </li> <li> <p>Very low certainty: we are very uncertain about the estimate.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007662-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007662-sec-0056"></div> <section id="CD007662-sec-0057"> <h3 class="title">Description of studies</h3> <section id="CD007662-sec-0058"> <h4 class="title">Results of the search</h4> <p>Our searches yielded 2458 records. After examination of their titles and abstracts, we obtained the full texts of 22 studies to analyse them for inclusion. Twelve studies met the inclusion criteria for the review (<a href="#CD007662-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD007662-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram" data-id="CD007662-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> </div> <p>We attempted to contact the principal investigators of 10 of the 12 included studies to obtain or verify information (eight people, as Christenson authored two studies (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>), and Grant was the primary contact person for four studies (<a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>)). We were successful in contacting and obtaining information from six of the eight study authors. </p> </section> <section id="CD007662-sec-0059"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD007662-sec-0203" title="">Characteristics of included studies</a>. </p> <section id="CD007662-sec-0060"> <h5 class="title">Design</h5> <p>Of the 12 studies identified as eligible for the review, all were RCTs. Eleven trials were conducted in the United States and one in Canada (<a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). Only two trials included children and adolescents under 18 years old (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>). Eleven trials were conducted with adult participants aged 18 to 65. Four of the trials used a cross‐over design (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>), and eight trials used a parallel‐group design (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>; <a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>; <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). The four cross‐over trials were 17 weeks, 13 weeks, 27 weeks and 10 weeks in duration, respectively. Of the parallel‐group trials, one was 6 weeks in duration, one was 8 weeks in duration, one was 9 weeks in duration, one was 10 weeks in duration, and four were 12 weeks in duration. All of the studies were published in English language journals, with the exception of one (<a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>), which was presented as a conference abstract. Four studies were funded by pharmaceutical companies (<a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). </p> </section> <section id="CD007662-sec-0061"> <h5 class="title">Sample sizes</h5> <p>The eleven studies conducted with adults involved a total of 298 participants with a mean sample size of 27 participants per trial, a median of 24 and a range from the smallest sample size of 13 to the largest of 51. The single study exclusively in children and adolescents included 39 participants (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>). A single study was conducted in adults, children and adolescents, and included 22 participants: 18 adults and 4 children and adolescents (<a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>). These adult participants are included in the total reported above. </p> </section> <section id="CD007662-sec-0062"> <h5 class="title">Setting</h5> <p>All studies were single‐centre trials, and all participants were seen on an outpatient basis. </p> </section> <section id="CD007662-sec-0063"> <h5 class="title">Participants</h5> <p>Nine of the 12 trials report using <i>DSM‐III‐R</i> (or later) criteria to select participants (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>; <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). The remaining three trials do not report the specific criteria employed in participant selection (<a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>). Three trials did not require <i>DSM‐III‐R</i> and <i>‐IV</i> criteria B and C for inclusion in the trials (i.e. a sense of tension before and a sense of relief after hair‐pulling) (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>). Of the 10 trials that reported the gender of participants, nine reported the proportion of female participants as 75% to 100%, reflecting female predominance in TTM (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>; <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>). The mean age of adult participants in the eight trials that reported this variable was between 28 and 40 years (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>; <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). The average age of participants in the trial on children and adolescents was 13 years (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>). The mean age of participants in the trial conducted in children, adolescents and adults was 28.1 years (<a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>). </p> <p>Lifetime prevalence rates of comorbid psychiatric conditions were reported in seven trials in adults. Rates of major depressive disorder or a history of major depressive disorder ranged from 15.8% to 46.2% in four trials (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>); and rates of anxiety disorders ranged from 20.0% to 75.0% in six trials (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). Two studies reported rates of 'another impulse‐control disorder' as 20.0% and 36.0%, respectively (<a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). The same two studies reported rates of eating disorders of 4.0% and 2.0%, respectively. One study reported rates of skin picking disorder as 34.2%, attention‐deficit hyperactivity disorder (ADHD) as 2.6%, and obsessive‐compulsive disorder (OCD) as 2.6% (<a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>). One study reported a significant rate of drug and alcohol use among participants (30.8%; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>), and one article stated that 52.9% of their participants had psychiatric comorbidities, although no further details were available (<a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>). The study in children and adolescents reported rates of depression as 33.3%, anxiety as 23.1%, ADHD as 10%, tic disorder as 7.7%, OCD as 5.1%, and skin picking disorder as 2.6% (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>). The study conducted in children, adolescents and adults reported current psychotropic medicine use as 35% (adults only = 25%; children and adolescents only = 75%), current ADHD as 25% (adults only = 18.8%; children and adolescents only = 50%), current depression as 35% (adults only = 25%; children and adolescents only = 75%), current anxiety as 30% (adults only = 18.8%; children and adolescents only = 75%), current nail‐biting as 25% (adults only = 25%; children and adolescents only = 25%) and current skin picking as 60% (adults only = 50%; children and adolescents only = 100%) (<a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>). </p> </section> <section id="CD007662-sec-0064"> <h5 class="title">Interventions</h5> <p>The 11 studies in adults included three studies of SSRIs (two fluoxetine (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>), and one sertraline (<a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>)); two of TCAs with predominantly SRI actions (clomipramine (<a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>)); one of an antipsychotic (olanzapine (<a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>)); one of a glutamate modulator (NAC (<a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>)); two of an opioid antagonist (naltrexone (<a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>)); one of a carbocyclic sugar involved in cell signal transduction (inositol (<a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>)); and one of a flavonoid derived from milk thistle extract with antioxidant properties (silymarin (<a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>)). The single study exclusively in children and adolescents examined a glutamate modulator (NAC (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>)). A placebo comparison group was employed in all but one trial, which involved an active agent comparator (<a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>). Of the four trials employing a cross‐over design (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>), two involved a five‐week washout period before cross‐over between fluoxetine and placebo (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>). In <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>, a washout period was not employed, as desipramine was used as an active control and has similar properties to the intervention (clomipramine); therefore, a washout period was not deemed necessary. In <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>, a one‐week washout period was employed between intervention (silymarin) and placebo arms. All trials employed gradual dose progression, except for one of the naltrexone trials (<a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>), for which a constant dose was given throughout the trial. All interventions were oral medications or placebo, taken by participants at home. </p> </section> <section id="CD007662-sec-0065"> <h5 class="title">Outcomes</h5> <p>In the adult studies, seven trials employed the Clinical Global Impression – Improvement item (CGI‐I) Scale to measure treatment response (<a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>; <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>); two trials employed an untitled scale that measured five aspects of self‐reported TTM severity (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>); six trials employed the validated National Institute of Mental Health (NIMH) Trichotillomania Severity Scale (TSS) and the Trichotillomania Impairment Scale (TIS) (<a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>; <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>); six trials employed the Massachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) (<a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>); two trials employed the Psychiatric Institute Trichotillomania Scale (PITS) (<a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>); one trial employed the Trichotillomania Impact Scale (TTMIS) (<a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>); and one trial employed the Yale‐Brown Obsessive‐Compulsive Scale for TTM (<a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). </p> <p>Secondary outcome measures employed in adult studies were the Hamilton Rating Scale for Depression (HAM‐D) (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>), the Hamilton Rating Scale for Anxiety (HAM‐A) (<a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>), the Beck Depression Inventory (BDI) (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>), the Beck Anxiety Inventory (BAI) (<a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>), the State‐Trait Anxiety Inventory (STAI) (<a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>), the NIMH Global Assessment Scales for Depression and Anxiety (NIMH‐GASD) (<a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>), the Quality of Life Enjoyment and Satisfaction Questionnaire (Q‐LES‐Q) (<a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>), the Quality of Life Inventory (QoLI) (<a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>), and the Sheehan Disability Scale (SDS) (<a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). </p> <p>The studies in children and adolescents used the CGI‐I to measure treatment response (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>). In the same studies, the MGH‐HPS, the NIMH‐TSS and the Trichotillomania Scale for Children–Child and Parent versions (TSC‐C,P) were used to measure symptom severity. The Children’s Depression Inventory (CDI) was used to measure symptoms of depression in one of the studies (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>). HAM‐A, HAM‐D and SDS were applied in the other study as secondary outcome measures (<a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>). </p> </section> </section> <section id="CD007662-sec-0066"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD007662-sec-0204" title="">Characteristics of excluded studies</a>. </p> <p>We excluded 10 studies for the following reasons: non‐RCT design (<a href="./references#CD007662-bbs2-0013" title="BlackDW , BlumN . Trichotillomania treated with clomipramine and a topical steroid. American Journal of Psychiatry1992;149(6):842-3. ">Black 1992</a>; <a href="./references#CD007662-bbs2-0014" title="ChamberlainSR , GrantJE , CostaA , MullerU , SahakianBJ . Effects of acute modafinil on cognition in trichotillomania. Psychopharmacology2010;212(4):597-601. ">Chamberlain 2010</a>; <a href="./references#CD007662-bbs2-0016" title="EppersonCN , McDougleCJ , PriceLH . Intranasal oxytocin in trichotillomania. Biological Psychiatry1996;40(6):559-60. ">Epperson 1996</a>; <a href="./references#CD007662-bbs2-0017" title="GolubchikP , SeverJ , WeizmanA , ZalsmanG . Methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder and comorbid trichotillomania: a preliminary report. Clinical Neuropharmacology2011;34(3):108-10. ">Golubchik 2011</a>; <a href="./references#CD007662-bbs2-0018" title="NinanPT , KnightB , KirkL , RothbaumBO , KelseyJ , NemeroffCB . A controlled trial of venlaflaxine in trichotillomania: interim phase I results. Psychopharmacology Bulletin1998;34(2):221-4. ">Ninan 1998</a>; <a href="./references#CD007662-bbs2-0019" title="RileyWT , SoodA , Al-MateenCS . Mixed effects of clomipramine in treating childhood trichotillomania. Journal of Child and Adolescent Psychopharmacology1993;3(3):169-71. ">Riley 1993</a>; <a href="./references#CD007662-bbs2-0020" title="SteinDJ , HollanderE , CohenL , SimeonD , AronowitzB . Serotonergic responsivity in trichotillomania: neuroendrocrine effects of m-chlorophenylpiperazine. Biological Psychiatry1995;15(37):414-6. ">Stein 1995</a>; <a href="./references#CD007662-bbs2-0021" title="SteinDJ , HollanderE , De CarciaC , CohenL , SimeonD . Behavioural response to m-chlorophenylpiperazine and clonidine in trichotillomania. Journal of Serotonin Research1997;4(1):11-5. ">Stein 1997</a>); waiting‐list control group instead of placebo (<a href="./references#CD007662-bbs2-0022" title="Van MinnenA , HoogduinKA , KeijsersGP , HellenbrandI , HendriksGJ . Treatment of trichotillomania with behavioral therapy or fluoxetine. Archives of General Psychiatry2003;60:517-22. ">Van Minnen 2003</a>); and dietary intervention, not pharmacotherapy (<a href="./references#CD007662-bbs2-0015" title="DufourBD , AdeolaO , ChengHW , DonkinSS , KleinJD , PajorEA , et al. Nutritional up-regulation of serotonin paradoxically induces compulsive behavior. Nutritional Neuroscience2010;13(6):256-64. ">Dufour 2010</a>). </p> </section> <section id="CD007662-sec-0067"> <h4 class="title">Ongoing studies</h4> <p>We identified four ongoing studies. Three ongoing studies were identified with protocols on <a href="http://Clinicaltrials.gov" target="_blank">ClinicalTrials.gov</a>, and one study on the Iranian Registry of Clinical Trials (<a href="http://en.ICRT.ir" target="_blank">en.ICRT.ir</a>). </p> <p>Of the three identified on <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>, one study investigated NAC, glutathione levels and compulsivity in anorexia nervosa and other disorders characterised by compulsive behaviour, including TTM (NCT02794389; completed, no results posted; <a href="./references#CD007662-bbs2-0024" title="NCT02794389 . Glutathione levels and compulsivity [How do glutathione levels affect compulsivity? A double-blind, placebo-controlled study]. clinicaltrials.gov/ct2/show/NCT02794389  (first received 9 June 2016). ">NCT02794389</a>). The second study is investigating dronabinol, a synthetic cannabinol, in TTM and other body‐focused repetitive behaviours (NCT03530800; recruiting; <a href="./references#CD007662-bbs2-0025" title="NCT03530800. Dronabinol in trichotillomania and other body focused repetitive behaviors [A double-blind, placebo-controlled study of dronabinol in trichotillomania and other body focused repetitive behaviors]. clinicaltrials.gov/ct2/show/NCT03530800  (first received 21 May 2018). ">NCT03530800</a>). The last study is focusing on an experimental drug, SXC‐2023, which may affect glutamatergic dysfunction and oxidative stress response (NCT03797521; active, recruitment completed; <a href="./references#CD007662-bbs2-0026" title="NCT03797521. A study in patients with trichotillomania (TTM) [A phase 2, double blind, placebo-controlled study to explore the safety, tolerability, and activity of SXC-2023 in adults with moderate to severe trichotillomania (TTM) when dosed for 6 weeks]. clinicaltrials.gov/ct2/show/NCT03797521  (first received 9 January 2019). ">NCT03797521</a>). The study on IRCT.ir investigates the individual and combined effects of habit‐reversal therapy (HRT) and citalopram in TTM (IRCT20181009041282N2; active, not recruiting; <a href="./references#CD007662-bbs2-0023" title="IRCT20181009041282N2. Compare the effectiveness of group therapy combination of acceptance and commitment therapy and habit reversal training to drug therapy in reducing symptoms, anxiety and depression of patients with trichotillomania. en.irct.ir/trial/34357  (first received 16 November 2018). ">IRCT20181009041282N2</a>). </p> </section> <section id="CD007662-sec-0068"> <h4 class="title">Studies awaiting classification</h4> <p>One study is awaiting publication of phase II trial results, which was conducted under randomised, placebo‐controlled conditions (<a href="./references#CD007662-bbs2-0018" title="NinanPT , KnightB , KirkL , RothbaumBO , KelseyJ , NemeroffCB . A controlled trial of venlaflaxine in trichotillomania: interim phase I results. Psychopharmacology Bulletin1998;34(2):221-4. ">Ninan 1998</a>). However, we could not find a reference for the phase II results of this trial, and therefore have excluded the publication of phase I results under ‘Excluded studies’. </p> </section> </section> <section id="CD007662-sec-0069"> <h3 class="title">Risk of bias in included studies</h3> <p>Full details of the determination of risk of bias can be found in <a href="./references#CD007662-sec-0203" title="">Characteristics of included studies</a> and in <a href="#CD007662-fig-0002">Figure 2</a> and <a href="#CD007662-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD007662-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD007662-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD007662-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD007662-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD007662-sec-0070"> <h4 class="title">Allocation</h4> <section id="CD007662-sec-0071"> <h5 class="title">Random sequence generation</h5> <p>We rated the risk of bias arising from the method of generation of the allocation sequence as low in ten studies (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>; <a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). These studies reported generating the sequence by computer or by a random number table, or such information was obtained from the first author. <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a> and <a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a> did not disclose a method of randomisation; therefore, the presence of selection bias is unclear for these studies. </p> </section> <section id="CD007662-sec-0072"> <h5 class="title">Allocation concealment</h5> <p>We rated the risk of bias arising from the method of allocation concealment as low in ten studies (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>; <a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). These studies reported the use of central allocation (e.g. pharmacy‐controlled allocation), or this information was obtained from the first author. <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a> and <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a> did not disclose a method of allocation; therefore, the presence of selection bias is unclear for these studies. </p> </section> </section> <section id="CD007662-sec-0073"> <h4 class="title">Blinding</h4> <section id="CD007662-sec-0074"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>We rated the risk of bias arising from lack of blinding of participants and personnel as low for 11 of the 12 studies. Most studies reported using a placebo or other form of control that was identical in appearance to the intervention. If not reported, blinding of participants was confirmed by correspondence with the author (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>; <a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). <a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a> disclosed quadruple blinding was employed and significant effort was taken to match the placebo to NAC in appearance and smell, thus performance bias was rated as low. <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a> did not disclose a method for blinding participants, but stated a double‐blind study design; therefore, the presence of performance bias is unclear for this study. </p> </section> <section id="CD007662-sec-0075"> <h5 class="title">Blinding of outcome assessors (detection bias)</h5> <p>We rated the risk of bias arising from lack of blinding of outcome assessors as low for all studies. Most studies reported blind outcome assessment; if not, this information was obtained from the first author (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>; <a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>; <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). </p> </section> </section> <section id="CD007662-sec-0076"> <h4 class="title">Incomplete outcome data</h4> <p>We rated risk of attrition bias as low in eight trials which employed ITT analysis or in which attrition rates were not differentially distributed between intervention and control groups, or both (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). We rated the risk of attrition bias as high in three trials, in which attrition was greater than 10% overall and/or ITT analysis was not employed, and/or attrition rates were differentially distributed between intervention and control groups (<a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>). Dropout rates were not reported for the <a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a> trial, and therefore we assessed this trial as unclear risk of bias. </p> </section> <section id="CD007662-sec-0077"> <h4 class="title">Selective reporting</h4> <p>We obtained trial protocols for six trials, with four trials reported additional outcomes in their publication compared to their protocol (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>). All outcomes from four of the protocols were reported in the publications of the studies. Therefore, we rated the risk of reporting bias for these trials as low (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>). One study reported an outcome in the protocol, but not in the publication (<a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>). However, the results would not change the conclusion, and therefore we rated the risk of reporting bias as low (<a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>). The other trial protocol obtained revealed no evidence for reporting bias and was also rated as low (<a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). We did not obtain trial protocols for the remaining six trials, and therefore, we rated the risk of reporting bias as unclear for those trials (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>; <a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>). </p> </section> <section id="CD007662-sec-0078"> <h4 class="title">Other potential sources of bias</h4> <p>There were few other potential sources of bias. Of note, most studies reported a marked female predominance in percentage of participants, however the effect of this is unclear (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>; <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). A few of the studies also reported either industry‐funding (<a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>), medication provided by the pharmaceutical industry (<a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>), or had authors who worked as consultants for pharmaceutical companies (<a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>). The relevance of this with regards to potential bias was rated as unclear. </p> </section> </section> <section id="CD007662-sec-0079"> <h3 class="title" id="CD007662-sec-0079">Effects of interventions</h3> <p>See: <a href="./full#CD007662-tbl-0001"><b>Summary of findings 1</b> Antioxidants versus placebo for trichotillomania in adults</a>; <a href="./full#CD007662-tbl-0002"><b>Summary of findings 2</b> Antioxidants versus placebo for trichotillomania in adolescents</a>; <a href="./full#CD007662-tbl-0003"><b>Summary of findings 3</b> Antipsychotics versus placebo for trichotillomania in adults</a>; <a href="./full#CD007662-tbl-0004"><b>Summary of findings 4</b> Cell signal transducers versus placebo for trichotillomania in adults</a>; <a href="./full#CD007662-tbl-0005"><b>Summary of findings 5</b> Glutamate modulators versus placebo for trichotillomania in adults</a>; <a href="./full#CD007662-tbl-0006"><b>Summary of findings 6</b> Glutamate modulators versus placebo for trichotillomania in children and adolescents</a>; <a href="./full#CD007662-tbl-0007"><b>Summary of findings 7</b> Opioid antagonists versus placebo for trichotillomania in adults</a>; <a href="./full#CD007662-tbl-0008"><b>Summary of findings 8</b> SSRIs versus placebo for trichotillomania in adults</a>; <a href="./full#CD007662-tbl-0009"><b>Summary of findings 9</b> TCAs with predominantly SRI actions versus placebo for trichotillomania in adults</a>; <a href="./full#CD007662-tbl-0010"><b>Summary of findings 10</b> TCAs with predominantly SRI actions versus other TCAs for trichotillomania in adults</a> </p> <p>See <a href="./full#CD007662-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD007662-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD007662-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD007662-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD007662-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD007662-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD007662-tbl-0007">summary of findings Table 7</a>; <a href="./full#CD007662-tbl-0008">summary of findings Table 8</a>; <a href="./full#CD007662-tbl-0009">summary of findings Table 9</a>; <a href="./full#CD007662-tbl-0010">summary of findings Table 10</a> for more information on the quality of the evidence. </p> <p>Please refer to <a href="#CD007662-sec-0026">Types of outcome measures</a> for a description of the scoring systems used in included studies. </p> <section id="CD007662-sec-0080"> <h4 class="title">Comparison 1: antioxidants versus placebo for trichotillomania in adults</h4> <section id="CD007662-sec-0081"> <h5 class="title">Primary outcomes</h5> <section id="CD007662-sec-0082"> <h6 class="title">Treatment response</h6> <p>The cross‐over study by <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a> showed no evidence of benefit for silymarin (milk thistle extract) compared to placebo with regards to treatment response in adult participants after six weeks of treatment. On the Clinical Global Impressions ‐ Improvement scale (CGI‐I), 5 of 14 (35.7%) participants in the silymarin group compared to 4 of 14 (28.6%) participants in the placebo group showed "much" or "very much" improvement. This excludes data from four participants who were lost to follow‐up. There was no difference between groups when analysed using a best‐case scenario, ITT analysis (risk ratio (RR) 2.25, 95% confidence interval (CI) 0.84 to 5.99; 1 study, 36 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0004" title="">Analysis 1.1</a>.1). We rated the certainty of the evidence as low due to high imprecision from a small sample size and wide confidence interval. </p> </section> <section id="CD007662-sec-0083"> <h6 class="title">Reduction of TTM symptom severity</h6> <p>In this single trial, adult participants in the silymarin group showed no difference in reduction of TTM symptom severity compared to those in the placebo group on any of the outcome scales employed, including the Clinical Global Impressions ‐ Severity scale (CGI‐S: mean difference (MD) ‐0.50, 95% CI ‐1.31 to 0.31; 1 study, 27 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0005" title="">Analysis 1.2</a>.1), the Massachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS: MD ‐1.80, 95% CI ‐6.22 to 2.62; 1 study, 27 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0005" title="">Analysis 1.2</a>.2), and the National Institute of Mental Health ‐ Trichotillomania Severity Scale (NIMH‐TSS: MD ‐1.00, 95% CI ‐5.00 to 3.00; 1 study, 27 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0005" title="">Analysis 1.2</a>.3). We rated the certainty of the evidence as low due to high imprecision from a small sample size and wide confidence intervals. </p> </section> </section> <section id="CD007662-sec-0084"> <h5 class="title">Secondary outcomes</h5> <section id="CD007662-sec-0085"> <h6 class="title">Reduction of comorbid symptoms of depression</h6> <p>In the adult participants of the <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a> study, there was no evidence to support the treatment of comorbid symptoms of depression with silymarin versus placebo based on the HAM‐D scale (MD 0.60, 95% CI ‐1.82 to 3.02; 1 study, 27 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0006" title="">Analysis 1.3</a>), and both groups were under the threshold for clinical depression at baseline and endpoint. We rated the certainty of this evidence as low for high imprecision due to small sample size and a wide confidence interval. </p> </section> <section id="CD007662-sec-0086"> <h6 class="title">Quality of life ‐ functional disability</h6> <p>In the <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a> study, quality of life in adults was assessed using the Sheehan Disability Scale (SDS). There was no evidence to support a beneficial effect of silymarin versus placebo for the improvement in functional impairment (MD ‐0.60, 95% CI ‐6.53 to 5.33; 1 study, 27 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0007" title="">Analysis 1.4</a>). We rated the certainty of this evidence as low for high imprecision due to small sample size and a wide confidence interval. </p> </section> <section id="CD007662-sec-0087"> <h6 class="title">Tolerability of treatment ‐ dropouts due to adverse events</h6> <p>In the <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a> trial of silymarin versus placebo, no adult participants withdrew from the study as the result of adverse events (0% for silymarin versus 0% for placebo; 1 study, 18 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD007662-sec-0088"> <h6 class="title">Tolerability of treatment ‐ common adverse events ( &gt; 20%)</h6> <p>In the <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a> trial, there were five reports of adverse events in the silymarin group; namely, nausea, upset stomach, bloating, insomnia and headache. In addition, there were four reports of nausea, upset stomach, bloating and dry mouth in the placebo group. The adverse effects were all of mild intensity. None of the adverse effects occurred at a rate of 20% or more. The trial did not report whether these were in adult or adolescent participants. </p> </section> </section> </section> <section id="CD007662-sec-0089"> <h4 class="title">Comparison 2: antioxidants versus placebo for trichotillomania in adolescents</h4> <section id="CD007662-sec-0090"> <h5 class="title">Primary outcomes</h5> <section id="CD007662-sec-0091"> <h6 class="title">Treatment response</h6> <p>The adolescents in the study by <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a> showed no difference between silymarin and placebo in terms of number of treatment responders using the CGI‐I scale, with two of four participants (50%) in the silymarin group showing response to treatment as compared to one of four (25%) in the placebo group, using an ITT analysis (RR 2.00, 95% CI 0.28 to 14.20; 1 study, 8 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0009" title="">Analysis 2.1</a>). We rated the certainty of this evidence as low for high imprecision, due to small sample size and wide confidence interval. </p> </section> <section id="CD007662-sec-0092"> <h6 class="title">Reduction of TTM symptom severity</h6> <p>Data calculated for adolescents in this trial showed no difference in reduction of TTM symptom severity for the silymarin group compared to those in the placebo group on any of the outcome scales employed, including the CGI‐S (MD ‐1.13, 95% CI ‐2.72 to 0.46; 1 study, 6 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0010" title="">Analysis 2.2</a>.1), the MGH‐HPS (MD ‐5.87, 95% CI ‐17.46 to 5.72; 1 study, 6 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0010" title="">Analysis 2.2</a>.2), the NIMH‐TSS (MD ‐2.94, 95% CI ‐8.14 to 2.26; 1 study, 6 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0010" title="">Analysis 2.2</a>.3), the Trichotillomania Scale for Children ‐ Child version (TSC‐C: MD 0.00, 95% CI ‐1.25 to 1.25; 1 study, 6 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0010" title="">Analysis 2.2</a>.4), and the TSC‐Parent version (TSC‐P: MD ‐1.20, 95% CI ‐1.48 to ‐0.92; 1 study, 6 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0010" title="">Analysis 2.2</a>.5). We assessed the certainty of the evidence as low due to high imprecision from a small sample size and wide confidence intervals. </p> </section> </section> <section id="CD007662-sec-0093"> <h5 class="title">Secondary outcomes</h5> <section id="CD007662-sec-0094"> <h6 class="title">Reduction of comorbid symptoms of depression</h6> <p>In the adolescents in the <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a> study, there was no evidence to support the treatment of comorbid symptoms of depression with silymarin versus placebo using the HAM‐D scale (MD ‐1.62, 95% CI ‐3.98 to 0.74; 1 study, 7 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0011" title="">Analysis 2.3</a>). Both the silymarin and placebo groups were under the threshold for clinical depression at baseline and endpoint. We rated the certainty of this evidence as low for high imprecision due to small sample size and a wide confidence interval. </p> </section> <section id="CD007662-sec-0095"> <h6 class="title">Quality of life ‐ functional disability</h6> <p><a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a> used the SDS to assess functional impairment for adolescents. There was no evidence to support a beneficial effect of silymarin versus placebo with regards to functional impairment (MD ‐1.30, 95% CI ‐8.43 to 5.83; 1 study, 6 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0012" title="">Analysis 2.4</a>). We rated the certainty of this evidence as low for high imprecision due to small sample size and a wide confidence interval. </p> </section> <section id="CD007662-sec-0096"> <h6 class="title">Tolerability of treatment ‐ dropouts due to adverse events</h6> <p>In the <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a> trial of silymarin versus placebo, no adolescents withdrew from the study as the result of adverse events (0% for silymarin versus 0% for placebo; 1 study, 4 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0013" title="">Analysis 2.5</a>). </p> </section> <section id="CD007662-sec-0097"> <h6 class="title">Tolerability of treatment ‐ common adverse events ( &gt; 20%)</h6> <p>As reported for adults above, in the single trial comparing silymarin to placebo, there were five reports of adverse effects in the silymarin group (nausea, upset stomach, bloating, insomnia and headache) and four reports of adverse effects in the placebo group (nausea, upset stomach, bloating and dry mouth), none of which occurred at a rate of 20% or more, and all of mild intensity. The trial did not report whether these were in adult or adolescent participants. </p> </section> </section> </section> <section id="CD007662-sec-0098"> <h4 class="title">Comparison 3: antipsychotics versus placebo for trichotillomania in adults</h4> <section id="CD007662-sec-0099"> <h5 class="title">Primary outcomes</h5> <section id="CD007662-sec-0100"> <h6 class="title">Treatment response</h6> <p>The study by <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a> yielded probable moderate treatment effects for olanzapine when compared with placebo on all primary outcome measures and was effective at a mean dose of 10.8 mg per day after a mean duration of 8.2 weeks (SD = 3.4 weeks). </p> <p>On the CGI‐I in a single trial, those in the olanzapine group were more likely to respond to treatment compared with placebo, with 11 of 13 (85%) participants in the olanzapine group showing response to treatment compared to 2 of 12 (17%) in the placebo group, based on low‐certainty evidence (RR 5.08, 95% CI 1.40 to 18.37; 1 study, 25 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0014" title="">Analysis 3.1</a>). The NNT with olanzapine to receive an additional beneficial outcome was 1.5 people (95% CI 1.0 to 2.5). We rated the certainty of the evidence as low due to high imprecision from a small sample size. </p> </section> <section id="CD007662-sec-0101"> <h6 class="title">Reduction of TTM symptom severity</h6> <p>In a single trial, participants in the olanzapine group showed likely greater reduction in TTM symptom severity compared to those in the placebo group, as seen across all outcome scales employed, including the CGI‐S (MD ‐1.68, 95% CI ‐2.31 to ‐1.05; 1 study, 25 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0015" title="">Analysis 3.2</a>.1), the MGH‐HPS (MD ‐4.87, 95% CI ‐8.84 to ‐0.90; 1 study, 25 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0015" title="">Analysis 3.2</a>.2), and the Yale‐Brown Obsessive‐Compulsive Scale for Trichotillomania (TTM‐YBOCS) (MD ‐7.63, 95% CI ‐12.35 to ‐2.91; 1 study, 25 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0015" title="">Analysis 3.2</a>.3). We rated the certainty of the evidence as low due to high imprecision from a small sample size. All effect sizes were moderate. </p> </section> </section> <section id="CD007662-sec-0102"> <h5 class="title">Secondary outcomes</h5> <section id="CD007662-sec-0103"> <h6 class="title">Tolerability of treatment ‐ dropouts due to adverse events</h6> <p>In the <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a> trial of olanzapine versus placebo, no participants withdrew from the study as the result of adverse effects (0% for olanzapine versus 0% for placebo; 1 study, 25 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0016" title="">Analysis 3.3</a>). </p> </section> <section id="CD007662-sec-0104"> <h6 class="title">Tolerability of treatment ‐ common adverse events ( &gt; 20%)</h6> <p>In a single trial, the most common adverse effects in the olanzapine group compared to the placebo group were dry mouth (54% for olanzapine (N = 7) versus 0% for placebo; RR 13.93, 95% CI 0.88 to 220.37; 1 study, 25 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0017" title="">Analysis 3.4</a>.1), fatigue (54% for olanzapine (N = 7) versus 0% for placebo; RR 13.93, 95% CI 0.88 to 220.37; 1 study, 25 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0017" title="">Analysis 3.4</a>.2), increased appetite (46% for olanzapine (N = 6) versus 0% for placebo; RR 12.07, 95% CI 0.75 to 193.73; 1 study, 25 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0017" title="">Analysis 3.4</a>.3), headache (38% for olanzapine (N = 5) versus 33% for placebo (N = 4); RR 10.21, 95% CI 0.62 to 167.12; 1 study, 25 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0017" title="">Analysis 3.4</a>.4) and weight gain (38% for olanzapine (N = 5) versus 8% for placebo (N = 1); RR 10.21, 95% CI 0.62 to 167.12; 1 study, 25 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0017" title="">Analysis 3.4</a>.5). Four of the 25 participants experienced no adverse events. We rated the certainty of this evidence as low due to high imprecision from a small sample size and wide confidence intervals. </p> </section> <section id="CD007662-sec-0105"> <h6 class="title">Reduction of comorbid symptoms of depression</h6> <p>Treatment of comorbid symptoms of depression was an outcome of interest in the <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a> study; however, no data were reported. A narrative summary reports little to no effect on the Beck Depression Inventory (<a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). Summary statistics were not available for further analysis. </p> </section> <section id="CD007662-sec-0106"> <h6 class="title">Quality of life ‐ functional disability</h6> <p>Quality of life was an outcome of interest in the <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a> study; however, no data were reported. A narrative summary reports little to no effect on the SDS and on the Quality of Life Enjoyment and Satisfaction Questionnaire (Q‐LES‐Q) (<a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>. Summary statistics were not available for further analysis. </p> </section> </section> </section> <section id="CD007662-sec-0107"> <h4 class="title">Comparison 4: cell signal transducers versus placebo for trichotillomania in adults</h4> <section id="CD007662-sec-0108"> <h5 class="title">Primary outcomes</h5> <section id="CD007662-sec-0109"> <h6 class="title">Treatment response</h6> <p>The study by <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a> showed no difference between inositol and placebo in terms of number of treatment responders using the CGI‐I scale with 8 of 19 (42.1%) in the inositol group showing response to treatment as compared to 6 of 12 (50%) in the placebo group, which excluded 7 participants who failed to complete the study. Using a best‐case scenario and ITT analysis, there was no effect of inositol on treatment response (RR 1.33, 95% CI 0.57 to 3.11; 1 study, 38 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0018" title="">Analysis 4.1</a>). We judged the certainty of this evidence as low due to high imprecision, small sample size and wide confidence interval. </p> </section> <section id="CD007662-sec-0110"> <h6 class="title">Reduction of TTM symptom severity</h6> <p>Using data from the trial protocol (NCT01875445 on <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>) we calculated the effect size of inositol versus placebo and found no difference between inositol and placebo in the reduction of TTM symptom severity on the MGH‐HPS (MD ‐1.30, 95% CI ‐5.12 to 2.52; 1 study, 38 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0019" title="">Analysis 4.2</a>.1) or on the NIMH‐TSS (MD 0.00, 95% CI ‐3.37 to 3.37; 1 study, 38 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0019" title="">Analysis 4.2</a>.2). We rated the certainty of this evidence as low due to high imprecision, small sample size and wide confidence intervals. </p> </section> </section> <section id="CD007662-sec-0111"> <h5 class="title">Secondary outcomes</h5> <section id="CD007662-sec-0112"> <h6 class="title">Tolerability of treatment ‐ dropouts due to adverse events</h6> <p>In the <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a> trial of inositol versus placebo, no participants withdrew from the study as the result of adverse events (0% for inositol versus 0% for placebo; 1 study, 38 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0020" title="">Analysis 4.3</a>). </p> </section> <section id="CD007662-sec-0113"> <h6 class="title">Tolerability of treatment ‐ common adverse events ( &gt; 20%)</h6> <p>In the <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a> study, within the inositol treatment group there were 11 minor adverse events reported and one case of ectopic pregnancy, a notable major adverse event. However, it was noted that the participant’s current birth control conferred an elevated risk of ectopic pregnancy, thus the event was likely unrelated to inositol. </p> <p>Other minor adverse experiences reported were of mild intensity and included nausea or upset stomach (4 of 19 (21%) for inositol versus 2 of 19 (10.5%) for placebo; RR 2.00, 95% CI 0.41 to 9.65; 1 study, 38 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0021" title="">Analysis 4.4</a>.1), stomach pain (10.5% for inositol versus 0% for placebo), diarrhoea (10.5% for inositol versus 0% for placebo), gas (5.3% for inositol versus 0% for placebo) and headache (10.5% for inositol versus 10.5% for placebo). RR was only calculated for adverse events with an incidence above 20%. There was little to no difference between groups regarding tolerability of treatment. We rated the certainty of this evidence as low due to high imprecision, small sample size and wide confidence interval. </p> </section> <section id="CD007662-sec-0114"> <h6 class="title">Reduction of comorbid symptoms of depression</h6> <p><a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a> measured comorbid depressive symptoms using the Hamilton Depression Rating scale (HAM‐D) and found little to no treatment type‐by‐time interaction for inositol versus placebo (<a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>). No further data were available for analysis. </p> </section> <section id="CD007662-sec-0115"> <h6 class="title">Quality of life ‐ functional disability</h6> <p><a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a> measured quality of life using the Quality of Life Inventory (QoLI) and SDS, and found little to no treatment type‐by‐time interactions for inositol versus placebo. No further data were available for analysis (<a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>). </p> </section> </section> </section> <section id="CD007662-sec-0116"> <h4 class="title">Comparison 5: glutamate modulators versus placebo for trichotillomania in adults</h4> <section id="CD007662-sec-0117"> <h5 class="title">Primary outcomes</h5> <section id="CD007662-sec-0118"> <h6 class="title">Treatment response</h6> <p>The study by <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a> of N‐acetylcysteine (NAC) versus placebo shows that NAC at a dose of 1200 mg twice a day was probably effective when compared with placebo. This finding was based on all primary outcome measures, although it is based on a single trial. NAC had a probable treatment effect on the CGI‐I compared to placebo, with a 3.5 times greater chance of responding to treatment for those receiving NAC (RR 3.50, 95% CI 1.34 to 9.17; 1 study, 50 participants; moderate‐certainty evidence; <a href="./references#CD007662-fig-0022" title="">Analysis 5.1</a>), and a number needed to treat (NNT) for an additional favourable outcome of 2.5 people (95% CI of 2 to 6). We judged the certainty of the evidence as moderate, downgrading for imprecision due to small sample size. </p> </section> <section id="CD007662-sec-0119"> <h6 class="title">Reduction of TTM symptom severity</h6> <p>Reduction of symptoms as measured by the CGI‐S showed a probable benefit for NAC over placebo, although based on a single trial (MD ‐1.24, 95% CI ‐1.93 to ‐0.55; 1 study, 50 participants; moderate‐certainty evidence; <a href="./references#CD007662-fig-0023" title="">Analysis 5.2</a>.1). This likely beneficial effect in favour of NAC over placebo was also found on the patient‐rated MGH‐HPS (MD ‐5.60, 95% CI ‐8.50 to ‐2.70; 1 study, 50 participants; moderate‐certainty evidence; <a href="./references#CD007662-fig-0023" title="">Analysis 5.2</a>.2) and the Psychiatric Institute Trichotillomania Scale (PITS: MD ‐6.90, 95% CI ‐10.56 to ‐3.24; 1 study, 50 participants; moderate‐certainty evidence; <a href="./references#CD007662-fig-0023" title="">Analysis 5.2</a>.3). The treatment effect on the MGH‐HPS was first noted at nine weeks. We judged the certainty of the evidence as moderate for each scale, and downgraded for imprecision due to small sample size. </p> </section> </section> <section id="CD007662-sec-0120"> <h5 class="title">Secondary outcomes</h5> <section id="CD007662-sec-0121"> <h6 class="title">Reduction of comorbid symptoms of depression</h6> <p>In the <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a> study, which compared NAC to placebo, depression severity was assessed using the HAM‐D. No clinical depression was detected in the group at baseline. No evidence was found to support the treatment of comorbid depression with NAC compared to placebo, based on a single trial (HAM‐D: MD ‐0.96, 95% CI ‐2.88 to 0.96; 1 study, 50 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0024" title="">Analysis 5.3</a>). We judged the certainty of the evidence as low due to high imprecision from a small sample size and wide confidence interval. </p> </section> <section id="CD007662-sec-0122"> <h6 class="title">Quality of life ‐ functional disability</h6> <p>For NAC versus placebo, SDS was used to measure psychosocial functioning and quality of life. Although there appeared to be some improvement in functioning and quality of life for those assigned to the NAC group, the evidence suggests no difference for the outcome on the Sheehan Disability Scale, based on a single trial (SDS: MD ‐2.76, 95% CI ‐5.58 to 0.06; 1 study, 50 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0025" title="">Analysis 5.4</a>) (<a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>). We rated the certainty of the evidence as low due to high imprecision from a small sample size and wide confidence interval. </p> </section> <section id="CD007662-sec-0123"> <h6 class="title">Tolerability of treatment ‐ dropouts due to adverse events</h6> <p>In the <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a> trial of NAC versus placebo, no participants withdrew from the study as the result of adverse events (0% for NAC versus 0% for placebo; 1 study, 50 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0026" title="">Analysis 5.5</a>). </p> </section> <section id="CD007662-sec-0124"> <h6 class="title">Tolerability of treatment ‐ common adverse events ( &gt; 20%)</h6> <p>In the <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a> trial of NAC versus placebo, participants receiving NAC (N = 25) did not experience any adverse effects. Of participants receiving placebo (N = 25), one complained of nausea (4%), two of diarrhoea (8%) and one of cough (4%). We did not calculate the risk ratio as no adverse event had a prevalence higher than 20%. </p> </section> </section> </section> <section id="CD007662-sec-0125"> <h4 class="title">Comparison 6: glutamate modulators versus placebo for trichotillomania in children and adolescents </h4> <section id="CD007662-sec-0126"> <h5 class="title">Primary outcomes</h5> <section id="CD007662-sec-0127"> <h6 class="title">Treatment response</h6> <p>The study by <a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a> of N‐acetylcysteine (NAC) versus placebo showed little to no treatment effect on the CGI‐I for NAC, although based on a single trial in children and adolescents (RR 1.19, 95% CI 0.37 to 3.77; 1 study, 39 participants; <a href="./references#CD007662-fig-0027" title="">Analysis 6.1</a>). We rated the certainty of this evidence as low due to high imprecision from a small sample size and wide confidence interval. </p> </section> <section id="CD007662-sec-0128"> <h6 class="title">Reduction of TTM symptom severity</h6> <p>Evidence for TTM symptom severity reduction, as measured by the MGH‐HPS, suggests a potentially large benefit for NAC over placebo in reducing TTM symptom severity, although based on a single trial in children and adolescents (MD ‐2.83, 95% CI ‐3.76 to ‐1.90; 1 study, 39 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0028" title="">Analysis 6.2</a>.1). A likely effect in favour of NAC over placebo was also found on the NIMH‐TSS (MD ‐1.33, 95% CI ‐1.97 to ‐0.69; 1 study, 39 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0028" title="">Analysis 6.2</a>.2). Little to no effect was found for NAC compared to placebo on the Trichotillomania Scale for Children ‐ Child version (TSC‐C: MD ‐0.08, 95% CI ‐0.22 to 0.06; 1 study, 39 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0028" title="">Analysis 6.2</a>.3) or Parent version (TSC‐P: MD ‐0.05, 95% CI ‐0.16 to 0.06; 1 study, 39 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0028" title="">Analysis 6.2</a>.4). We rated the certainty of this evidence as low due to high imprecision from a small sample size. </p> </section> </section> <section id="CD007662-sec-0129"> <h5 class="title">Secondary outcomes</h5> <section id="CD007662-sec-0130"> <h6 class="title">Reduction of comorbid symptoms of depression</h6> <p>In the <a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a> study, which compared NAC to placebo, depression severity was assessed using the Children's Depression Inventory (CDI). At baseline assessment, 20% of participants reported current depression. The evidence suggests benefit for the placebo group compared to the NAC group on the CDI, although based on a single trial (MD 3.1, 95% CI 1.91 to 4.29; 1 study, 39 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0029" title="">Analysis 6.3</a>). We rated the certainty of this evidence as low due to high imprecision from a small sample size. </p> </section> <section id="CD007662-sec-0131"> <h6 class="title">Tolerability of treatment ‐ dropouts due to adverse events</h6> <p>In the <a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a> trial of NAC versus placebo, one participant in the NAC group developed a whole‐body rash at week 4 and withdrew from the study as a result of this adverse event. There was no difference between NAC and placebo groups regarding attrition rate due to adverse events (5% for NAC versus 0% for placebo; RR 2.86, 95% CI 0.12 to 66.11; 1 study, 39 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0030" title="">Analysis 6.4</a>). We rated the certainty of this evidence as low due to high imprecision from a small sample size and a wide confidence interval. </p> </section> <section id="CD007662-sec-0132"> <h6 class="title">Tolerability of treatment ‐ common adverse events ( &gt; 20%)</h6> <p>In the <a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a> trial of NAC versus placebo, nausea was experienced by participants receiving both NAC (6 of 20; 30%) and placebo (12 of 19; 63%). Nausea was reported more frequently in the placebo group in this single trial (RR 0.47, 95% CI 0.22 to 1.01; 1 study, 39 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0031" title="">Analysis 6.5</a>). There were no other common adverse events ( &gt; 20%) in either group. We rated the certainty of this evidence as low due to high imprecision from a small sample size and a wide confidence interval. </p> </section> <section id="CD007662-sec-0133"> <h6 class="title">Quality of life ‐ functional disability</h6> <p>This was not an outcome of interest in the <a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a> study; therefore, no data were available. </p> </section> </section> </section> <section id="CD007662-sec-0134"> <h4 class="title">Comparison 7: opioid antagonists versus placebo for trichotillomania in adults</h4> <p>Two studies compared naltrexone to placebo (<a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>). We report the results of the two studies together, although we could not fully synthesise the results. Most analyses were possible for only one of the two studies (<a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>), due to lack of available data from the other study (<a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>). However, we did conduct meta‐analysis for the first outcome of treatment response. </p> <section id="CD007662-sec-0135"> <h5 class="title">Primary outcomes</h5> <section id="CD007662-sec-0136"> <h6 class="title">Treatment response</h6> <p>The study by <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a> reports little to no difference between naltrexone and placebo in terms of number of treatment responders on the CGI‐I with 9 of 25 (36%) of those in the naltrexone group showing “much” or “very much” improvement as compared to 9 of 26 (34.6%) of those in the placebo group. The study by <a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a> was not published, and the study authors have not kept the raw data. They report that three (43%) of the participants receiving naltrexone as compared to zero (0%) in the placebo group experienced a greater than 50% reduction in TTM symptom severity as measured by the NIMH‐TSS. Meta‐analysis showed no beneficial treatment effect; however, the evidence is very uncertain about the effect of opioid antagonists on treatment response (RR 2.14, 95% CI 0.25 to 18.17; I² = 59%; 2 studies, 68 participants; very low‐certainty evidence; <a href="./references#CD007662-fig-0032" title="">Analysis 7.1</a>). We rated the certainty of this evidence as very low due to inconsistency and high imprecision from a small sample size and a wide confidence interval. </p> </section> <section id="CD007662-sec-0137"> <h6 class="title">Reduction of TTM symptom severity</h6> <p>In the study by <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>, on the CGI‐S, there was no effect of naltrexone versus placebo in reducing TTM symptom severity (MD ‐0.37, 95% CI ‐1.10 to 0.36; 1 study, 51 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0033" title="">Analysis 7.2</a>.1). On the MGH‐HPS, their primary outcome for reduction in TTM symptom severity, there was no effect of naltrexone versus placebo (MD ‐1.14, 95% CI ‐4.18 to 1.90; 1 study, 51 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0033" title="">Analysis 7.2</a>.2). Using the NIMH‐TSS scale, there was also no effect seen (MD ‐0.79, 95% CI ‐3.62 to 2.04; 1 study, 51 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0033" title="">Analysis 7.2</a>.3). We rated the certainty of the evidence as low due to high imprecision from a small sample size and wide confidence intervals. </p> <p><a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a> reported evidence for benefit of naltrexone based on the NIMH‐TSS, although summary statistics were unavailable for meta‐analysis. The other outcome measures, however, did not yield evidence in favour of naltrexone on the NIMH‐Trichotillomania Impairment Scale (NIMH‐TIS), the NIMH Physician Rating Scale score, the number of hair‐pulling episodes, and the estimated number of hairs pulled as per narrative summaries in the original abstract. We did not assess the certainty of the evidence for this study as we were unable to calculate MD or SMD, and it was not clear which statistical tests were employed. </p> </section> </section> <section id="CD007662-sec-0138"> <h5 class="title">Secondary outcomes</h5> <section id="CD007662-sec-0139"> <h6 class="title">Reduction of comorbid symptoms of depression</h6> <p>In the <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a> study, there was no evidence to support the treatment of comorbid symptoms of depression with naltrexone versus placebo based on the HAM‐D scale (MD 0.66, 95% CI ‐1.26 to 2.58; 1 study, 51 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0034" title="">Analysis 7.3</a>), and both groups were under the threshold for clinical depression at baseline and endpoint. We rated the certainty of the evidence as low for high imprecision due to small sample size and a wide confidence interval. </p> <p>In the <a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a> study, no data measuring comorbid symptoms of depression were available as this was not an outcome of interest. </p> </section> <section id="CD007662-sec-0140"> <h6 class="title">Quality of life ‐ functional disability</h6> <p>In the <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a> study, no evidence was found on the SDS to support the use of naltrexone versus placebo for the reduction of functional disability (MD ‐1.91, 95% CI ‐5.82 to 2.00; 1 study, 51 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0035" title="">Analysis 7.4</a>). We rated the certainty of the evidence as low due to high imprecision from a small sample size and a wide confidence interval. </p> <p>Quality of life ‐ reduction of functional disability was not an outcome of interest for the other naltrexone trial (<a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>); therefore, no data were available. </p> </section> <section id="CD007662-sec-0141"> <h6 class="title">Tolerability of treatment ‐ common adverse events ( &gt; 20%)</h6> <p>In the <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a> study of naltrexone, there were few adverse experiences. Sedation was the only reported adverse effect that occurred more frequently in those taking naltrexone (3 of 25; 12%) compared to placebo (1 of 26; 3.8%), although based on a single trial (RR 3.12, 95% CI 0.35 to 28.03; 1 study, 51 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0036" title="">Analysis 7.5</a>). Liver function testing by alanine aminotransferase (ALT), aspartate aminotransferase (AST) and ALT/AST ratio demonstrated little to no change between or within groups from baseline to endpoint. We rated the certainty of the evidence as low due to high imprecision from a small sample size and wide confidence interval. </p> <p>No data related to adverse effects were derived from the other trial on naltrexone versus placebo as this was not an outcome of interest (<a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>). </p> </section> <section id="CD007662-sec-0142"> <h6 class="title">Tolerability of treatment ‐ dropouts due to adverse events</h6> <p>This was not an outcome of interest in either the <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a> or <a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a> studies; therefore, no data were available. </p> </section> </section> </section> <section id="CD007662-sec-0143"> <h4 class="title">Comparison 8: SSRIs versus placebo for trichotillomania in adults</h4> <p>Within the SSRI class, two studies of fluoxetine versus placebo presented drug‐by‐period interaction data as F, df and P values (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>). Neither of the principal authors of these studies was able to provide the original data from the trials to make individual participant analysis (IDP) possible. Therefore, we describe the results of these trials individually. For the third SSRI study, a sertraline study, we obtained mean change scores for the primary outcome measure from the first author (<a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>). None of the SSRI trials reported effect of SSRI on treatment response compared to placebo; therefore, data were unavailable for further analysis of this outcome. </p> <section id="CD007662-sec-0144"> <h5 class="title">Primary outcomes</h5> <section id="CD007662-sec-0145"> <h6 class="title">Treatment response</h6> <p>Dichotomous treatment response was not an outcome of interest in the <a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>, <a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a> or <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a> studies; therefore, no further data were available for analysis. </p> </section> <section id="CD007662-sec-0146"> <h6 class="title">Reduction of TTM symptom severity</h6> <p>Results of the initial 12‐week phase of the <a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a> trial comparing sertraline versus placebo were not published, as this phase of the trial was not the focus of the study. We obtained from the first author the mean change scores on their primary outcome measure, the MGH‐HPS (mean change score for sertraline = ‐1.53, SD 5.54; mean change score for placebo = ‐1.06, SD 5.34). Our analysis showed the evidence was very uncertain with regards to the effect of sertraline compared with placebo in reduction of TTM symptom severity, based on a single trial (MD ‐0.47, 95% CI ‐4.30 to 3.36; 1 study, 31 participants; very low‐certainty evidence; <a href="./references#CD007662-fig-0038" title="">Analysis 8.2</a>). We judged the certainty of this evidence as very low due to indirectness (using mean change scores rather than MD), high imprecision (wide confidence interval and small sample size) and risk of attrition bias. </p> </section> </section> <section id="CD007662-sec-0147"> <h5 class="title">Secondary outcomes</h5> <section id="CD007662-sec-0148"> <h6 class="title">Reduction of comorbid symptoms of depression</h6> <p>In the cross‐over study by <a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>, mean baseline scores on both the HAM‐D and the BDI were below the threshold for clinical depression. Mean differences between fluoxetine and placebo showed no difference on either scale (HAM‐D: MD 0.80, 95% CI ‐1.90 to 3.50; 1 study, 32 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0039" title="">Analysis 8.3</a>). A drug‐by‐period interaction was noted for the HAM‐D scores, but in the opposite direction of that anticipated: an improvement in depression was observed during the placebo phase and a worsening of depression during the fluoxetine phase. We rated the certainty of this evidence as low due to imprecision with a wide confidence interval and small sample size. </p> <p>In the cross‐over study by <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>, mean baseline scores on both the HAM‐D and the BDI were below the threshold for clinical depression. Scores from the fluoxetine and placebo treatment periods were combined, so that the effect of fluoxetine cannot be differentiated from the effect of placebo. No drug‐by‐period interaction was reported for the HAM‐D or the BDI. We did not rate the certainty of this evidence as we were unable to calculate MD or SMD. </p> <p>No data were available on symptoms of comorbid depression for the pharmacotherapy phase of the trial comparing sertraline versus placebo (<a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>). However, a narrative summary stated that there were no differences between groups observed on final scores on the HAM‐D or BDI (<a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>). </p> </section> <section id="CD007662-sec-0149"> <h6 class="title">Tolerability of treatment ‐ dropouts due to adverse events</h6> <p>In the <a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a> cross‐over trial of fluoxetine versus placebo, 1 of 17 participants (5.9%) withdrew from the trial after developing urticaria during week four of fluoxetine. In the <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a> cross‐over trial of fluoxetine versus placebo, 1 of 23 participants (4.3%) withdrew from the trial during the fluoxetine phase because of a severe serum sickness–like syndrome during week seven. Meta‐analysis shows no effect of fluoxetine on dropouts due to adverse events, based on two trials (5.1% for SSRI versus 0% for placebo; RR 3.00, 95% CI 0.33 to 27.62; I² = 0%; 2 studies, 78 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0040" title="">Analysis 8.4</a>). We judged the certainty of this evidence as low due to high imprecision from a small sample size and wide confidence interval. No data were available on adverse drug effects for the pharmacotherapy phase of the trial comparing sertraline to placebo, as it was not an outcome of interest for this study (<a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>). </p> </section> <section id="CD007662-sec-0150"> <h6 class="title">Tolerability of treatment ‐ common adverse events ( &gt; 20%)</h6> <p>In the <a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a> trial, the most common adverse event was nausea, which was reported in 5 of 17 (29.4%) participants taking fluoxetine and in 2 of 17 (11.8%) of participants taking placebo (RR 2.5, 95% CI 0.56 to 11.16; 1 study, 34 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0041" title="">Analysis 8.5</a>.1). We rated the certainty of this evidence as low due to high imprecision and risk of attrition bias. In the <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a> trial, common adverse events were categorised as central nervous system (CNS) and gastrointestinal (GIT) effects. CNS effects (including nightmares, insomnia, dizziness, irritability, anxiety and a feeling of doom) as a category affected 22 of 23 participants (95.7%) during the fluoxetine phase of the trial versus 16 of 23 participants (69.6%) during the placebo phase in this single trial (RR 1.38, 95% CI 1.04 to 1.83; 1 study, 46 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0041" title="">Analysis 8.5</a>.2). GIT effects (including decreased appetite, diarrhoea, constipation, nausea, increased weight, abdominal pain and dyspepsia) as a category affected 14 of 23 participants (60.9%) in the fluoxetine phase of the trial and only 3 of 23 participants (13.0%) during the placebo phase (RR 4.67, 95% CI 1.55 to 14.09; 1 study, 46 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0041" title="">Analysis 8.5</a>.3). We rated the certainty of this evidence as low due to high imprecision and risk of attrition bias. No data were available on adverse drug effects for the pharmacotherapy phase of the trial comparing sertraline versus placebo as it was not an outcome of interest for this trial (<a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>). </p> </section> <section id="CD007662-sec-0151"> <h6 class="title">Quality of life ‐ functional disability</h6> <p>There were no data available for analysis of the effect of sertraline on quality of life or functional disability compared to placebo. A narrative summary of the effect of sertraline on quality of life compared to placebo states that no differences between groups were observed in final scores on the Quality of Life Enjoyment and Satisfaction Questionnaire (Q‐LES‐Q) (<a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>). </p> <p>Data were unavailable from the fluoxetine versus placebo trials as quality of life was not an outcome of interest in these studies (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>). </p> </section> </section> </section> <section id="CD007662-sec-0152"> <h4 class="title">Comparison 9: TCAs <i>with predominantly SRI actions</i> versus placebo for trichotillomania in adults </h4> <p>One parallel‐arm trial of clomipramine versus placebo is included in the review (<a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>). The evidence was very uncertain regarding the efficacy of clomipramine in this study. </p> <section id="CD007662-sec-0153"> <h5 class="title">Primary outcomes</h5> <section id="CD007662-sec-0154"> <h6 class="title">Treatment response</h6> <p>In the study by <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>, scores on the CGI‐I favoured clomipramine, with 4 of 10 participants in the clomipramine group showing response to treatment, compared with 0 of 6 in the placebo group. The evidence from this single trial was very uncertain (RR 5.73, 95% CI 0.36 to 90.83; 1 study, 16 participants; very low‐certainty evidence; <a href="./references#CD007662-fig-0042" title="">Analysis 9.1</a>). We rated the overall certainty of the evidence as very low due to risk of attrition bias and high imprecision from a small sample size and wide confidence interval. </p> </section> <section id="CD007662-sec-0155"> <h6 class="title">Reduction of TTM symptom severity</h6> <p>Reduction of TTM symptom severity was reported on the NIMH‐TIS and the NIMH‐TSS. On the NIMH‐TIS, there was very uncertain evidence about the effect of clomipramine on the reduction of TTM symptom severity compared to placebo, based on a single trial (MD 1.60, 95% CI ‐0.82 to 4.02; 1 study, 16 participants; very low‐certainty evidence; <a href="./references#CD007662-fig-0043" title="">Analysis 9.2</a>.1). We rated the certainty of the evidence as very low due to risk of attrition bias and high imprecision due to small sample size and wide confidence interval. </p> <p>On the NIMH‐TSS, there was very uncertain evidence about the effect of clomipramine on the reduction of TTM symptom severity compared to placebo in a single trial (MD ‐3.00, 95% CI ‐6.52 to 0.52; 1 study, 16 participants; very low‐certainty evidence; <a href="./references#CD007662-fig-0043" title="">Analysis 9.2</a>.2). We rated the certainty of the evidence as very low due to risk of attrition bias and high imprecision due to small sample size and wide confidence interval. </p> </section> </section> <section id="CD007662-sec-0156"> <h5 class="title">Secondary outcomes</h5> <section id="CD007662-sec-0157"> <h6 class="title">Tolerability of treatment ‐ dropouts due to adverse events</h6> <p>In the <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a> trial of clomipramine versus placebo, 3 of 10 participants (30%) receiving clomipramine dropped out of the study because of significant drug‐related adverse effects, although it is not stated which adverse effects caused participants to withdraw from the study. There was very uncertain evidence for increased dropouts due to adverse events in the clomipramine group compared to the placebo group, based on this single trial (30% for clomipramine versus 0% for placebo; RR 4.45, 95% CI 0.27 to 73.81; 1 study, 16 participants; very low‐certainty evidence; <a href="./references#CD007662-fig-0044" title="">Analysis 9.3</a>). We rated the certainty of the evidence as very low due to risk of attrition bias and high imprecision from a small sample size and wide confidence interval. </p> </section> <section id="CD007662-sec-0158"> <h6 class="title">Tolerability of treatment ‐ common adverse events ( &gt; 20%)</h6> <p>Common adverse effects in participants taking clomipramine, in a single trial, were tremor (3 of 10; 30%) (RR 4.45, 95% CI 0.27 to 73.81; 1 study, 16 participants; very low‐certainty evidence; <a href="./references#CD007662-fig-0045" title="">Analysis 9.4</a>.1), sedation (2 of 10; 20%) (RR 3.18, 95% CI 0.18 to 56.95; 1 study, 16 participants; very low‐certainty evidence; <a href="./references#CD007662-fig-0045" title="">Analysis 9.4</a>.2), dry mouth (2 of 10; 20%) (RR 3.18, 95% CI 0.18 to 56.95; 1 study, 16 participants; very low‐certainty evidence; <a href="./references#CD007662-fig-0045" title="">Analysis 9.4</a>.3) and constipation (2 of 10; 20%) (RR 3.18, 95% CI 0.18 to 56.95; 1 study, 16 participants; very low‐certainty evidence; <a href="./references#CD007662-fig-0045" title="">Analysis 9.4</a>.4). There is very uncertain evidence regarding the effect of clomipramine compared to placebo on the risk of experiencing the above adverse events, although the six participants who were taking placebo in the <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a> trial reported no adverse events. We rated the certainty of this evidence as very low due to high imprecision from small sample size, wide confidence intervals and risk of attrition bias. </p> </section> <section id="CD007662-sec-0159"> <h6 class="title">Reduction of comorbid symptoms of depression</h6> <p>This was not an outcome of interest in the <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a> study; therefore, no further data were available for analysis. </p> </section> <section id="CD007662-sec-0160"> <h6 class="title">Quality of life ‐ functional disability</h6> <p>This was not an outcome of interest in the <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a> study; therefore, no further data were available for analysis. </p> </section> </section> </section> <section id="CD007662-sec-0161"> <h4 class="title">Comparison 10: TCAs with predominantly SRI actions versus other TCAs for trichotillomania in adults </h4> <section id="CD007662-sec-0162"> <h5 class="title">Primary outcomes</h5> <section id="CD007662-sec-0163"> <h6 class="title">Treatment response</h6> <p>The <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a> study provided evidence that clomipramine may be effective when compared with desipramine on the unvalidated Physician‐Rated Clinical Progress scale (PRCP) for treatment response (MD ‐4.00, 95% CI ‐6.13 to ‐1.87; 1 study, 26 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0046" title="">Analysis 10.1</a>). We rated the certainty of the evidence as low due to high imprecision from a small sample size. Dichotomous treatment response was not measured using a formal scale in the original study, and therefore dichotomous treatment response is not available for analysis. </p> </section> <section id="CD007662-sec-0164"> <h6 class="title">Reduction of TTM symptom severity</h6> <p>Clomipramine may have a beneficial effect on the reduction of TTM symptom severity compared to desipramine on the NIMH‐TIS, although based on a single trial (MD ‐2.00, 95% CI ‐3.58 to ‐0.42; 1 study, 26 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0047" title="">Analysis 10.2</a>.1). On another measure, the NIMH‐TSS, in the same trial clomipramine showed no effect on reduction of TTM symptom severity (MD ‐3.80, 95% CI ‐8.08 to 0.48; 1 study, 26 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0047" title="">Analysis 10.2</a>.2). We assessed the overall certainty of this evidence as low due to high imprecision from a small sample size. </p> </section> </section> <section id="CD007662-sec-0165"> <h5 class="title">Secondary outcomes</h5> <section id="CD007662-sec-0166"> <h6 class="title">Reduction of comorbid symptoms of depression</h6> <p>In the study by <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>, the NIMH‐GASD was used to assess severity of depression symptoms. The study authors report that no participants scored in the range of clinical depression at the beginning of the study. There was no difference in effect between clomipramine and desipramine (MD ‐0.7, 95% CI ‐1.6 to 0.2; 1 study, 26 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0048" title="">Analysis 10.3</a>). We judged the overall certainty of this evidence as low due to high imprecision from a small sample size. </p> </section> <section id="CD007662-sec-0167"> <h6 class="title">Tolerability of treatment ‐ dropouts due to adverse events</h6> <p>In the <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a> cross‐over study comparing clomipramine versus desipramine, of the 13 participants, none withdrew because of adverse events (0% for clomipramine versus 0% for desipramine; 1 study, 26 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0049" title="">Analysis 10.4</a>). </p> </section> <section id="CD007662-sec-0168"> <h6 class="title">Tolerability of treatment ‐ common adverse events ( &gt; 20%)</h6> <p>The three common adverse events affecting participants in this single trial (N = 13) were constipation (5 of 13 (38.5%) for clomipramine compared with 6 of 13 (46.2%) for desipramine; RR 0.83, 95% CI 0.34 to 2.06; 1 study, 26 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0050" title="">Analysis 10.5</a>.1), dry mouth (5 of 13 (38.5%) for clomipramine and 8 of 13 (61.5%) for desipramine; RR 0.63, 95% CI 0.28 to 1.41; 1 study, 26 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0050" title="">Analysis 10.5</a>.2) and tremor (7 of 13 (53.8%) for clomipramine and 3 of 13 (23.1%) for desipramine; RR 2.33, 95% CI 0.77 to 7.10; 1 study, 26 participants; low‐certainty evidence; <a href="./references#CD007662-fig-0050" title="">Analysis 10.5</a>.3). The authors report that there were no differences between clomipramine and desipramine with regards to adverse effects. We judged the certainty of the evidence for common adverse events as low due to high imprecision from a small sample size and wide confidence intervals. </p> </section> <section id="CD007662-sec-0169"> <h6 class="title">Quality of life ‐ functional disability</h6> <p>This was not an outcome of interest in the <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a> study; therefore, no further data were available for analysis. </p> </section> </section> </section> <section id="CD007662-sec-0170"> <h4 class="title">Heterogeneity</h4> <p>There were not enough studies to permit investigation of heterogeneity and its clinical sources. Heterogeneity for individual outcomes is addressed in the relevant section above. </p> </section> <section id="CD007662-sec-0171"> <h4 class="title">Subgroup analyses</h4> <p>There were insufficient studies to permit a subgroup analysis ( &lt; 10 studies per subgroup).</p> </section> <section id="CD007662-sec-0172"> <h4 class="title">Sensitivity analyses</h4> <p>There were insufficient studies to allow a sensitivity analysis ( &lt; 10 studies for any single outcome). </p> </section> <section id="CD007662-sec-0173"> <h4 class="title">Publication bias</h4> <p>There were insufficient studies to permit detection of publication bias ( &lt; 10 studies in any comparison). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007662-sec-0174" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007662-sec-0174"></div> <section id="CD007662-sec-0175"> <h3 class="title" id="CD007662-sec-0175">Summary of main results</h3> <p>Overall, a small body of evidence is available on pharmacotherapy for TTM. Twelve studies, all RCTs, are included in this review, all published between 1989 and 2019. Three studies of SSRIs (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>), two studies of TCAs with predominantly SRI actions (<a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>), two studies of opioid antagonists (<a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>), and two studies of glutamate modulators were included (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>). The three remaining studies focused on an atypical antipsychotic (<a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>), an antioxidant (<a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>), and a cell signal transducer (<a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>). The eleven studies in adults involved a total of 298 participants with a mean sample size of 27 participants per trial and a range of 13 (<a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>), to 51 participants (<a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>). Only one included study was conducted exclusively in children and adolescents, which had a sample size of 39 participants (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>). One study included 4 adolescent and 18 adult participants in a single cross‐over study (<a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>). </p> <p>We did not conduct meta‐analysis across medication classes due to the varying neurochemical actions of the agents utilised. For adults, meta‐analysis within medication class was undertaken for the following select outcomes with sufficient data: treatment response to opioid antagonists across two studies (<a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>), and dropout rate due to adverse events with SSRIs across two studies (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>). The remaining classes each contained a single study (antioxidants, antipsychotics, cell signal transducers and glutamate modulators) or had multiple studies that could not be combined due to different comparator groups (TCAs with predominantly SRI actions). We primarily conducted analyses on data from single studies, generating summary statistics in the form of MDs and RRs for our outcomes of interest. For children and adolescents, we included only two studies in this review (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>). As they investigated different medications, meta‐analysis was not possible. For these studies of a glutamate modulator and an antioxidant, we report summary statistics in the form of MDs and RRs for our outcomes of interest. </p> <p>Overall, it is difficult to draw high‐quality conclusions of treatment efficacy, as most medications are represented by a single, relatively small trial. However, four individual trials in adults demonstrated preliminary evidence for the possible efficacy of three individual agents. Clomipramine (a TCA with predominantly SRI action) showed potential benefit compared to desipramine in reducing TTM symptom severity, with low‐certainty (<a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>). Olanzapine, an atypical antipsychotic, also showed a possible beneficial effect on treatment response compared to placebo, and reduced TTM symptom severity, again albeit with low‐certainty (<a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). There was also evidence of a probable, beneficial effect of NAC (a glutamate modulator) on treatment response and reduction of TTM symptom severity in adults, with moderate‐certainty in the effect estimate, although based on a single trial (<a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>). </p> <p>A single RCT in children and adolescents found evidence that NAC may have a potential beneficial effect on TTM symptom severity in children and adolescents compared to placebo (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>). However, this finding may have been influenced by baseline differences between intervention and placebo groups on the MGH‐HPS and NIMH‐TSS. This finding was also not consistent across all rating scales of TTM symptom severity, suggesting the need for further studies, and certainty in this estimate is low. Moreover, the study showed no beneficial treatment effect of NAC when measuring treatment response on the CGI‐I (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>). This may indicate differences in the neurobiology of TTM in adults and children. Additionally, the inconsistency between self‐reported and clinician‐rated scales suggests a need for further scale validation studies in children and adolescents with TTM. As trichotillomania is a disorder commonly occurring in childhood, this warrants further investigation. </p> <p>The overall certainty of the evidence as per GRADE ratings was low on average, with only NAC having some moderate‐certainty evidence for possible beneficial effects in adults. Common factors for downgrading the certainty of evidence included wide confidence intervals and small sample size. We found no further substantial evidence of beneficial or harmful effects for fluoxetine, sertraline, desipramine, naltrexone, silymarin or inositol. </p> </section> <section id="CD007662-sec-0176"> <h3 class="title" id="CD007662-sec-0176">Overall completeness and applicability of evidence</h3> <p>We have presented data from all published and unpublished trials that assessed the efficacy and tolerability of pharmacotherapeutic options for adult TTM and TTM in children and adolescents. The current evidence base of RCTs is not sufficient to permit robust meta‐analysis; thus, there was insufficient evidence to confirm or refute the efficacy or acceptability of any particular agent or class of medication for the treatment of TTM in adults or in children and adolescents. There is a particular lack of randomised, placebo‐controlled trials for the treatment of paediatric TTM. As TTM often has its onset in childhood or adolescence, this is an important area that warrants further investigation. </p> <p>The 12 included studies cover 7 different medication classes; therefore, evidence within individual medication classes is insufficient to generalise from individual agents to class. A greater number of larger studies across a broad range of medication classes is needed before robust conclusions can be drawn from meta‐analysis. Nevertheless, evidence from single studies suggests that certain medications (clomipramine, olanzapine, NAC) may provide some benefit in adults (<a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>) or children and adolescents (NAC: <a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>). </p> <p>Meta‐analysis was restricted by methodological heterogeneity in terms of statistical reporting, and the use of a wide variety of TTM symptom scales, including some that have not been well validated or previously published. This is a matter of concern because evidence indicates that unpublished rating scales are more likely to favour the treatment group over the control group (<a href="./references#CD007662-bbs2-0083" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249-52.">Marshall 2000</a>). Several possible reasons have been proposed for this, one of which is that post hoc 'adjustment' of unpublished scales by removing unfavourable items can skew the results in favour of the treatment group (<a href="./references#CD007662-bbs2-0083" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249-52.">Marshall 2000</a>). In future studies, the use of one or two validated symptom scales, such as the CGI‐I and MGH‐HPS, and reporting group means and variance will enhance the meta‐analytic options. </p> <p>It is important for future studies to include participants with psychiatric comorbidities, and to measure and report participant response to medication (e.g. depression and anxiety). The exclusion of participants with comorbid disorders means that study participants are likely not a good representation of clinical populations. Amongst the included studies in this review, three studies excluded participants with comorbid psychiatric disorders (<a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>); three studies excluded participants with bipolar disorder, dementia, psychotic disorders or substance use disorders (<a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>); one study excluded only participants with bipolar disorder or psychotic disorders (<a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>); and two studies did not specify comorbidities (<a href="./references#CD007662-bbs2-0003" title="ChristensonGA , CrowSJ , MackenzieTB , CrosbyRD , MitchellJE . A placebo controlled double-blind study of naltrexone for trichotillomania [Abstract NR597]. In: New Research Program and Abstracts. The Sesquicentennial Annual Meeting of the American Psychiatric Association. Vol. 1994. Philadelphia (PA): APA, 1994 May 21-26:212. ">Christenson 1994</a>; <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>). The study exclusively in children and adolescents excluded participants with bipolar disorder, psychotic disorder, substance use disorder, developmental disorder or mental retardation (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>). Where information about comorbidities was available, we extracted and reported it. </p> <p>With the exception of clomipramine and desipramine, direct comparisons of the relative clinical effectiveness of medications in treating TTM are lacking. Direct comparisons of agents may shed light on the neurobiology and treatment of TTM. Clomipramine, which exhibits potent serotonergic activity, showed potential, positive treatment effects, which were lacking for other strongly serotonergic agents – namely, the SSRIs included in this study. This observation may be explained by clomipramine’s noradrenergic metabolite, desmethylclomipramine (<a href="./references#CD007662-bbs2-0082" title="MajJ , StalaL , GórkaZ , AdamusA . Comparison of the pharmacological actions of desmethylclomipramine and clomipramine. Psychopharmacology1982 ;78(2):165-9.">Maj 1982</a>). However, desipramine, which has strong noradrenergic effects, failed to produce potentially positive treatment effects. This suggests the involvement of both serotonergic and noradrenergic pathways and is supported by positive findings from an open‐label trial of venlafaxine, a serotonin‐noradrenaline reuptake inhibitor (SNRI), which has both serotonergic and noradrenergic effects (<a href="./references#CD007662-bbs2-0018" title="NinanPT , KnightB , KirkL , RothbaumBO , KelseyJ , NemeroffCB . A controlled trial of venlaflaxine in trichotillomania: interim phase I results. Psychopharmacology Bulletin1998;34(2):221-4. ">Ninan 1998</a>). Thus, the role of specific monoamines requires further study with head‐to‐head comparisons of agents from within medication classes to investigate the roles of each neurotransmitter in turn. </p> <p>A multiple‐treatment meta‐analysis (MTM) might be a useful method in future updates of this review to allow comparison of three or more different interventions (potentially from different studies) in one meta‐analysis. For MTM to be performed, the included studies would have to be similar in all ways other than the interventions being compared, which is currently not the case. </p> <p>Given the relative lack of evidence to confirm or refute efficacy of any particular medication in treating TTM in adults or children and adolescents, the presence of a comorbid disorder that is known to be responsive to medication may be useful in choosing a medication. Currently, there is no established first‐line recommendation for medication in TTM (<a href="./references#CD007662-bbs2-0054" title="FarhatLC , OlfsonE , NasirM , LevineJL , LiF , MiguelEC , et al. Pharmacological and behavioral treatment for trichotillomania: an updated systematic review with meta‐analysis. Depression and Anxiety2020;37(8):715-27.">Farhat 2020</a>; <a href="./references#CD007662-bbs2-0063" title="GrantJE , ChamberlainSR . Trichotillomania. American Journal of Psychiatry2016;173(9):868–74.">Grant 2016</a>). The presence of psychiatric comorbidities, such as anxiety or depressive disorders, may play a role in selecting an appropriate treatment option. Similarly, knowledge of common adverse events associated with each medication may further assist clinical decision‐making. </p> <p>Whilst medication may provide some benefit in treating TTM, habit‐reversal therapy and other psychotherapeutic approaches remain viable first‐line treatment options, as discussed in other reviews (<a href="./references#CD007662-bbs2-0037" title="BlochMH , Landeros-WeisenbergerA , DombrowskiP , KelmendiB , WegnerR , NudelJ , et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Journal of Biological Psychiatry2007;62:839-46.">Bloch 2007</a>; <a href="./references#CD007662-bbs2-0054" title="FarhatLC , OlfsonE , NasirM , LevineJL , LiF , MiguelEC , et al. Pharmacological and behavioral treatment for trichotillomania: an updated systematic review with meta‐analysis. Depression and Anxiety2020;37(8):715-27.">Farhat 2020</a>; <a href="./references#CD007662-bbs2-0090" title="RehmI , MouldingR , NedeljkovicM . Psychological treatments for trichotillomania: update and future directions. Australasian Psychiatry2015;23(4):365-8.">Rehm 2015</a>). </p> <p>Future treatment options include the cannabinoid agonist dronabinol (NCT03530800 on ClinicalTrials.gov; <a href="./references#CD007662-bbs2-0025" title="NCT03530800. Dronabinol in trichotillomania and other body focused repetitive behaviors [A double-blind, placebo-controlled study of dronabinol in trichotillomania and other body focused repetitive behaviors]. clinicaltrials.gov/ct2/show/NCT03530800  (first received 21 May 2018). ">NCT03530800</a>), an experimental drug targeting System x<sub>c</sub>‐ called SXC‐2023 (NCT03797521 on ClinicalTrials.gov; <a href="./references#CD007662-bbs2-0026" title="NCT03797521. A study in patients with trichotillomania (TTM) [A phase 2, double blind, placebo-controlled study to explore the safety, tolerability, and activity of SXC-2023 in adults with moderate to severe trichotillomania (TTM) when dosed for 6 weeks]. clinicaltrials.gov/ct2/show/NCT03797521  (first received 9 January 2019). ">NCT03797521</a>), and other NAC derivatives that improve blood‐brain barrier permeability being developed by Promentis Pharmaceuticals (<a href="https://patents.google.com/patent/WO2015070034A1/en" target="_blank">patents.google.com/patent/WO2015070034A1/en</a>). </p> </section> <section id="CD007662-sec-0177"> <h3 class="title" id="CD007662-sec-0177">Quality of the evidence</h3> <p>This review included 12 studies of 341 participants, in total spanning 7 different medication classes (SSRIs, TCAs, antipsychotics, opioid antagonists, glutamate modulators, antioxidants and cell signal transducers). The number of participants in the included studies was very small, ranging from 13 to 51, and 4 of the 12 included studies had fewer than 20 participants. Small sample size was the primary reason for downgrading the certainty of the evidence. </p> <p>In addition to these small numbers, attrition rates of greater than 10% were seen in 7 of the 12 trials (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>; <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>). In the <a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a> study, 37 participants were randomly assigned, but only 31 of the 37 participants had their outcome data included in the final analysis, representing an attrition rate of 19%. In the <a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a> study, 23 participants were randomly assigned and data from only 16 participants were analysed, for an attrition rate of 30%. In the <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a> study, 23 participants were randomly assigned with data from only 16 participants included in the final analysis, for an attrition rate of 30%. These trials did not employ intention‐to‐treat (ITT) analyses, representing a high risk of attrition bias. Four other studies by <a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>, <a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>, <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a> and <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a> had attrition rates of 10% (4 of 39 participants), 14% (7 of 51 participants), 18% (4 of 22 participants) and 18% (7 of 38 participants), respectively, but all randomised participants were included in analyses using an ITT principle. </p> <p>The use of different, unvalidated scales in some of the included studies diminishes the certainty of evidence available from these studies. For example, two studies used a self‐reported rating scale that relied on participants to count the number of hair‐pulling episodes, as well as to rate the urgency and severity of hair‐pulling (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>). Given that hair‐pulling is often done without awareness, participants may be limited in their ability to keep track of their own hair‐pulling. </p> <p>Protocols for some of these trials were not publicly available, which limited our ability to determine whether there was reporting bias that might in turn have influenced outcomes. In line with other efforts to enhance replicability, we would encourage publication of TTM clinical trial protocols in the future. More recent trials had published protocols on the ClinicalTrials.gov portal (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>), which aids interrogation of possible reporting bias. </p> <p>Four of the trials included in this review employed a cross‐over design (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>). Failure to include a washout period in the <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a> trial comparing clomipramine with desipramine may have impacted the trial results because of the persistent effects of these agents on both TTM and comorbid conditions such as depression. </p> <p>The limited number of studies and the limited number of participants, as well as the high attrition rates in many of the studies and the lack of intention‐to‐treat analyses, indicate that any conclusions about the use of medication for treating TTM must be made with caution. The NAC and olanzapine trials in adults are methodologically robust (<a href="./references#CD007662-bbs2-0005" title="GrantJE , OdlaugBL , KimSW . N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Archives of General Psychiatry2009;66(7):756-63. ">Grant 2009</a>; <a href="./references#CD007662-bbs2-0012" title="Van AmeringenM , ManciniC , PattersonB , BennettM , OakmanJ . A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Journal of Clinical Psychiatry2010;71(10):1336-43. ">Van Ameringen 2010</a>). However, the certainty of the evidence (GRADE) from a meta‐analytic perspective for treatment response and reduction of TTM symptom severity was moderate for NAC and low for olanzapine (downgraded for high imprecision from small sample sizes). Moderate‐certainty evidence implies that further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate, whereas low‐certainty evidence implies that further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. These studies deserve replication to further examine the efficacy of olanzapine and NAC for TTM in adults. </p> <p>Over time, we note more consistent reporting of outcomes in both published articles on TTM and protocols on ClinicalTrials.gov. In addition, there have been improvements in study design, use of validated scales and reduction of risk of bias in the included studies, with newer studies reporting outcomes as intention‐to‐treat analyses. More high‐quality trials that are appropriately powered are required before a robust meta‐analysis can be undertaken. Psychometric evaluation of validated, clinician‐rated scales would also aid future synthesis of findings. </p> </section> <section id="CD007662-sec-0178"> <h3 class="title" id="CD007662-sec-0178">Potential biases in the review process</h3> <p>We attempted to be as comprehensive as possible in the review process. As recommended for all Cochrane reviews, we conducted an extensive and comprehensive search of multiple electronic bibliographic databases to identify trials eligible for inclusion. We applied no language or publication restrictions in our search. Further, we engaged directly with many of the authors to obtain missing data or to ask for clarification when this was required. We minimised potential bias in the conduct of our review by having two independent researchers extract data and assess the methodological quality of each study. This detailed process allowed a thorough assessment of trial conduct and an exploration of the possible biases that may be present in each trial. Despite all of the measures taken, it is possible that unpublished data have been reported that we did not find; this represents a potential bias in the review process. </p> </section> <section id="CD007662-sec-0179"> <h3 class="title" id="CD007662-sec-0179">Agreements and disagreements with other studies or reviews</h3> <p>The methodology employed in this study differs from that employed in the meta‐analysis of pharmacological trials conducted by <a href="./references#CD007662-bbs2-0037" title="BlochMH , Landeros-WeisenbergerA , DombrowskiP , KelmendiB , WegnerR , NudelJ , et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Journal of Biological Psychiatry2007;62:839-46.">Bloch 2007</a>, <a href="./references#CD007662-bbs2-0054" title="FarhatLC , OlfsonE , NasirM , LevineJL , LiF , MiguelEC , et al. Pharmacological and behavioral treatment for trichotillomania: an updated systematic review with meta‐analysis. Depression and Anxiety2020;37(8):715-27.">Farhat 2020</a> and <a href="./references#CD007662-bbs2-0084" title="McGuireJF , UngD , SellesRR , RahmanO , LewinAB , MurphyTK , et al. Treating trichotillomania: a meta-analysis of treatment effects and moderators for behavior therapy and serotonin reuptake inhibitors. Journal of Psychiatric Research2014;58:76-83.">McGuire 2014</a>. Unlike in the present review, <a href="./references#CD007662-bbs2-0037" title="BlochMH , Landeros-WeisenbergerA , DombrowskiP , KelmendiB , WegnerR , NudelJ , et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Journal of Biological Psychiatry2007;62:839-46.">Bloch 2007</a>, <a href="./references#CD007662-bbs2-0054" title="FarhatLC , OlfsonE , NasirM , LevineJL , LiF , MiguelEC , et al. Pharmacological and behavioral treatment for trichotillomania: an updated systematic review with meta‐analysis. Depression and Anxiety2020;37(8):715-27.">Farhat 2020</a> and <a href="./references#CD007662-bbs2-0084" title="McGuireJF , UngD , SellesRR , RahmanO , LewinAB , MurphyTK , et al. Treating trichotillomania: a meta-analysis of treatment effects and moderators for behavior therapy and serotonin reuptake inhibitors. Journal of Psychiatric Research2014;58:76-83.">McGuire 2014</a> chose to perform a meta‐analysis of the SSRI trials (<a href="./references#CD007662-bbs2-0002" title="ChristensonGA , MackenzieTB , MitchellJE , CalliesAL . A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. American Journal of Psychiatry1991;148(11):1566-71. ">Christenson 1991a</a>; <a href="./references#CD007662-bbs2-0004" title="DoughertyDD , LohR , JenikeMA , KeuthenNJ . Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?Journal of Clinical Psychiatry2006;67(7):1086-92. ">Dougherty 2006</a>; <a href="./references#CD007662-bbs2-0010" title="StreichenweinSM , ThornbyJI . A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. American Journal of Psychiatry1995;152(8):1192-6. ">Streichenwein 1995</a>), and included a fourth trial, <a href="./references#CD007662-bbs2-0022" title="Van MinnenA , HoogduinKA , KeijsersGP , HellenbrandI , HendriksGJ . Treatment of trichotillomania with behavioral therapy or fluoxetine. Archives of General Psychiatry2003;60:517-22. ">Van Minnen 2003</a>, which the present review excluded in view of its waiting‐list control group (i.e. lack of a placebo group). In addition, <a href="./references#CD007662-bbs2-0037" title="BlochMH , Landeros-WeisenbergerA , DombrowskiP , KelmendiB , WegnerR , NudelJ , et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Journal of Biological Psychiatry2007;62:839-46.">Bloch 2007</a> and <a href="./references#CD007662-bbs2-0054" title="FarhatLC , OlfsonE , NasirM , LevineJL , LiF , MiguelEC , et al. Pharmacological and behavioral treatment for trichotillomania: an updated systematic review with meta‐analysis. Depression and Anxiety2020;37(8):715-27.">Farhat 2020</a> included trials that used different rating scales. The review authors did not find a statistically significant benefit of SSRIs over placebo (<a href="./references#CD007662-bbs2-0037" title="BlochMH , Landeros-WeisenbergerA , DombrowskiP , KelmendiB , WegnerR , NudelJ , et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Journal of Biological Psychiatry2007;62:839-46.">Bloch 2007</a>; <a href="./references#CD007662-bbs2-0054" title="FarhatLC , OlfsonE , NasirM , LevineJL , LiF , MiguelEC , et al. Pharmacological and behavioral treatment for trichotillomania: an updated systematic review with meta‐analysis. Depression and Anxiety2020;37(8):715-27.">Farhat 2020</a>). In the meta‐analysis of the clomipramine trials, <a href="./references#CD007662-bbs2-0037" title="BlochMH , Landeros-WeisenbergerA , DombrowskiP , KelmendiB , WegnerR , NudelJ , et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Journal of Biological Psychiatry2007;62:839-46.">Bloch 2007</a> and <a href="./references#CD007662-bbs2-0054" title="FarhatLC , OlfsonE , NasirM , LevineJL , LiF , MiguelEC , et al. Pharmacological and behavioral treatment for trichotillomania: an updated systematic review with meta‐analysis. Depression and Anxiety2020;37(8):715-27.">Farhat 2020</a> found that clomipramine demonstrated efficacy compared with placebo or active control conditions, and this difference was found to be statistically significant. In the present review, we decided that it was not appropriate to combine the two clomipramine trials in a meta‐analysis, as one used a placebo group as a control and the other used desipramine as a control (<a href="./references#CD007662-bbs2-0009" title="NinanPT , RothbaumBO , MarstellerFA , KnightBT , EccardMA . A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Journal of Clinical Psychiatry2000;61(1):47-50. ">Ninan 2000</a>; <a href="./references#CD007662-bbs2-0011" title="SwedoSE , LenaneMC , LeonardHL . Long-term treatment of trichotillomania (hair pulling). New England Journal of Medicine1993;329(2):131-2. SwedoSE , LeonardHL , RapoportJL , LenaneMC , GoldbergerEL , CheslowDL . A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New England Journal of Medicine1989;321(8):497-501. SwedoSE , LeonardHL . Trichotillomania. An obsessive compulsive spectrum disorder?Psychiatric Clinics of North America1992;15(4):777-90. ">Swedo 1989</a>). <a href="./references#CD007662-bbs2-0084" title="McGuireJF , UngD , SellesRR , RahmanO , LewinAB , MurphyTK , et al. Treating trichotillomania: a meta-analysis of treatment effects and moderators for behavior therapy and serotonin reuptake inhibitors. Journal of Psychiatric Research2014;58:76-83.">McGuire 2014</a> combined SSRIs and TCAs with predominantly SRI actions in a meta‐analysis and found a significant treatment effect (SMD 0.41). We chose not to combine these classes in a meta‐analysis due to heterogeneity in neurochemical actions. Finally, we report treatment response in terms of a dichotomised measure of the CGI‐I, which is not reported on by <a href="./references#CD007662-bbs2-0037" title="BlochMH , Landeros-WeisenbergerA , DombrowskiP , KelmendiB , WegnerR , NudelJ , et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Journal of Biological Psychiatry2007;62:839-46.">Bloch 2007</a>, <a href="./references#CD007662-bbs2-0054" title="FarhatLC , OlfsonE , NasirM , LevineJL , LiF , MiguelEC , et al. Pharmacological and behavioral treatment for trichotillomania: an updated systematic review with meta‐analysis. Depression and Anxiety2020;37(8):715-27.">Farhat 2020</a> or <a href="./references#CD007662-bbs2-0084" title="McGuireJF , UngD , SellesRR , RahmanO , LewinAB , MurphyTK , et al. Treating trichotillomania: a meta-analysis of treatment effects and moderators for behavior therapy and serotonin reuptake inhibitors. Journal of Psychiatric Research2014;58:76-83.">McGuire 2014</a>. </p> <p>Compared to our original review, we have included summary of findings tables, applied GRADE criteria to rate the certainty in the evidence presented, included three new studies in adults (<a href="./references#CD007662-bbs2-0006" title="GrantJE , OdlaugBL , SchreiberLR , KimSW . The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2014;34(1):134-8. ">Grant 2014</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>; <a href="./references#CD007662-bbs2-0008" title="LeppinkEW , ReddenSA , GrantJE . A double-blind, placebo-controlled study of inositol in trichotillomania. International Clinical Psychopharmacology2017;32(2):107-14. ">Leppink 2017</a>), and included two new studies in children and adolescents (<a href="./references#CD007662-bbs2-0001" title="BlochM , PanzaK , GrantJE , LeckmanJ , PittengerC . N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2012;38:S270. BlochMH , PanzaKE , GrantJE , PittengerC , LeckmanJF . N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry2013;52(3):231-40. ">Bloch 2013</a>; <a href="./references#CD007662-bbs2-0007" title="GrantJE , ReddenSA , ChamberlainSR . Milk thistle treatment for children and adults with trichotillomania: a double-blind, placebo-controlled, crossover negative study. Journal of Clinical Psychopharmacology2019;39(2):129-34. ">Grant 2019</a>). Additionally, we calculated the number needed to treat for an additional beneficial outcome (NNTB) for NAC and olanzapine in adults. We also include additional graphs and analyses for all outcomes, including meta‐analyses for select outcomes within medication classes and for total effectiveness of medication in TTM. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007662-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram" data-id="CD007662-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD007662-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD007662-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidants versus placebo in adults, Outcome 1: Treatment response" data-id="CD007662-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Antioxidants versus placebo in adults, Outcome 1: Treatment response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidants versus placebo in adults, Outcome 2: Reduction of TTM symptom severity" data-id="CD007662-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Antioxidants versus placebo in adults, Outcome 2: Reduction of TTM symptom severity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidants versus placebo in adults, Outcome 3: Reduction of comorbid symptoms of depression" data-id="CD007662-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Antioxidants versus placebo in adults, Outcome 3: Reduction of comorbid symptoms of depression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidants versus placebo in adults, Outcome 4: Quality of Life ‐ functional disability" data-id="CD007662-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Antioxidants versus placebo in adults, Outcome 4: Quality of Life ‐ functional disability </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidants versus placebo in adults, Outcome 5: Tolerability of treatment ‐ Dropouts due to adverse events" data-id="CD007662-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Antioxidants versus placebo in adults, Outcome 5: Tolerability of treatment ‐ Dropouts due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antioxidants versus placebo in adolescents, Outcome 1: Treatment response" data-id="CD007662-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Antioxidants versus placebo in adolescents, Outcome 1: Treatment response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antioxidants versus placebo in adolescents, Outcome 2: Reduction of TTM symptom severity" data-id="CD007662-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Antioxidants versus placebo in adolescents, Outcome 2: Reduction of TTM symptom severity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antioxidants versus placebo in adolescents, Outcome 3: Reduction of comorbid symptoms of depression" data-id="CD007662-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Antioxidants versus placebo in adolescents, Outcome 3: Reduction of comorbid symptoms of depression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antioxidants versus placebo in adolescents, Outcome 4: Quality of Life ‐ functional disability" data-id="CD007662-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Antioxidants versus placebo in adolescents, Outcome 4: Quality of Life ‐ functional disability </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antioxidants versus placebo in adolescents, Outcome 5: Tolerability of treatment ‐ Dropouts due to adverse events" data-id="CD007662-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Antioxidants versus placebo in adolescents, Outcome 5: Tolerability of treatment ‐ Dropouts due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antipsychotics versus placebo in adults, Outcome 1: Treatment response" data-id="CD007662-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Antipsychotics versus placebo in adults, Outcome 1: Treatment response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antipsychotics versus placebo in adults, Outcome 2: Reduction of TTM symptom severity" data-id="CD007662-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Antipsychotics versus placebo in adults, Outcome 2: Reduction of TTM symptom severity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antipsychotics versus placebo in adults, Outcome 3: Tolerability of treatment ‐ Dropouts due to adverse events" data-id="CD007662-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Antipsychotics versus placebo in adults, Outcome 3: Tolerability of treatment ‐ Dropouts due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antipsychotics versus placebo in adults, Outcome 4: Tolerability of treatment ‐ Common adverse events (&gt; 20%)" data-id="CD007662-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Antipsychotics versus placebo in adults, Outcome 4: Tolerability of treatment ‐ Common adverse events (&gt; 20%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Cell signal transducers versus placebo in adults, Outcome 1: Treatment response" data-id="CD007662-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Cell signal transducers versus placebo in adults, Outcome 1: Treatment response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Cell signal transducers versus placebo in adults, Outcome 2: Reduction of TTM symptom severity" data-id="CD007662-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Cell signal transducers versus placebo in adults, Outcome 2: Reduction of TTM symptom severity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Cell signal transducers versus placebo in adults, Outcome 3: Tolerability of treatment ‐ Dropouts due to adverse events" data-id="CD007662-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Cell signal transducers versus placebo in adults, Outcome 3: Tolerability of treatment ‐ Dropouts due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Cell signal transducers versus placebo in adults, Outcome 4: Tolerability of treatment ‐ Common adverse events (&gt; 20%)" data-id="CD007662-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Cell signal transducers versus placebo in adults, Outcome 4: Tolerability of treatment ‐ Common adverse events (&gt; 20%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Glutamate modulators versus placebo in adults, Outcome 1: Treatment response" data-id="CD007662-fig-0022" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Glutamate modulators versus placebo in adults, Outcome 1: Treatment response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Glutamate modulators versus placebo in adults, Outcome 2: Reduction of TTM symptom severity" data-id="CD007662-fig-0023" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Glutamate modulators versus placebo in adults, Outcome 2: Reduction of TTM symptom severity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Glutamate modulators versus placebo in adults, Outcome 3: Reduction of comorbid symptoms of depression" data-id="CD007662-fig-0024" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Glutamate modulators versus placebo in adults, Outcome 3: Reduction of comorbid symptoms of depression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Glutamate modulators versus placebo in adults, Outcome 4: Quality of Life ‐ functional disability" data-id="CD007662-fig-0025" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Glutamate modulators versus placebo in adults, Outcome 4: Quality of Life ‐ functional disability </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Glutamate modulators versus placebo in adults, Outcome 5: Tolerability of treatment ‐ Dropouts due to adverse events" data-id="CD007662-fig-0026" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Glutamate modulators versus placebo in adults, Outcome 5: Tolerability of treatment ‐ Dropouts due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Glutamate modulators versus placebo in children and adolescents, Outcome 1: Treatment response" data-id="CD007662-fig-0027" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Glutamate modulators versus placebo in children and adolescents, Outcome 1: Treatment response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Glutamate modulators versus placebo in children and adolescents, Outcome 2: Reduction of TTM symptom severity" data-id="CD007662-fig-0028" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Glutamate modulators versus placebo in children and adolescents, Outcome 2: Reduction of TTM symptom severity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Glutamate modulators versus placebo in children and adolescents, Outcome 3: Reduction of comorbid symptoms of depression" data-id="CD007662-fig-0029" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Glutamate modulators versus placebo in children and adolescents, Outcome 3: Reduction of comorbid symptoms of depression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Glutamate modulators versus placebo in children and adolescents, Outcome 4: Tolerability of treatment ‐ Dropouts due to adverse eventsDropouts due to adverse events" data-id="CD007662-fig-0030" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Glutamate modulators versus placebo in children and adolescents, Outcome 4: Tolerability of treatment ‐ Dropouts due to adverse eventsDropouts due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Glutamate modulators versus placebo in children and adolescents, Outcome 5: Tolerability of treatment ‐ Common adverse events (&gt; 20%)" data-id="CD007662-fig-0031" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Glutamate modulators versus placebo in children and adolescents, Outcome 5: Tolerability of treatment ‐ Common adverse events (&gt; 20%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Opioid antagonists versus placebo in adults, Outcome 1: Treatment response" data-id="CD007662-fig-0032" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Opioid antagonists versus placebo in adults, Outcome 1: Treatment response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Opioid antagonists versus placebo in adults, Outcome 2: Reduction of TTM symptom severity" data-id="CD007662-fig-0033" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Opioid antagonists versus placebo in adults, Outcome 2: Reduction of TTM symptom severity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Opioid antagonists versus placebo in adults, Outcome 3: Reduction of comorbid symptoms of depression" data-id="CD007662-fig-0034" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Opioid antagonists versus placebo in adults, Outcome 3: Reduction of comorbid symptoms of depression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Opioid antagonists versus placebo in adults, Outcome 4: Quality of Life ‐ functional disability" data-id="CD007662-fig-0035" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Opioid antagonists versus placebo in adults, Outcome 4: Quality of Life ‐ functional disability </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Opioid antagonists versus placebo in adults, Outcome 5: Tolerability of treatment ‐ Common adverse events (&gt; 20%)" data-id="CD007662-fig-0036" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Opioid antagonists versus placebo in adults, Outcome 5: Tolerability of treatment ‐ Common adverse events (&gt; 20%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0037"> <p> <div class="table" id="CD007662-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Treatment response</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 1</b> </p> </th> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: SSRIs versus placebo in adults, Outcome 1: Treatment response</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0037">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007662-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: SSRIs versus placebo in adults, Outcome 2: Reduction of TTM symptom severity" data-id="CD007662-fig-0038" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: SSRIs versus placebo in adults, Outcome 2: Reduction of TTM symptom severity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: SSRIs versus placebo in adults, Outcome 3: Reduction of comorbid symptoms of depression" data-id="CD007662-fig-0039" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: SSRIs versus placebo in adults, Outcome 3: Reduction of comorbid symptoms of depression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: SSRIs versus placebo in adults, Outcome 4: Tolerability of treatment ‐ Dropouts due to adverse events" data-id="CD007662-fig-0040" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: SSRIs versus placebo in adults, Outcome 4: Tolerability of treatment ‐ Dropouts due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: SSRIs versus placebo in adults, Outcome 5: Tolerability of treatment ‐ Common adverse events (&gt; 20%)" data-id="CD007662-fig-0041" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: SSRIs versus placebo in adults, Outcome 5: Tolerability of treatment ‐ Common adverse events (&gt; 20%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: TCAs with predominantly SRI actions versus placebo in adults, Outcome 1: Treatment response" data-id="CD007662-fig-0042" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: TCAs with predominantly SRI actions versus placebo in adults, Outcome 1: Treatment response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: TCAs with predominantly SRI actions versus placebo in adults, Outcome 2: Reduction of TTM symptom severity" data-id="CD007662-fig-0043" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: TCAs with predominantly SRI actions versus placebo in adults, Outcome 2: Reduction of TTM symptom severity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: TCAs with predominantly SRI actions versus placebo in adults, Outcome 3: Tolerability of treatment ‐ Dropouts due to adverse eventsDropouts due to adverse events" data-id="CD007662-fig-0044" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: TCAs with predominantly SRI actions versus placebo in adults, Outcome 3: Tolerability of treatment ‐ Dropouts due to adverse eventsDropouts due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: TCAs with predominantly SRI actions versus placebo in adults, Outcome 4: Tolerability of treatment ‐ Common adverse events (&gt; 20%)" data-id="CD007662-fig-0045" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: TCAs with predominantly SRI actions versus placebo in adults, Outcome 4: Tolerability of treatment ‐ Common adverse events (&gt; 20%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: TCAs with predominantly SRI actions versus other TCAs in adults, Outcome 1: Treatment response" data-id="CD007662-fig-0046" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: TCAs with predominantly SRI actions versus other TCAs in adults, Outcome 1: Treatment response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: TCAs with predominantly SRI actions versus other TCAs in adults, Outcome 2: Reduction of TTM symptom severity" data-id="CD007662-fig-0047" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: TCAs with predominantly SRI actions versus other TCAs in adults, Outcome 2: Reduction of TTM symptom severity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: TCAs with predominantly SRI actions versus other TCAs in adults, Outcome 3: Reduction of comorbid symptoms of depression" data-id="CD007662-fig-0048" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: TCAs with predominantly SRI actions versus other TCAs in adults, Outcome 3: Reduction of comorbid symptoms of depression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-010.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: TCAs with predominantly SRI actions versus other TCAs in adults, Outcome 4: Tolerability of treatment ‐ Dropouts due to adverse events" data-id="CD007662-fig-0049" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-010.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-010.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10: TCAs with predominantly SRI actions versus other TCAs in adults, Outcome 4: Tolerability of treatment ‐ Dropouts due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-010.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007662-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/urn:x-wiley:14651858:media:CD007662:CD007662-CMP-010.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: TCAs with predominantly SRI actions versus other TCAs in adults, Outcome 5: Tolerability of treatment ‐ Common adverse events (&gt; 20%)" data-id="CD007662-fig-0050" src="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-010.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_t/tCD007662-CMP-010.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10: TCAs with predominantly SRI actions versus other TCAs in adults, Outcome 5: Tolerability of treatment ‐ Common adverse events (&gt; 20%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/media/CDSR/CD007662/image_n/nCD007662-CMP-010.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007662-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antioxidants versus placebo for trichotillomania in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antioxidants versus placebo for trichotillomania in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> antioxidants versus placebo in adults </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Antioxidants versus placebo in adults</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment response</b><sup>a</sup><br/>Clinical Global Impressions ‐ Improvement Scale (CGI‐I) or similar (no. of responders) </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.25</b> <br/>(0.84 to 5.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>36<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was low‐certainty evidence showing no difference in treatment response between the antioxidant group and the placebo group in adults. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b><br/>(187 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b><br/>(186 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><br/>Massachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean MGH‐HPS score for the antipsychotic intervention group was 12.5.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention groups was <b>1.8 lower</b><br/>(6.22 lower to 2.62 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was low‐certainty evidence showing no difference in reduction of TTM symptom severity in the antioxidant group compared to the placebo group on the MGH‐HPS in adults. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b><br/>Dropout rate </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Differences between groups could not be calculated as there were no dropouts due to adverse events in either group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is uncertain about the effect of dropouts due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by two levels due to wide confidence interval and very small sample size ( &lt; 50). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antioxidants versus placebo for trichotillomania in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007662-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antioxidants versus placebo for trichotillomania in adolescents</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antioxidants versus placebo for trichotillomania in adolescents</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> antioxidants versus placebo in adolescents </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Antioxidants versus placebo in</b> adolescents </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment response</b><sup>a</sup><br/>Clinical Global Impressions ‐ Improvement Scale (CGI‐I) or similar (no. of responders) </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2</b> <br/>(0.28 to 14.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>8<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was low‐certainty evidence showing no difference in treatment response between the antioxidant group and the placebo group in adolescents. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b><br/>(70 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>666 per 1000</b><br/>(110 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><br/>Massachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean MGH‐HPS score for the antipsychotic intervention group was 6.83.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention groups was<br/><b>5.87 lower</b><br/>(17.46 lower to 5.72 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was low‐certainty evidence showing no difference in reduction of TTM symptom severity in the antioxidant group compared to the placebo group on the MGH‐HPS in adolescents. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b><br/>Dropout rate </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Differences between groups could not be calculated as there were no dropouts due to adverse events in either group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is uncertain about the effect of dropouts due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by two levels due to wide confidence interval and very small sample size ( &lt; 50). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antioxidants versus placebo for trichotillomania in adolescents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007662-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Antipsychotics versus placebo for trichotillomania in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antipsychotics versus placebo for trichotillomania in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> antipsychotics </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Antipsychotics versus placebo in adults</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment response</b><sup>a</sup><br/>Clinical Global Impressions ‐ Improvement Scale (CGI‐I) </p> <p>(no. of responders)</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 5.08</b> <br/>(1.4 to 18.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>25<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was low‐certainty evidence of benefit on the number of participants who responded to treatment in the antipsychotic group compared to the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>847 per 1000</b><br/>(233 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>848 per 1000</b><br/>(234 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><br/>Massachusetts General </p> <p>Hospital Hair‐Pulling Scale (MGH‐HPS)</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean MGH‐HPS score for the antipsychotic intervention group was 8.38.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention group was<br/><b>4.87 points lower</b><br/>(8.84 to 0.9 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was low‐certainty evidence for a reduction of TTM symptom severity in the antipsychotic group compared to the placebo group on the MGH‐HPS. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b><br/>Dropout rate<br/>Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Differences between groups could not be calculated as there were no dropouts due to adverse events in either group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence was uncertain about the effect of dropouts due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by two levels due to very small sample size ( &lt; 50).<br/><sup>c</sup>Downgraded by two levels due to zero events and very small sample size ( &lt; 50). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Antipsychotics versus placebo for trichotillomania in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007662-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Cell signal transducers versus placebo for trichotillomania in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cell signal transducers versus placebo for trichotillomania in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> cell signal transducers </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cell signal transducers versus placebo in adults</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment response</b><sup>a</sup><br/>Clinical Global Impressions ‐ Improvement Scale (CGI‐I) (no. of responders) </p> <p>Follow‐up: 10 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.33</b> <br/>(0.57 to 3.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>38<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was low‐certainty evidence showing no difference in treatment response between the cell signal transducer group and the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>316 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>420 per 1000</b><br/>(180 to 982) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>316 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>420 per 1000</b><br/>(180 to 983) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><br/>Massachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) </p> <p>Follow‐up: 10 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean MGH‐HPS score for the cell signal transducer intervention group was 13.2.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention groups was<br/><b>1.3 points lower</b><br/>(5.12 lower to 2.52 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was low‐certainty evidence showing no difference in reduction of TTM symptom severity in the cell signal transducer group compared to the placebo group on the MGH‐HPS. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b><br/>Dropout rate<br/>Follow‐up: 10 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Differences between groups could not be calculated as there were no dropouts due to adverse events in either group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence was uncertain about the effect of dropouts due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by two levels due to wide confidence interval and very small sample size ( &lt; 50).<br/><sup>c</sup>Downgraded by two levels due to zero events and very small sample size ( &lt; 50). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Cell signal transducers versus placebo for trichotillomania in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007662-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Glutamate modulators versus placebo for trichotillomania in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Glutamate modulators versus placebo for trichotillomania in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> glutamate modulators </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Glutamate modulators versus placebo in adults</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment response</b><sup>a</sup><br/>Clinical Global Impressions ‐ Improvement Scale (CGI‐I) (no. of responders) </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.5</b> <br/>(1.34 to 9.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>50<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was moderate‐certainty evidence of benefit on the number of participants who responded to treatment in the glutamate modulator group compared to the placebo group in adults. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>560 per 1000</b><br/>(214 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>560 per 1000</b><br/>(214 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><br/>Massachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean MGH‐HPS score for the glutamate modulator intervention group was 10.4.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention groups was<br/><b>5.6 points lower</b><br/>(8.5 to 2.7 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was moderate‐certainty evidence for a reduction of TTM symptom severity in the glutamate modulator group compared to the placebo group on the MGH‐HPS in adults. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b><br/>Dropout rate<br/>Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Differences between groups could not be calculated as there were no dropouts due to adverse events in either group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence was uncertain about the effect of dropouts due to adverse events in adults.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by one level due to small sample size (50 to 400).<br/><sup>c</sup>Downgraded by two levels due to zero events and small sample size (50 to 400). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Glutamate modulators versus placebo for trichotillomania in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007662-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Glutamate modulators versus placebo for trichotillomania in children and adolescents</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Glutamate modulators versus placebo for trichotillomania in children and adolescents</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children and adolescents with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> glutamate modulators </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Glutamate modulators versus placebo in children and adolescents</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment response</b><sup>a</sup><br/>Clinical Global Impressions ‐ Improvement Scale (CGI‐I) (no. of responders) </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.19</b> <br/>(0.37 to 3.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>39<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was low‐certainty evidence showing no difference in treatment response between the glutamate modulator group and the placebo group in children and adolescents. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>211 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>251 per 1000</b><br/>(78 to 794) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>211 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>251 per 1000</b><br/>(78 to 795) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><br/>Massachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean MGH‐HPS score for the glutamate modulator intervention group was 10.7.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention groups was<br/><b>2.83 points lower</b><br/>(3.76 to 1.9 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was low‐certainty evidence for a potentially large reduction of TTM symptom severity in the glutamate modulator group compared to the placebo group on the MGH‐HPS in children and adolescents. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b><sup>c</sup><br/>Dropout rate </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.86</b> <br/>(0.12 to 66.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>39<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was low‐certainty evidence showing no difference in dropouts due to adverse events between groups. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 0/19</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 1/20</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 0/19</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 1/20</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by two levels due to very small sample size ( &lt; 50).<br/><sup>c</sup>Numbers presented as raw values for N (events) in study population (intervention and control groups), and not modelled on RR.<br/><sup>d</sup>Downgraded by two levels due to wide confidence interval and very small sample size ( &lt; 50). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Glutamate modulators versus placebo for trichotillomania in children and adolescents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007662-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Opioid antagonists versus placebo for trichotillomania in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Opioid antagonists versus placebo for trichotillomania in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> opioid antagonists </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Opioid antagonists versus placebo in adults</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment response</b><sup>a</sup><br/>Clinical Global Impressions ‐ Improvement Scale (CGI‐I) (no. of responders) &amp; NIMH Trichotillomania Severity Scale (NIMH‐TSS) </p> <p>(no. of responders as &gt; 50% reduction)</p> <p>Follow‐up: 6 to 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.14</b> <br/>(0.25 to 18.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>68<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There is very uncertain evidence showing no effect of opioid antagonists on treatment response. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>535 per 1000</b><br/>(62 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>173 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>370 per 1000</b><br/>(43 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><br/>Massachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean MGH‐HPS score for the opioid antagonist intervention group was 12.21.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention groups was<br/><b>1.14 points lower</b><br/>(4.18 lower to 1.9 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was low‐certainty evidence showing no difference in reduction of TTM symptom severity in the opioid antagonist group compared to the placebo group on the MGH‐HPS. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by one level due to moderate heterogeneity (I² = 59%)<br/><sup>c</sup>Downgraded by two levels due to wide confidence interval and small sample size (50 to 400). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Opioid antagonists versus placebo for trichotillomania in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007662-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">SSRIs versus placebo for trichotillomania in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>SSRIs versus placebo for trichotillomania in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> SSRIs </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>SSRIs versus placebo in adults</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data available for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><sup>a</sup><br/>Massachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) mean change score </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change of the MGH‐HPS score for the SSRI intervention group was ‐1.5333.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention groups was<br/><b>0.47 points lower</b><br/>(4.3 lower to 3.36 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of SSRIs on reduction of TTM symptom severity on the MGH‐HPS. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b><sup>e</sup><br/>Dropout rate </p> <p>Follow‐up: 6 to 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3</b> <br/>(0.33 to 27.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>78<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was low‐certainty evidence showing no difference in dropouts due to adverse events between groups. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 0/39</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 2/39</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 0/39</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 2/39</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by one level due to serious risk of bias. Concerns with attrition bias. Intention‐to‐treat analysis not used. No reasons for attrition given.<br/><sup>c</sup>Downgraded by one level as mean and standard deviations at endpoint were unavailable. Data provided from correspondence were mean change scores from baseline to endpoint.<br/><sup>d</sup>Downgraded by two levels due to wide confidence interval and very small sample size ( &lt; 50).<br/><sup>e</sup>Numbers presented as raw values for N (events) in study population (intervention and control groups), and not modelled on RR.<br/><sup>f</sup>Downgraded by two levels due to wide confidence interval and small sample size (50 to 400). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">SSRIs versus placebo for trichotillomania in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007662-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">TCAs with predominantly SRI actions versus placebo for trichotillomania in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TCAs with predominantly SRI actions versus placebo for trichotillomania in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> TCAs with predominantly SRI actions </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>TCAs with predominantly SRI actions versus placebo in adults</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment response</b><sup>a</sup><br/>Clinical Global Impressions ‐ Improvement Scale (CG‐I) (no. of responders) </p> <p>Follow‐up: 9 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 5.73</b> <br/>(0.36 to 90.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>16<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The evidence is very uncertain about the effect of TCAs with predominantly SRI actions on treatment response. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><br/>NIMH Trichotillomania Severity Scale (NIMH‐TSS) </p> <p>Follow‐up: 9 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean NIMH‐TSS score for the TCA with predominantly SRI actions intervention group was 9.3. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention group was<br/><b>3 points lower</b><br/>(6.52 lower to 0.52 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of TCAs with predominantly SRI actions on reduction of TTM symptom severity on the NIMH‐TSS. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b><sup>d</sup><br/>Dropout rate </p> <p>Follow‐up: 9 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 4.45</b> <br/>(0.27 to 73.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>16<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The evidence is very uncertain about the effect of TCAs with predominantly SRI actions on dropouts due to adverse events. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 0/6</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 3/10</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 0/6</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N = 3/10</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by one level due to serious risk of bias. Concerns with attrition bias. Intention‐to‐treat analysis not used, 3 withdrew from clomipramine group due to adverse events. 40% overall attrition rate in clomipramine group.<br/><sup>c</sup>Downgraded by two levels due to wide confidence interval and very small sample size ( &lt; 50).<br/><sup>d</sup>Numbers presented as raw values for N (events) in study population (intervention and control groups), and not modelled on RR. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">TCAs with predominantly SRI actions versus placebo for trichotillomania in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007662-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">TCAs with predominantly SRI actions versus other TCAs for trichotillomania in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TCAs with predominantly SRI actions versus other TCAs for trichotillomania in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with trichotillomania<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> TCAs with predominantly SRI actions </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>TCAs with predominantly SRI actions versus other TCAs in adults</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment response</b><sup>a</sup><br/>Physician‐rated Clinical </p> <p>Progress Scale</p> <p>Follow‐up: 5 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Physician‐rated Clinical Progress Scale score for the TCA with predominantly SRI actions intervention group was 4.7. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean treatment response in the intervention group was<br/><b>4 points lower</b><br/>(6.13 to 1.87 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was low‐certainty evidence for a beneficial effect on treatment response in the TCAs with predominantly SRI actions group compared to the other TCAs group on the Physician‐rated Clinical Progress Scale. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of TTM symptom severity</b><br/>NIMH Trichotillomania Severity Scale (NIMH‐TSS) </p> <p>Follow‐up: 5 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean NIMH‐TSS score for the TCA with predominantly SRI actions intervention group was 10.6 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of TTM symptom severity in the intervention groups was<br/><b>3.8 points lower</b><br/>(8.08 lower to 0.48 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was low‐certainty evidence of no difference in reduction of TTM symptom severity in the TCAs with predominantly SRI actions group compared to the other TCAs group on the NIMH‐TSS. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tolerability of treatment ‐ dropouts due to adverse events</b><br/>Dropout rate </p> <p>Follow‐up: 5 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Differences between groups could not be calculated as there were no dropouts due to adverse events in either group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is uncertain about the effect of dropouts due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Response is defined as the number of participants with TTM who responded to treatment, as assessed by the CGI‐I or similar.<br/><sup>b</sup>Downgraded by two levels due to wide confidence interval and very small sample size ( &lt; 50).<br/><sup>c</sup>Downgraded by two levels due to zero events and very small sample size ( &lt; 50). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">TCAs with predominantly SRI actions versus other TCAs for trichotillomania in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/full#CD007662-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007662-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antioxidants versus placebo in adults</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Treatment response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Clinical Global Impressions ‐ Improvement Scale (CGI‐I) (no. of responders)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.84, 5.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Reduction of TTM symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Clinical Global Impression ‐ Severity Scale (CGI‐S)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.31, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Massachusetts General Hospital Hairpulling Scale (MGH‐HPS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐6.22, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 NIMH Trichotillomania Severity Scale (NIMH‐TSS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐5.00, 3.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Reduction of comorbid symptoms of depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Hamilton Depression Rating Scale (HAM‐D)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐1.82, 3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Quality of Life ‐ functional disability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Sheehan Disability Scale (SDS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐6.53, 5.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Tolerability of treatment ‐ Dropouts due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antioxidants versus placebo in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007662-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antioxidants versus placebo in adolescents</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Treatment response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Clinical Global Impressions ‐ Improvement Scale (CGI‐I) (no. of responders)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.28, 14.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Reduction of TTM symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Clinical Global Impression ‐ Severity Scale (CGI‐S)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.13 [‐2.72, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Massachusetts General Hospital Hairpulling Scale (MGH‐HPS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.87 [‐17.46, 5.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 NIMH Trichotillomania Severity Scale (NIMH‐TSS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.94 [‐8.14, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.4 Trichotillomania Scale For Children ‐ Child Version (TSC‐C)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐1.25, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.5 Trichotillomania Scale For Children ‐ Parent Version (TSC‐P)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐1.48, ‐0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Reduction of comorbid symptoms of depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Hamilton Depression Rating Scale (HAM‐D)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.62 [‐3.98, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Quality of Life ‐ functional disability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Sheehan Disability Scale (SDS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐8.43, 5.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Tolerability of treatment ‐ Dropouts due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antioxidants versus placebo in adolescents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007662-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Antipsychotics versus placebo in adults</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Treatment response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Clinical Global Impressions ‐ Improvement Scale (CGI‐I) (no. of responders)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.08 [1.40, 18.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Reduction of TTM symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Clinical Global Impressions ‐ Severity Scale (CGI‐S)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.68 [‐2.31, ‐1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Massachusetts General Hospital Hairpulling Scale (MGH‐HPS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.87 [‐8.84, ‐0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.3 Yale‐Brown Obsessive Compulsive Scale for Trichotillomania (TTM‐YBOCS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.63 [‐12.35, ‐2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Tolerability of treatment ‐ Dropouts due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Tolerability of treatment ‐ Common adverse events (&gt; 20%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Dry mouth (no. of participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.93 [0.88, 220.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Fatigue (no. of participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.93 [0.88, 220.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.3 Increased appetite (no. of participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.07 [0.75, 193.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.4 Headache (no. of participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.21 [0.62, 167.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.5 Weight gain (no. of participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.21 [0.62, 167.12]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Antipsychotics versus placebo in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007662-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Cell signal transducers versus placebo in adults</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Treatment response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Clinical Global Impressions ‐ Improvement Scale (CGI‐I) (no. of responders)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.57, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Reduction of TTM symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Massachusetts General Hospital Hairpulling Scale (MGH‐HPS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐5.12, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 NIMH Trichotillomania Severity Scale (NIMH‐TSS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐3.37, 3.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Tolerability of treatment ‐ Dropouts due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Tolerability of treatment ‐ Common adverse events (&gt; 20%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Nausea / upset stomach (no. of participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.41, 9.65]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Cell signal transducers versus placebo in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007662-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Glutamate modulators versus placebo in adults</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Treatment response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Clinical Global Impressions ‐ Improvement Scale (CGI‐I) (no. of responders)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [1.34, 9.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Reduction of TTM symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Clinical Global Impression ‐ Severity Scale (CGI‐S)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.24 [‐1.93, ‐0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 Massachusetts General Hospital Hairpulling Scale (MGH‐HPS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.60 [‐8.50, ‐2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.3 Psychiatric Institute Trichotillomania Scale (PITS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.90 [‐10.56, ‐3.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Reduction of comorbid symptoms of depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 Hamilton Depression Rating Scale (HAM‐D)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.96 [‐2.88, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Quality of Life ‐ functional disability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 Sheehan Disability Scale (SDS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.76 [‐5.58, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Tolerability of treatment ‐ Dropouts due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Glutamate modulators versus placebo in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007662-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Glutamate modulators versus placebo in children and adolescents</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Treatment response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 Clinical Global Impressions ‐ Improvement Scale (CGI‐I) (no. of responders)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.37, 3.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Reduction of TTM symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Massachusetts General Hospital Hairpulling Scale (MGH‐HPS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.83 [‐3.76, ‐1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 NIMH Trichotillomania Severity Scale (NIMH‐TSS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.33 [‐1.97, ‐0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.3 Trichotillomania Scale for Children ‐ Child version (TSC‐C)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.22, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.4 Trichotillomania Scale for Children ‐ Parent version (TSC‐P)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.16, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Reduction of comorbid symptoms of depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 Children's Depression Inventory (CDI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.10 [1.91, 4.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Tolerability of treatment ‐ Dropouts due to adverse eventsDropouts due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.86 [0.12, 66.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Tolerability of treatment ‐ Common adverse events (&gt; 20%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.1 Nausea (no. of participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.22, 1.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Glutamate modulators versus placebo in children and adolescents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007662-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Opioid antagonists versus placebo in adults</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Treatment response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [0.25, 18.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Clinical Global Impressions ‐ Improvement Scale (CGI‐I) (no. of responders)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.49, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 NIMH Trichotillomania Severity Scale (NIMH‐TSS) (no. of responders as &gt;50% reduction)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.62 [0.57, 161.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Reduction of TTM symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 Clinical Global Impression ‐ Severity Scale (CGI‐S)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐1.10, 0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 Massachusetts General Hospital Hairpulling Scale (MGH‐HPS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.14 [‐4.18, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.3 NIMH Trichotillomania Severity Scale (NIMH‐TSS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.79 [‐3.62, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Reduction of comorbid symptoms of depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 Hamilton Depression Rating Scale (HAM‐D)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [‐1.26, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Quality of Life ‐ functional disability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.1 Sheehan Disability Scale (SDS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.91 [‐5.82, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Tolerability of treatment ‐ Common adverse events (&gt; 20%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.1 Sedation (no. of participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.35, 28.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Opioid antagonists versus placebo in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007662-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">SSRIs versus placebo in adults</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Treatment response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Reduction of TTM symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 Massachusetts General Hospital Hairpulling Scale (MGH‐HPS) mean change score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐4.30, 3.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Reduction of comorbid symptoms of depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 Hamilton Depression Rating Scale (HAM‐D)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐1.90, 3.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 Tolerability of treatment ‐ Dropouts due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.33, 27.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 Tolerability of treatment ‐ Common adverse events (&gt; 20%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.1 Nausea (no. of participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.57, 11.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.2 Insomnia (no. of participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.11, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.3 Central nervous system or psychiatric effects (nightmares, insomnia, dizziness, irritability, anxiety, feeling of doom) (no. of participants) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.04, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.4 GIT effects (no. of participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.67 [1.55, 14.09]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">SSRIs versus placebo in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007662-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">TCAs with predominantly SRI actions versus placebo in adults</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Treatment response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 Clinical Global Impressions ‐ Improvement Scale (CGI‐I) (no. of responders)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.73 [0.36, 90.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Reduction of TTM symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 NIMH Trichotillomania Impairment Scale (NIMH‐TIS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [‐0.82, 4.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.2 NIMH Trichotillomania Severity Scale (NIMH‐TSS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.00 [‐6.52, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Tolerability of treatment ‐ Dropouts due to adverse eventsDropouts due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.45 [0.27, 73.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Tolerability of treatment ‐ Common adverse events (&gt; 20%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.1 Tremor (no. of participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.45 [0.27, 73.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.2 Sedation (no. of participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.18 [0.18, 56.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.3 Dry mouth (no. of participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.18 [0.18, 56.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.4 Constipation (no. of participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.18 [0.18, 56.95]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">TCAs with predominantly SRI actions versus placebo in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007662-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">TCAs with predominantly SRI actions versus other TCAs in adults</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Treatment response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 Physician‐rated Clinical Progress Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.00 [‐6.13, ‐1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Reduction of TTM symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 NIMH Trichotillomania Impairment Scale (NIMH‐TIS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐3.58, ‐0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.2 NIMH Trichotillomania Severity Scale (NIMH‐TSS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.80 [‐8.08, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Reduction of comorbid symptoms of depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.1 NIMH Global Assessment Scale for Depression (NIMH‐GASD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐1.60, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.4 Tolerability of treatment ‐ Dropouts due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.5 Tolerability of treatment ‐ Common adverse events (&gt; 20%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.1 Constipation (no. of participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.34, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.2 Dry mouth (no. of participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.28, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.3 Tremor (no. of participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.33 [0.77, 7.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">TCAs with predominantly SRI actions versus other TCAs in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007662.pub3/references#CD007662-tbl-0020">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007662.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007662-note-0021">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007662-note-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007662-note-0020">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD007662-note-0018">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD007662-note-0017">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD007662-note-0016">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD007662-note-0015">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007662-note-0013">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007662-note-0014">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007662\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007662\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007662\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007662\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007662\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007662\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007662\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007662\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007662\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007662\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007662\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007662\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007662\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007662\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007662\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007662\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007662\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007662\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007662.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007662.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007662.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007662.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007662.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714750061"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007662.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714750065"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007662.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d764bcce7937d',t:'MTc0MDcxNDc1MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 